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ABSTRACT 
Tumor-associated macrophages (TAMs) form a significant cell population in malignant 
tumors and contribute to tumor growth, metastasis and neo-vascularization. Gliomas 
are characterized by extensive neo-angiogenesis and knowledge of the role of TAMs in 
neovascularization is important for future anti-angiogenic therapies. The phenotypes 
and functions of TAMs are heterogeneous and more complex than a classification into 
M1 and M2 inflammation response types would suggest. In this review, we provide an 
update on the current knowledge of the ontogeny of TAMs, focussing on diffuse glio-
mas. The role of TAMs in the regulation of the different processes in tumor angiogene-
sis is highlighted and the most recently discovered mechanisms by which TAMs mediate 
resistance against current anti-vascular therapies are mentioned. Novel compounds 
tested in clinical trials are discussed and brought in relation to different TAMs-related 
angiogenesis pathways. In addition, potential therapeutic targets used to intervene 
TAM-regulated tumor angiogenesis are summarized. 
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THE ORIGIN AND ACTION OF TUMOR-ASSOCIATED MACROPHAGES (TAMS). 
The initiation of malignant tumors is associated with a sustained state of chronic in-
flammation 
1
. In the initial stage of tumorigenesis, the first activated immune cells are 
usually the tissue resident macrophages. In glioma, these cells are mainly represented 
by microglial cells 
2
. Activated microglial cells generate high levels of O
2
 radicals that 
induce genomic mutations, and enhance IL-6 and TNF production supporting tumor 
cell survival 
3
. Recruitment of peripheral monocytes enhances this initial response. Vari-
ous tumor cell-derived factors work together with hypoxia and trigger monocyte re-
cruitment 
4
. For example, glioma stem cells produce periostin, an extracellular matrix 
component that provides interactive binding sites to αVβ3 integrins on the cell surface 
of infiltrating M2-like TAMs (Figure 1a). Hypoxia can trigger activation of VEGFR1 and 
Neuropilin-1 (NRP1) in monocytes, leading to chemotaxis in e.g. glioma and breast can-
cer 
5
. Neuropilin-1 (NRP1) and VEGFR1 bind with VEGFA secreted by cancer cells in 
glioma 
6,7
. Tumor cell (including glioma
8
)-derived Semaphorin 3a also serves to recruit 
monocytes 
9
. Semaphorin 3A activation of NRP1 enhances VEGFR1 signalling in mono-
cytes via the NRP-1/Plexin A1/PlexinA4 complex 
10
 (Figure 1b). In glioma, monocyte 
recruitment was also mediated by NG2-positive pericytes via macrophage inhibitory 
factor (MIF) secretion 
11
 (Figure 1c).  
In mammary tumors, recruited VCAM1+ monocytes are triggered to undergo matu-
ration via Notch upregulation of transcription factor RBP-J 
12
(Figure 1d). Similarly, sialic 
acid, which is abundantly available in e.g. breast cancer and melanoma, triggers mono-
cyte differentiation via HIF-1α-mediated disruption of CD45 dimerization, causing de-
creased activation of STAT3 
13
 (Figure 1e).  
PHENOTYPES OF TAMS: BEYOND THE M1/M2 SPECTRUM. 
The classification into M1/M2 profiles is a way to separate macrophage functions into 
pro- (Th1) and anti-inflammatory (Th2) responses of T lymphocytes 
14
. M1 and M2 pro-
files represent the extremes of a continuum of phenotypical characteristics marked by 
sets of cytokines and surface markers. M1 macrophages regulate the acute inflammato-
ry response and are induced by LPS and IFN-γ stimulation. M1 macrophages are charac-
terized by expression of CD40, CD80, CD16/32, CD86, CCR7 and HLA-DR 
15
, and are 
capable of phagocytosis and antigen presentation to T cells. M2 macrophages reduce 
acute inflammation and promote tissue repair. The M2 profile is induced by IL-4 and IL-
13, and macrophage-stimulating factor (M-CSF). Studies on Murine and human cancers, 
including glioblastomas, show that TAMs can express M1 and M2 markers, dependent 
on tumor stage and area 
16,17
,
18
. Glioma-associated macrophages may resemble naïve 
macrophages more than classic M1 or M2 macrophage subtypes 
19
 illustrative of the 
complex nature of TAMs in glioma.     
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Figure 1. Routes of TAM recruitment. 
 
(a) Maturation of VCAM-1+ monocytes triggered by NOTCH signaling. (b) Glioma stem cells (pink) deposit 
periostin in the tumor stroma (green cells represent glioma cells), where it serves as a chemoattractant to 
infiltrating (M2-like) TAMs. (c) Under hypoxic stress in the tumor microenvironment levels of Silica acid (SA) 
increase leading to decreased CD45 dimer signaling, increase of CD45PTP (CD45 phosphatase) and a inhibition 
of STAT3 signaling in recruited monocytes, triggering differentiation of the TAM phenotype. (d) VEGFA and 
Semaphorin 3A (Sema 3A) released by the tumor cells activates Neuropilin-1 (NRP-1), triggering the activation 
of VEGFR1 and contribute to the recruitment of TAMs. (f) IL-34 derived from tumor cells stimulates M2 mac-
rophages and mediates the attachment of monocytes to the endothelial layer of blood vessel through binding 
to CSF1R on the surface of peripheral monocytes. IL-33, released from perivascular pericytes via PDGF-BB-
PDGFRβ-SOX7 signaling serves as chemoattractant to peripheral monocytes. Macrophage inhibitory factor 
(MIF) and NG2+ pericytes expressing ICAM-1 provide a guiding signal to monocytes during extravasation. 
 
Analysis of TAMs in glioblastomas in our laboratory showed co-expression of the M1 
surface markers HLA-DR and CD16 with M2 CD204 and CD163 (unpublished data), 
which is in line with previous findings demonstrating that the M2 marker CD204 colocal-
ized with the M1 marker HLA-DR in perivascular macrophages in glioblastoma 
20
. Simi-
larly, in other malignant tumors like ovarian cancer, the M2 macrophage surface marker 
CD163 was co-expressed with classical Th1 cytokines as IL-6 and IL-8 
21
. Cytokines from 
the M1 profile like IL-6, CCL5, and CCL2 are typically tumor supportive and are associat-
ed with poor prognosis 
22
. The mixed phenotypes of TAMs encountered in tumors may 
well result from simultaneous stimulation by both pro-inflammatory and anti-
inflammatory factors in the tumor micro-environment.  
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TAMs and Tumor Neovascularization. 
TAMs promote proliferation, invasion and metastasis of cancer cells, but also stimulate 
neo-angiogenesis 
1
. Macrophages contribute to angiogenesis under a variety of condi-
tions such as tissue regeneration/wound healing 
23
, immune-mediated diseases like 
rheumatoid arthritis 
24
,  and neoplasia 
25
. The number of macrophages present around 
blood vessels in healthy tissues is significantly increased in tumors such as glioblastoma 
26,27
, particularly during proliferative microvessels 
28-30
. In glioblastoma, CD163+ TAMs 
are found in parenchymal and perivascular areas 
31
. In addition, Tie-2+ TAMs are found 
at perivascular sites in various malignant cancers, including glioblastoma 
32
. Perivascular 
TAMs in glioblastomas are positively correlated with microvascular density and higher 
expression of VEGFA, HO-1
33
, and thymigen phosphorylase (TP)
34
, which is not detected 
in anaplastic oligodendroglioma or ependymoma
35
.  The secretion of inflammatory 
cytokines by TAMs promote neovascularization along various molecular pathways. For 
example, CCL18 secretion by (M2) type TAMs in breast cancer binds to PITPNM3, a 
membrane-associated phosphatidylinositol transfer domain-containing protein located 
on endothelial cells. This interaction triggers downstream ERK and Akt/GSK-3β/Snail 
signalling, and promotes the Endothelial Mesenchymal Transition (EndoMT) process, 
increasing the migration ability of endothelial cells 
36
 (Figure 2a). Secretion of VEGFA by 
macrophages is regulated by macrophage-derived factors in an autocrine fashion in 
both non-cancerous and tumoral conditions: In macrophages, IL-10 activates STAT3 
leading to VEGFA production 
37,38
. Similarly, Il-1 secretion, induced by COX-2 activation 
in tumor cells and macrophages, is linked with the upregulation of IL-8, VEGFA, and HIF-
1α 
39,40
. TAM-derived WNT7b and M-CSF in breast cancer and glioma respectively, acti-
vate the canonical WNT/ catenin and IGFBP1 pathways in endothelial cells, thereby 
increasing the expression of VEGFA 
41,42
.  
In glioblastoma, a link between inflammation-associated c-reactive protein (CRP) 
with IL-6 secretion, JAK-STAT activation, and production of IL-1 by TAMs, was discov-
ered 
43
. In this pathway, elevated CRP levels stimulate TAMs to secrete IL-1β that pro-
motes the proliferation of endothelial cells, and causes IL-6 production of COX-2 posi-
tive TAMs. IL-6 promotes epithelial-mesenchymal transition (EMT) of cancer cells, which 
is typically operative in high-grade gliomas 
36
 (Figure 2b). In addition, YKL-40, a secreted 
protein member of the chitinase gene family, can act as a prognostic marker in various 
cancers including glioblastoma 
44
. YKL-40 expression is regulated by IL-6 and was shown 
to be associated with angiogenesis 
45
. Stimulation of macrophages by M-CSF or GM-CSF 
can induce 100-200 fold more YKL-40 
46
. YKL-40 activates the expression of VEGFR1 and 
VEGFR2 in endothelial cells through the FAK-MAPK signalling pathway, promoting vessel 
sprouting -the initial step in the formation of a new tubule structure from pre-existing 
vasculature 
47
. YKL-40 also stimulates vascular smooth muscle cells (VSMCs) to secrete 
higher levels of IL-8 under the regulation of the MAPK and NF-κB pathways 
48
 (figure 
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2c). YKL-40 also promotes the contacts between glioma stem cell-derived pericvascular 
cells with endothelial cells, resulting in the stabilization of blood vessels in glioma 
49
. 
Macrophages make contact with sprouting endothelial cells and actively contribute 
to new vessel formation
50
. Rymo et al. showed a VEGFA-independent involvement of 
microglial cells in the process of vessel sprouting and branching in vivo 
51
. In a model of 
retinal vascular development, macrophages expressing Notch1 contact Jagged1-positive 
tip cells and mediate the elongation of vascular sprouts via this molecular interaction 
(Figure 2d) 
52
. Tip cells are endothelial cells at the tip of newly formed blood vessels that 
determine the direction of growth. Tip cells are trailed by stalk cells, which are endothe-
lial cells that form the new bloodvessel lining (creating an open lumen for blood flow).  
Proangiogenic NRP-1 expressed by macrophages binds to VEGFR2 present on tip 
cells leading to vessel branching 
53,54
. Macrophages also contribute to the maturation 
and remodelling of newly formed blood vessels in tumors: Macrophages act as cellular 
chaperons for tip cells to form anastomoses, which are fused junctions composed of 
two neighbouring vessel sprouts. Macrophages can secrete VEGF-C causing upregula-
tion of DLL4 in endothelial cells through VEGFR3 signalling, followed by activation of 
transcription factor FoxC2. The VEGFC-VEGFR3-FoxC2 pathway mediates conversion of 
tip cells into stalk cells, contributing to the anastomose process (Figure 2e) 
55
.  
Various in vitro and in vivo experiments have indicated that monocytes themselves 
are capable to transform into cord-like structures and can express endothelial markers 
like vWF, CD31, VE-Cadherin, and CD105, following exposure to proangiogenic factors 
such as VEGFA and IGF-1 
56,57
. In multiple myeloma, TAMs that expressed multiple en-
dothelial markers cooperate with endothelial cells in the formation of the endothelial 
lining of tumor blood vessels 
58
. The expression of endothelial lineage markers like VE-
Cadherin, VEGFR2, FVIII-RA, and vWF is induced in macrophages/monocytes in vitro 
through VEGFA, bFGF 
59
 or pleiotrophin 
60
 stimulation. Exposure to these factors can 
induce the creation of capillary-like structures in vitro 
60
 (Figure 3f). In glioma, TAMs can 
enhance the vascular mimicry of glioma cells, a process mediated via COX-2 and IL-6 
61,62
. Macrophages are also involved in activation of IL-6 and JAK-STAT pathways in the 
recruitment of endothelial progenitor cells (EPC) that take part in de novo vasculariza-
tion 
63
 (Figure 3g).  
Newly formed blood vessels require the coverage of perivascular cells called “mural 
cells” for vascular stabilization and vasomotion control. These mural cells include peri-
cytes in and VSMCs. PDGF-BB acts as one of the most potent chemoattractant of mural 
cells. Although PDGF-BB is produced by endothelial cells during angiogenesis, it is also 
secreted by TAMs. Perivascular TAMs aid in the recruitment of PDGFR+ mural cells, 
contributing to the coverage of newly formed blood vessels 
64
. The recently discovered 
TAM-derived factor Semaphorin 4D (Sema 4D) is involved in the pericyte recruitment of 
neo-vessels as demonstrated in a murine breast cancer model (Figure 3h).  
Taken together, these data suggest that TAMs participate in all stages of angiogene-
sis from early sprouting to late maturation, and the physical integration into vessel 
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endothelium under the direct (paracrine) influence of tumor cells. Since TAMs play such 
a critical role in the entire angiogenetic process in tumors, their role in the resistance to 
anti-angiogenic drug deserves to be scrutinized 
65
. 
 
Figure 2. Various roles of macrophages in angiogenesis. 
 
(a) CCL18 released by TAMs adding to the EndoMT process by interaction with the receptor PITPNM3, triggering 
activation of the ERK1/2 and AKT/GSK-3 signaling pathway. This results in decreased expression of VE-Cadherin 
and upregulation of Vimentin as well as Fibronectin. (b) IL-10 upregulates VEGFA expression in an autocrine 
fashion in order to activate STAT3 in TAMs. C-reactive protein (CRP) in glioma upregulates IL-6 and IL-1β expres-
sion in COX-2+ TAMs. As a result, IL-6 and IL-1β signal together with WNT-7b to increase the VEGFA expression in 
endothelial cells. (c) Putative interaction mechanisms between TAMs and Tip cells via ligand-receptor binding of 
Jagged-1(Tip cell) with NOTCH-1(MФ) as well as VEGFR2(Tip cell) with NRP-1(MФ). (d) Under the stimulation of 
GM/M-CSF and IL-6, TAM releases YKL-40 that triggers the signaling of FAK-MAPK in endothelial cells and of 
MAPK-NFκB in vascular smooth muscle cells (VSMCs), leading to overexpression of VEGFR1 and 2 in endothelial 
cells and IL-8 secretion by VSMCs. (e) VEGFC released by macrophages contributes to the expression of DLL4 in 
Tip cells via VEGFRC-FOXC3 signaling promoting fusion of sprouting anastomosis. (f) Stimulation via VEFGA, βFGF 
and Pleiotrophin triggers expression of the endothelial markers VEGFR2, FGFR2, FVIII-RA and VE-Cadherin by 
TAMs, and promotes the process of vasculogenesis. (g) IL-6 released by TAMs recruits endothelial progenitor cells 
(EPCs) from the peripheral circulation by activating JAK-STAT signaling to contribute to vasculogenesis. (h) Sema-
phorin-4D (Sema 4D) from TAMs stimulates the recruitment of pericytes via activating Plexin B1-RhoA signaling, 
increasing the expression of PDGFB and AGPTL4 in the endothelial cells. Increased expression of AGPTL4 leads to 
the endocytosis of VE-Cadherin in endothelial cells, enhancing the permeability of the blood vessels. 
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TAMS AND ANTI-ANGIOGENIC THERAPY. 
Because neo-angiogenesis is an important component of tumorigenesis it was expected 
that anti-angiogenic agents would be effective in the treatment of solid tumors. Unfor-
tunately, the results of trials in which anti-angiogenic therapies were tested have been 
disappointing so far. The agents were designed to interfere with target molecules from 
common angiogenic pathways. The lack of success of these agents may be partly due to 
overlooking the critical role of TAMs in tumor angiogenesis 
66
. The main effect of anti-
angiogenic therapy is reduction of the vascular bed, causing hypoxia and raised lactate 
levels. Subsequent elevation in intracellular HIF-1α levels leads to higher levels of pro-
angiogenic factors secreted by the tumor cells that result in the paracrine activation of 
TAMs 
67,68
. In experimental mammary tumors, the administration of combretastatin A4 
phosphate (CA4P) caused narrowing of the tumor blood vessel diameters and tumor 
necrosis, but increased CXCL12 levels, leading to raised numbers of CXCR4+ Tie-2+ 
monocytes in the tumors, limiting treatment efficiency 
69
. Over the last decennia, anti-
angiogenic drugs targeting the receptor-ligand interactions by monoclonal antibodies 
like bevacizumab or tyrosine kinase inhibitors (TKIs) were widely applied in clinical prac-
tice. Both act as tumor suppressors by promoting TAMs with an anti-tumor phenotype 
70-74
 or by decreasing monocyte recruitment 
75-79
. This beneficial effect is partially com-
promised by activation of hypoxia-induced HIF1 pathways that lead to an angiogenic 
counter response 
80
. In pancreatic adenocarcinoma and murine breast cancers, activa-
tion of the Akt/PI3K pathway by prolonged exposure to Sorafenib triggers TAMs to 
adapt a tumor supportive and pro-angiogenic phenotype 
81
. Similar effects are observed 
in glial tumors: bevacizumab and aflibercept reduce the effects of VEGFA, and increased 
CD206-positive and Tie-2-positive macrophages in human and murine gliomas by raising 
levels of endothelial cell-derived Angiopoietin-2. The inhibition of Angiopoietin-2 action 
together with the administration of bevacizumab or alibercept results in significant 
improvement of therapeutic efficiency 
82
. Recent studies showed that treatment with 
the Ang-2/VEGF bispecific antibody shifted TAM into an anti-tumor phenotype, conse-
quently resulting in vascular normalization and tumor regression in a mouse glioblasto-
ma model
83,84
. Following treatment with bevacizumab and cetuximab, the numbers of 
TAMs in glioblastoma and colorectal cancer increased and the cells became activated 
respectively 
80,85
. In biopsies of recurrent gliomas treated with bevacizumab, more Tie-2 
expressing monocytes and macrophages were detected.  Furthermore, in an orthotopic 
glioma mouse model an increase in Tie-2-positive TAMs in response to anti-VEGF agents 
was observed
86
; Recently, reduced MIF expression was observed in bevacizumab-
resistant glioma cells, which in turn increased M2-like TAM recruitment, promoting 
tumor progression
87
. In experimentally induced primitive neuroectodermal tumors 
similar observations were made following drug-induced VEGFR2 blockade 
88
. Con-
trasting with these data are the reported effects of the pan-VEGFR inhibitor cediranib 
that transiently decreases the intra-tumoral infiltration of macrophages. However, 
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Cediranib also increases the VEGFA levels in serum and the number of CXCR4 and CD45 
positive circulatory cells in peripheral blood, boosting angiogenesis in murine models of 
pancreatic neuroendocrine and mammary tumors 
81
. Cediranib induces JAK-STAT signal-
ing in macrophages leading to the activation of STAT3 that triggers angiogenesis by 
VEGFA production. In murine xenograft glioma model, adverse effects of STAT3 activa-
tion in TAMs were counteracted by using the JAK-STAT-specific inhibitor AZD1480 
89
. 
Likewise, in a metastatic renal cell carcinoma model, the anti-angiogenic effects of 
sunitinib was enhanced by simultaneous treatment with STAT3 inhibitors 
74
. Tyrosine 
kinase inhibitors (TKIs) have more effects on immune cells. Erlotinib reportedly induces 
apoptosis of monocytic cell lines in vitro 
76
. The monoclonal antibodies cetuximab and 
SR1 enhance the phagocytic capability of macrophages, contributing to elimination of 
circulatory tumor cells 
72,73
. Sunitinib and imatinib change the cytokine secretion profiles 
of macrophages from pro-inflammatory to anti-inflammatory (IL-12 versus IL-10) 
71
, and 
following the treatment with sorafnib, increased numbers of TAMs and levels of angio-
genic factors including CXCL12 and IL-6 were detected 
81
. Recruitment of M2-like TAMs 
or in situ differentiation towards a tumor supportive TAM phenotype was reported after 
cediranib and axitinib treatment in glioma patients 
90,91
. A summary of TAM-mediated 
effects of different tyrosine kinase inhibitors in various therapeutic regimes are provid-
ed in Table 1 and Table 2. 
CURRENT PERSPECTIVES ON TARGETING PROANGIOGENIC TAMS. 
1) Inhibition of tumor-related haematopoiesis and blocking of activating signals 
for TAMs. 
Because the majority of TAMs are recruited from bone marrow-derived peripheral 
monocytes, the inhibition of tumor-related granulo-monocytopoiesis and interference 
with the monocyte recruitment signals will contribute to tumor suppression and inhibit 
tumor vascularization 
92
. Inhibition of CSF-1R to deplete the TAM population increases 
survival time and decrease tumor microvascular density in animal cancer models 
93,94
. 
Patients with tenosynovial giant cell tumors and glioblastomas treated with PLX3397 
(CSF-1R blocker) showed a good tolerance to the drug, but only the patients with teno-
synovial giant cell tumors showed a significant reduction in tumor size 
95
. In recurrent 
GBM only a trend towards a decrease in the number of Iba-1 positive micro-
glia/macrophages and a lower number of CD14
dim
, CD16-positive monocytes in the 
glioma tissues was observed 
96
. 
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2) Inhibition of recruitment signals that guide circulatory monocytes into tumor 
tissue. 
TAMs predominantly originate from recruited peripheral inflammatory monocytes. 
CCL2-CCR2 chemo-attractive signalling is the most studied mechanism in monocyte 
recruitment. The effectiveness of a CCR2 antagonist in decreasing macrophage infiltra-
tion and reducing tumor size was demonstrated in hepatocellular carcinoma 
97
 and 
AMD3100, an inhibitor of CXCR4, blocks the infiltration of Tie-2+ monocytes 
98
. By re-
sponding to VEGFA gradients via cell surface expression of Flt-1, infiltrating monocytes 
are guided into cancer tissues. The agent IVR blocks the phosphorylation of VEGFR1 and 
decreases migration capacity of TAMs in experimental colonic cancer, resulting in re-
duced numbers of TAMs and reduction in tumor angiogenesis 
99
. 
3) Targeting macrophage mediated/secreted angiogenic molecules. 
Current studies in cancer therapy focus on the development of inhibitors and monoclo-
nal antibodies against central regulatory molecules. Some of these interfere with TAM-
mediated tumor angiogenesis and were tested in clinical trials. Monoclonal antibody-
based therapy that targets VEGF-C has proven to inhibit vascularization and reduce 
carcinogenesis of skin squamous carcinoma 
100
. Blocking of VEGF-C using the monoclo-
nal antibody VGX-100 also inhibited infiltration of CD11b+ myeloid cells 
101
. Monoclonal 
antibodies targeting Sema 4D showed promising results in inhibiting cancer growth and 
reduced tumor angiogenesis
102
. WNT7b activates the VEGFA-mediated angiogenic 
switch through stimulation of the Wnt/β-catenin canonical pathway. In contrast, Wnt5a, 
a Wnt ligand that mainly triggers non-canonical pathways, suppresses vessel sprouting 
by upregulation of soluble VEGFR1 
103
. The canonical and non-canonical Wnt signalling 
pathways may well mediate opposite angiogenic responses. Both inhibition of the Wnt 
canonical pathway by inhibitors, and agonist stimulation of the non-canonical Wnt 
pathways, may become future strategies for anti-angiogenesis. The presence of certain 
TAM subtypes, as well as circulatory TAM-secreted serum markers, could also be used 
as parameters to select receptive patients for anti-angiogenic therapy and predict ther-
apeutic efficiency. For example, in a single arm phase II clinical trial, GBM patients who 
received the VEGF-trapper aflibercept showed elevated serum levels of PIGF and MMP-
9, indicative of a poor prognosis. Patients with lower serum levels of PIGF and VEGFR1-
positive monocytes and elevated levels of MIF, MCP-3, and CCL27, benefited from anti-
VEGF treatment 
104
. 
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CONCLUSION. 
Investigations of the recently identified roles of TAMs in angiogenesis may well lead to 
the development of biomarkers for assessing the anti-angiogenic therapy efficacy and 
receptiveness, and could help to identify therapeutic targets for novel anti-angiogenic 
treatments. 
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Table 1. Pro- and anti-tumor effects of multiple tyrosine kinase inhibitors mediated 
via TAMs 
 
Tyrosine  ki-
nase inhibitor 
Molecular 
target(s) 
Investigation Set-
ting 
TAM effect Ref. 
 Sunitinib VEGFR1-
3, PDGFR-
α/β, c-Kit, 
CSF-1R, 
Flt-3 
Inflammatory Cor-
neal Lymphangio-
genesis 
Decreases recruitment of 
F4/80+ macrophages and 
activity of their secreted 
factors such as VEGFA, 
VEGFC 
77 
  Human Renal Cell 
Carcinoma 
Inhibits myeloid cell prolif-
eration. However, GM-CSF 
induced resistance of 
Sunitinib was found in intra-
tumor myeloid cells 
105 
  Human Recurrent 
Glioblastoma 
More severe hypoxia was 
induced, which increased 
macrophage infiltration 
80 
  Gastrointestinal 
stroma tumor 
(GIST) 
Promotes M1 macrophage 
secretion of IL-10 in vitro 
106 
  Human primary 
breast cancer 
Synergizes with α-GITR to 
induce anti-tumor macro-
phages via inhibition of 
STAT3 activity 
74 
Sorafenib VEGFR1-
3, PDGFR-
β, Raf-1, 
B-Raf, 
CSF-1R 
Hepatocellular 
Carcinoma 
Converts alternative TAMs 
to M1-like TAMs and in-
creases secretion of pro-
inflammatory cytokines  
70 
   Triggers macrophage-
mediated cytotoxic NK cell 
activation 
 
  Murine breast 
cancer 
Increases IL-12 and sup-
pression of IL-10 levels in 
macrophage 
71 
  Human peripheral 
CD14+ monocyte 
derived macro-
phage 
Induces apoptosis and au-
tophagy in macrophages  
108 
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  Mouse model for 
metastatic liver 
cancer model 
Increases peripheral and 
F4/80+ and CD11b+ macro-
phages recruitment and 
infiltration in cancer tissues 
109 
  Mouse breast 
cancer model and 
pancreatic β-cell 
tumor model 
Increases angiogenic and 
immunosuppressive mole-
cules. Can be blocked by 
PI3K Inhibitor IPI145 
81 
  Classical 
Hodgekin's Lym-
phoma 
Blocks CSF-1R activity   107 
Imatinib c-KIT Murine GIST mod-
el; Human GIST 
Shifts TAM into a more M2-
like pro-tumor phenotype 
macrophage 
110 
   Promotes M1 macrophage 
secretion of IL-10 in vitro 
106 
Cediranib  VEGFR1-3 Alveolar Soft Part 
Sarcoma (ASPS) 
Increases CD68+ and M2-
like TAMs and increases 
CD163, Tie-2, and CCL2 
mRNA levels  
111 
   Transiently decreases macrophage 
infiltration. Increases plasma VEG-
FA levels and CXCR4+ CD45+ im-
mune cells. 
  Murine glioma 
xenograft model 
Increase phosphorylation of 
STAT3 in macrophages. In 
combination with AZD1480 
JAK2 inhibitor, decreases 
the phospho-STAT3 positive 
macrophages  
89 
Axitinib VEGFR1-
3, PDGFR-
β and c-
kit 
Murine glioma 
xenograft model 
Inhibits metronomic cyclo-
phosphamide activated 
antitumor innate immunity 
and shifts TAM into a M2-
like phenotype 
91 
Erlotinib EGFR, 
ErbB1 
Human U937 cell 
line induced mac-
rophage 
Inhibits monocyte-
macrophage differentiation 
and proliferation 
76 
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   Non Small Cell 
Lung Cancer  
Administration of Erlotinib 
induces macrophage and 
other mononuclear cells 
infiltration into skin 
112 
Dasatinib EGFR, 
ErbB1 
Murine bone mar-
row-drived macro-
phage; RAW264.7 
cell line 
Induces macrophages with 
anti-inflammatory function 
by increasing IL-10 produc-
tion and suppressing TNF-α 
and IL-12p40 
113 
Bosutinib     
PLX3397 c-kit ,c-
fms inhib-
itor 
Malignant Periph-
eral Nerve Sheath 
Tumor 
Depleting Iba-1+ macro-
phages, combined with 
rapamycin lead to more 
severe depletion of tumor 
associated macrophages 
78 
  Recurrent gliobla-
toma 
Depleting CD11b+ cells and 
potentiating the response of 
the intracranial tumors to 
irradiation 
79 
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Table 2. Effects of monoclonal antibodies-based 
angiogenic therapies on TAMs 
  
Monoclonal 
antibodies based 
therapeutic 
agent 
Molecular 
target 
Tumor Type TAM effect Ref. 
Bevacizumab VEGFA Glioblastoma Induces Tie-2+ monocyte 
infiltration and vast infil-
tration of M2-like macro-
phages 
86 
   Increases phosphorylation 
of STAT3 in macrophages, 
promoting a tumor sup-
portive phenotype 
89 
Crossmab，A2V Angiopoietin-
2/VEGFA 
Bispecific 
 Transite TAM from M2-like 
phenotype to M1-like 
phenotype. Prolonging 
tumor-bearing mice sur-
vival time 
84 
 MEDI3617  Angiopoietin-
2 
 Promoting tumor vessel 
normalizaion and M1-like 
polarization of TAM when 
co-administration with 
cediranib 
83 
Cetuximab EGFR Colorectal 
Carcinoma 
Increases phagocytosis by 
macrophages to eliminate 
circulating cancer cells 
72 
   Activation of M2-like mac-
rophages  
85 
  Heck and 
neck cancer 
Ameliorates suppressive 
phenotypes of FcγR bear-
ing myeloid cells in cancer 
patients 
112 
Trastuzumab HER2  HER2 posi-
tive breast 
cancers 
Decreases CD68+ macro-
phages infiltration 
75 
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SR1 c-KIT Imatinib 
resistant 
GIST (Gastric 
Intestinal 
Stromal 
Tumor) 
Increases phagocytosis in 
macrophages  
73 
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CECR1 
CECR1 [1] is a secreted member of the adenyl-deaminase growth factor family. Mem-
bers of this family share similar functions with ADA (Adenosine Deaminase), which ena-
bles CECR1 to degrade adenosine to inosine in purine metabolism [2]. Homologs of 
CECR1 in other species like IDGF in flesh fly or MDGF in sea slug has been shown to also 
act as growth factors whose function requires their adenosine deaminase (AD) activity 
[3, 4]. Although little is known about the function of CECR1 in both invertebrates and 
vertebrates, it was shown to regulate immune function, maintaining hematopoietic 
stem cell pluripotency in Drosophila and regulate Xenopus embryogenesis via interact-
ing with Adenosine P1 receptor [5].   
 In humans, CECR1 was found to be expressed by the monocyte/macrophage sys-
tem[6]. CECR1 is activated in the context of hypoxia under a variety of pathologic cir-
cumstances in response to excessive extracellular adenosine [7]. Reportedly, higher 
production of CECR1 is detected in the serum and pleural fluid in patients with tubercu-
losis[8]. Similarly, in the serum of patients with breast carcinoma [9] and systemic 
erythroid lupus [10], CECR1 levels are higher than the physiological levels. CECR1 pro-
motes the differentiation of monocytes into macrophages and stimulates the prolifera-
tion of lymphocytes and macrophages [11]. Further, CECR1 was proven to bind with 
adenosine receptors serving as a mechanism in regulating macrophage differentiation 
and proliferation [12]. CECR1 anchors on the surface of monocytes / macrophages and 
lymphocytes via binding to adenosine receptors and HPSG [5]. Unlike ADA 1 that binds 
to CD26, CECR1 binds to CD39 on the surface of regulatory T cells, indicative of a role in 
mediating ATP hydrolysis and Adenosine biosynthesis [13]. In addition, CECR1 functions 
in the immune regulation by influencing the subpopulation of CD4+ T cells. In diabetic 
retinopathy CECR1 is highly expressed in macrophages, activated monocytes and in 
retinal microglia [14]. Elevated levels of CECR1 adenosine deaminase activity was found 
in several neoplasm [9, 15-17] and considered as a marker for regression of cancer after 
chemotherapy [18]. 
Recent studies strengthen the link of CECR1 with immune functions. Several somatic 
mutations in exons of CECR1 were found in patients with auto-immune diseases charac-
terized by early-onset lacunar stroke, severe peripheral vasculitis and systemic inflam-
mation [19-21]. Overproduction of pro-inflammatory factors like TNF-α, iNOS, IL-1β 
were detected in either patient serum or skin biopsies. Coincidently, in peripheral blood 
mononuclear cell (PBMC) of patients with CECR1 mutations, neutrophil gene signatures 
pointing to an altered immune response were recorded. In monocytes of these pa-
tients, CECR1 mutations caused IFN-γ responses featured by the expression of genes 
like ISG15, IFI27, IFI44L [22]. Data from in vitro experiments showed loss of CECR1 or 
CECR1 mutations in monocytic cell lines or patient derived monocytes causing blockage 
of the differentiation of monocytes into M2 macrophages in response to M-CSF, the 
main growth factor regulating the survival of macrophages [21]. Very little is known 
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about CECR1 expression in the microglia cells of the CNS and the contribution of CECR1 
in the development of glioma remains to be investigated. In this thesis, in Chapter 3, we 
investigated the contribution of CECR1 in the differentiation of specific tumor-
associated-macrophages (TAM) subtypes in glial tumors. Furthermore, we investigated 
in Chapter 4 the role of CECR1-mediated crosstalk between macrophages and vascular 
mural cells in angiogenesis in glioma. Proteosome adaptation of TAMS in response to 
CECR1 is also investigated in Chapter 6.  
PERIOSTIN 
Periostin is a member of the TGF family of which the expression is induced by TGF-β as 
well as BMP-2 [23]
.
. Periostin is an adhesion-related protein containing 4 repetitive 
conservative fasciclin domains that are similar in sequence to the insect protein fasci-
clin-1. As a matricellular protein, periostin is a multifunctional protein that regulates 
formation of the peridontal ligaments and the cardiac valves. It also contributes to bone 
morphogenesis[24]. Additionally, recent studies revealed that periostin is involved in 
various neoplasms including gastric cancer [25], colorectal cancer [26], pancreatic can-
cer [27] and cerebral tumors [28]. Periostin plays a role among extracellular matrix 
proteins in regulating the proliferation, migration and epithelial-mesenchymal transition 
of cancer cells [29]. Structurally, Periostin interacts with other ECM components like 
Tenascin-C [30] and bone morphogenic proteins 1/2 (BMP1/2) [31] which promote the 
remodeling of extracellular matrix by promoting the secretion of fibronectin [32] and 
collagen [31]. A wide spectrum of molecules can interact with periostin. The N-terminal 
region binds to the integrins αVβ+3,αVβ5,α6β4 through its FAS domain [29] thereby 
promoting the migration of tumor associated endothelial cells and cancer cells via the 
activation of Akt/PKB and Focal Adhesion Kinase(FAK)-mediated signaling pathways 
[33]. The intracellular domain of pre-NOTCH1 is recognized by periostin causing the 
activation of the Notch pathway [34]. Loss of Postn in the ErbB2/Neu-driven mouse 
breast tumor models results in a reduced Notch signaling pathway and deceleration of 
tumor growth [35].   
Periostin was shown to be expressed by the stromal cells like fibroblast in the mi-
croenvironment of breast cancer and enhances the metastatic potential of breast can-
cer cells [36]. Canonical Wnt signaling is activated by periostin by its interaction with 
Wnt3/4 and LRP5/6. The signal of periostin, secreted by tumor stroma, particularly by 
tumor associated fibroblasts, is vital in maintaining the breast cancer stem cells. In addi-
tion, during breast cancer-associated angiogenesis the so-called tip cells (endothelial 
cells that navigate the branching of newly formed vessels), transiently express periostin 
as well. As a consequence, periostin promotes the resuscitation and proliferation of 
perivascular located metastatic breast cancer cells [37]. In GBM, periostin is overex-
pressed and deposited in the neuropil. The expression of periostin in GBM is reversely 
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related to clinical outcome (Disease free survival and overall survival) [38]. Glioma stem 
cells defined by SOX-2 and Oligo-2 also produce periostin. Through interaction with 
Integrin αVβ3 on the surface of monocytes, peripheral monocytes are recruited by 
glioma stem cells that express periostin and subsequently differentiate into M2-like 
macrophages [39]. In GBM samples periostin expression is foremost perivascular and it 
appears that cells with the phenotype of pericytes express this protein [40]. In mice, cell 
types that express periostin have been reported to include pericytes and glioma stem 
cells (GSCs). Periostin interaction between GSCs, pericytes, TAMs and perhaps other 
cells of the perivascular niche, may contribute to glioma growth and tumor angiogene-
sis. 
In Chapter 5 the expression of periostin in human gliomas is detailed and its contri-
bution to neo-angiogenesis is studied in an in vitro model of angiogenesis.   
 
P2RY12 
 
The receptor P2RY12 was proposed as a specific marker for healthy rodent CNS micro-
glial cells, rather than any other type of tissue resident macrophages or blood-derived 
monocytes [41]. P2RY12 belongs to the family of P2 purinergic receptors, consisting of 
seven transmembrane G protein coupled receptors (GPCRs) that have been implicated 
to contribute to ATP-and ADP-mediated cell migration in vitro [42]. Except for expres-
sion in activated platelets [43], P2RY12 was found to be mainly expressed by microglial 
cells. P2RY12 deficiency in P2RY12 knockdown mice significantly compromised microgli-
al chemotaxis and extension of microglial foot processes in response to CNS injury [44, 
45]. In Chapter 7, we aimed to label glioma samples with P2RY12 to distinguish the 
expression of CECR1 by either resident microglia, or recruited/infiltrated macrophages. 
We found that P2RY12 is a consistent marker for resident microglial cells in low grade 
glioma. However, the P2RY12 signal tends to translocate from cell surface to the nucle-
us in high grade glioma. We also investigated the relation between the expression of 
the marker and the M1/M2 profiles of the microglial cells, and the relation with malig-
nant behavior of the gliomas.  
 
OBJECTIVES AND OUTLINE OF THIS THESIS 
 
The scope of this thesis is to elucidate the role of the CECR1 molecule on angiogenesis, 
and specifically, glioma neo-angiogenesis. In Chapter 3 and 4, the expression, distribu-
tion, localization and function of CECR1 in glioma-associated macrophages is described. 
The influence of CECR1 through macrophage-mediated paracrine effects on glial cell 
proliferation and migration, and on glioma angiogenesis is demonstrated. In Chapter 6, 
proteomic analysis revealed the CECR1 mediated intracellular pathways that contribut-
ed to the observed M2-like TAM phenotype associated with CECR1 expression.  In addi-
tion, the cell types that express CECR1 are pin-pointed and their position among other 
immune-regulating cells and the cells engaged in the formation of blood vessels (endo-
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thelial cells, pericytes and other mural cells) is studied in detail. In Chapter 5 the expres-
sion of periostin in human gliomas is detailed and its contribution to neo-angiogenesis is 
studied in an in vitro model of angiogenesis. In Chapter 7, we investigated the subpopu-
lation of microglial cells in glioma using the P2RY12 marker.  
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CECR1 in M2-like TAMs promotes glioma progression 
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ABSTRACT 
Background: The majority of glioma associated microglia/macrophages have been iden-
tified as M2-type macrophages with immune suppressive and tumor supportive action. 
Recently, the extracellular adenosine deaminase protein Cat Eye Syndrome Critical 
Region Protein 1(CECR1) was shown to regulate macrophage maturation. In this study, 
we investigate the role of CECR1 in the regulation of the glioma-associated macrophage 
response. 
Methods: Expression of CECR1 was assessed in human glioma samples. CECR1 mediated 
macrophage response was studied in vitro, using donor derived CD14+ monocytes and 
THP-1 monocytic cell line. The response of human glioma cell line U87 to conditioned 
medium of macrophages preconditioned with recombinant human (rh)CECR1 or CECR1 
silencing was also assessed.  
Results: CECR1 was strongly expressed in high-grade gliomas (P<0.001) and correlated 
positively with that of the M2 phenotype markers in tumor associated micro-
glia/macrophages (TAMs) (overall, P<0.05). In vitro studies confirmed the presence of a 
significant higher level of CECR1 expression in M2-like macrophages exposed to U87 
conditioned medium (P<0.001). CECR1 knockdown or stimulation of macrophages af-
fected differentiation towards the M2-like phenotype. Stimulation of U87 cells with 
conditioned medium of CECR1 knockdown or stimulated macrophages affected tumor 
cell proliferation and migration, coinciding with altered intracellular MAPK signaling. In 
glioma tissue samples. CECR1 expression correlated with Ki67 and MAPK signaling pro-
tein. 
Conclusions: CECR1 is a potent regulator of TAM polarization, and is consistently highly 
expressed by M2-type TAMs, particularly in high-grade glioma. Paracrine effects in-
duced by CECR1 in M2-like TAMs activate MAPK signaling and stimulate the prolifera-
tion and migration of glioma cells.  
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INTRODUCTION 
The heterogeneity of glial tumor cells and the immune privileged environment of the 
central nervous system hamper the development of effective treatment strategies. The 
immune system plays a complex and largely undiscovered role in the development of 
gliomas. Infiltrating myeloid cells including monocytes and macrophages are key players 
in promoting tumor progression and recurrences
1,2
, as their robust presence with the 
accumulation of microglial cells in GBM facilitate an immune suppressive and oncogenic 
micro-environment. Macrophages in GBM are heterogeneous and display considerable 
plasticity, complicating their characterization and analysis
2
. To ease data interpretation, 
tumor associated macrophages (TAMs) are divided in M1- and M2-like cells. M1-like 
cells express high levels of CD80, CD86, MHC II molecules and secrete higher levels of 
TNF-α, IL1β and IL-12. M1-like TAMs are reportedly anti-tumoral and associated with 
better prognosis
3,4
. However, it has been reported that (paracrine) stimulation of glial 
tumor cells and the hypoxic microenvironment trigger resident microglial cells and infil-
trating macrophages to adopt the M2-like phenotype
5
. Indeed, M2-like TAMs outnum-
ber their M1 counterparts in GBM. M2-like TAMs are defined by high cell surface levels 
of CD163, CD204, CD14; lower levels of CD80 and MHC II, and mediate the immuno-
suppressive response by secreting cytokines like IL-10, CCL20, CCL22, and PGE2
5
. M2-
like glioma associated microglia/macrophages are also known to mediate tumor angio-
genesis by producing pro-angiogenic factors such as VEGFA, and uPA and are associated 
with high-grade tumors and poor clinical outcomes
6,7
. Thus, microglial/macrophages are 
relevant to glial tumorigenesis and could become targets of therapeutic intervention. 
In humans, the Cat Eye Syndrome Critical Region Protein 1 (CECR1) is highly ex-
pressed by monocyte/macrophage
8
. Recent reports indicate that in patients with genet-
ic loss of function of CECR1, monocyte maturation and polarization into M2 macro-
phage subtype are reduced, coinciding with loss of vessel integrity
9
’
10
. CECR1 is an evo-
lutionary highly conserved member of the adenyl-deaminase growth factor family, 
known for its immune modulatory function
11
. To date, the role of CECR1 in TAMs regu-
lation in gliomas has not been explored. In this study, we investigated the role of CECR1, 
specifically with respect to TAMs, in glial tumors. 
MATERIAL AND METHODS 
Patient samples  
Patient samples as listed in Supplementary table 1 and 2 and were obtained from the 
Biobank of the Department of Pathology, Erasmus MC, Rotterdam. The use of these 
samples was approved by the medical ethical committee of the Erasmus Medical Cen-
ter. 
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siRNA transfection 
SiRNA targeting CECR1 and scrambled non-targeting siRNAs were obtained from Dhar-
macon (GE health care, Netherland). THP-1 derived macrophage cultures were trans-
fected after 48 hours of PMA treatment, following the manufacture’s protocol (using 
Dharmafect transfection reagent). Efficiency of CECR1 knockdown was assessed after 24 
and 48 hours at transcriptional level and protein level (see supplements). For functional 
assays or to obtain Macrophage-derived conditioned medium, siRNA transfected cells 
were used 24 hours post transfection. 
Cell Cultures 
CD14+ monocytes were obtained according to manufacturer’s protocols. Cells were 
induced with 10 ng/ml GM-CSF (R&D, United States) or 10 ng/ml M-CSF (Immunotools, 
Germany) as previously reported
12
.  
THP-1 cells were cultured in RPMI-1640 supplemented with antibiotics and 10% FCS 
and matured by PMA (sigma, Sweden). IFN-γ/LPS, IL-4 and IL-10 were applied to gener-
ate M1, and M2a/M2c phenotypes in vitro. rhCECR1 was used for macrophage treat-
ment for 96 hours. 
Human glioblastoma cell lines U87, U373, and U251 were cultured in DMEM medi-
um supplemented with 10%FCS and antibiotics. U87-derived conditioned medium (U87-
CM) was used to stimulate macrophages for 48 hours. 
MTT Assay 
U87, U373, and U251 cells were seeded in 96-well setup followed by treatment with 
macrophage-conditioned medium. The growth of U87 cells was monitored by MTT 
(Sigma, Sweden) for five days. One plate without macrophage conditional medium was 
measured at the same day for reference (see Supplements).  
Migration Assay 
The Oris cell migration assay kit (Platypus Technologies, United States) was used to 
measure migration of PKH-67 labeled U87, U373, and U251 cells according to manufac-
turer’s protocols in 96-well plate setup. Macrophage conditional medium was added 
and after 24 hours of incubation, pictures were taken at 0 and 24 h and quantified using 
image J. (see Supplements). 
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RNA isolation and Quantitative real-time PCR 
Total RNA was isolated and reversely transcripted to cDNA from cryo-materials and 
macrophages. For the cryo-samples, transcripts of CECR1, CD68, CD86, CD16, CD204, 
CD206, NOS-2, IL-10, IL-12p35 and -actin (reference gene) were measured. For in vitro 
experiments, transcripts of CECR1, IL-10, IL-12p35, IL-6, CXCL12, CCL18 and CCL22 were 
measured and normalized to -actin level. Primers are listed in supplemental Table 3 
(see Supplements). 
Western blot analysis  
Total protein was loaded onto SDS-PAGE gel and blotted to Nitro cellulose membranes 
followed by blocking and immunoblotting using specific antibodies. Incubation of sec-
ondary antibodies and detection of signals was followed using the Odyssey imaging 
system (Licor Bioscience, USA) (See Supplements).   
Flow cytometry analysis 
Macrophages were harvested and incubated with primary antibody against CD163 (Abd 
Serotec, 1:400) followed by Alexa Fluor-555 conjugated secondary antibody. Cells were 
counterstained with Hoechst 33258 and analyzed with a BD FACS Aria III. (See Supple-
ments). 
Immunostaining 
Adjacent (cryo)sections were used for immunohistochemical and immunofluorescence 
analysis. Immunostaining and slide scanning were performed according to the protocol 
described previously
13
.  
Macrophages and U87 cells were fixed using 4% PFA/PBS, followed by antibody in-
cubation. Signal areas were quantified using Image J (See Supplements and Supple-
mental Table 4). 
Statistics 
Data from clinical samples were analyzed by Mann-Whitney U test and Spearman Corre-
lation using SPSS 21.0. All in vitro data were tested using unpaired two-tailed student’s T 
test (Significance levels P<0.05). All data are presented in Mean ± S.E.M. unless other-
wise stated.  
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RESULTS 
Expression of CECR1 is skewed to high-grade astrocytoma and associated with 
the M2-like macrophage phenotype 
Transcription of CECR1 was assessed in astrocytomas of various malignancy grades, 
using 2 different online GEO database (GDS 4467, GDS1813). CECR1 was mainly ex-
pressed in GBMs (Supplementary Figure 1a). QPCR analysis of astrocytoma samples 
from our biobank (19 astrocytomas grade II, 5 astrocytomas grade III, and 19 GBMs) 
shows that expression of the M2-microglia/macrophage specific markers CD16, CD204 
and IL-10 was significantly higher in the astrocytomas grade III and GBM than in the 
grade II astrocytomas (Supplementary Figure 1b). The microglia/macrophage markers 
CD68 (pan macrophage marker), CD86 (M1 marker), CD206 (M2 marker), iNOS (M1 
marker), and IL-12p35 (M1 marker) were equally expressed in the low and high grade 
tumors (Supplementary Figure 1c, d). Seven autopsy brains, 6 astrocytomas grade II, 
and 8 astrocytomas grade IV (GBM) were immunostained for CECR1, CD204, CD206 and 
CD16. CECR1 overlapped with CD204+, CD206+, and CD16+ perivascular cells in autopsy 
brain and low grade glioma (Figure 1a, Supplementary Figure 2a).  In GBM, the CECR1 
signal mainly overlapped with CD204+ and CD16+ cells at both perivascular and in the 
tumor parenchymal locations. Areas where CECR1 negative cell with features of M2-like 
macrophages located were also detected (Supplementary 3a,b). Overlap between 
CECR1 and CD206+ cells was only detected at the peripheral perivascular locations. 
Quantitation of the sections revealed significant higher numbers of CECR1, CD204, 
CD206, CD16+ cells in GBM versus the autopsy brains and astrocytomas grade II (Figure 
1b, Supplementary Figure 2b). 
qPCR dataset showed  in astrocytomas grade III and IV (GBM) positive correlations 
of CECR1 expression with CD68, CD86, CD16, CD204, and IL-10. In astrocytomas grade 
III, CECR1 expression showed a negative correlation with IL-12p35. In contrast, no signif-
icant correlations between the markers iNOS, IL-12p35, CD206 and CECR1 was detected 
in high grade GBM samples (Figure 1c).  
In GBM, CECR1 co-localized with the pan macrophage markers CD68 and Iba-1 (Fig-
ure 1d). CECR1 co-localized with CD68 in both perivascular areas and sites remote from 
the vasculature in autopsy brains (Supplemental Figure 4a-d), but only at perivascular 
locations in grade II astrocytoma (Supplemental Figure 4e, f). No CECR1 signal was de-
tected in CD68+ macrophages remote from blood vessels (data not shown). In addition, 
CECR1 co-localized with markers of M2-like TAMs (CD204, CD163, CD16) in GBM  (Fig-
ure 1e and f , Supplementary Figure 2c and d). CECR1+/CD163+ cells were only detected 
in the perivascular areas in autopsy brains and in astrocytomas grade II (Supplemental 
Figure 5a-d). 
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Figure 1 CECR1 is highly expressed by M2-like macrophage in GBM  
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(a) Immunohistochemistry for CECR1, CD204, and CD206 in autopsy brain, astrocytoma grade II (AII) and 
grade IV (GBM) (scale bar: 200 µm). (b) Box plots displaying the mean percentages of CECR1, CD204, CD206 
positive areas per image view in autopsy brains, AII and GBM. * P<0.05, ***P<0.005. (c) Heat map summariz-
ing the Spearman correlation coefficients between CECR1 and CD68, IL-12p35, iNOS, CD86, CD206, CD16, 
CD204, IL-10 in autopsy, astrocytoma grade II and III and GBMs. * P<0.05, ** P<0.01. (d) Confocal images 
showing the co-localization of CECR1 with CD68 and Iba-1 in GBM (scale bar: 20 µm). (e) (f) Confocal images 
showing the co-localization of CECR1 with CD204, CD163 in GBM (scale bar: 50 µm for the low magnification 
field; 10 µm for high magnification inlet). 
CECR1 is preferentially expressed in M2-like U87 stimulated macrophages in 
vitro 
M-CSF induced (M2-like) macrophages showed a higher protein level of CECR1 than 
GM-CSF induced (M1-like) macrophages (figure 2a). This was coincided by higher pro-
tein levels of M2 phenotype markers (CD204, CD163) and higher mRNA levels of M2 
cytokines (IL10, CXCL12) (supplementary figures 6 a-d).    
CECR1 protein levels in both types of macrophages were further up-regulated in re-
sponse to stimulation with U87 conditioned medium (U87-CM)(1.4 and 2.4 fold increase 
in GM/M-CSF induced macrophage respectively, figure 2a). Similarly, expression of 
CECR1 was detected in THP-1 derived macrophages (figure 2b). Elevated levels of CECR1 
protein were detected in M2a and M2c macrophages (1.2 and 1.6 fold increase in IL4 
and IL-10 stimulated groups respectively) and U87-CM stimulated macrophages (1.8 
fold increase) compared to control (RPMI) group. In contrast, in M1 macrophages 
(LPS+INF group), a lower level of CECR1 (0.8 fold change) was detected (figure 2b).    
CECR1 protein levels were further assessed in GM/M-CSF induced macrophages 
(Figure 2c and d). CECR1 protein detected by immunostaining was significantly higher in 
M-CSF induced (M2-like) macrophages than in GM-CSF induced (M1-like) counterparts. 
Furthermore, stimulation of U87-CM increased CECR1 protein levels in both M-CSF and 
GM-CSF induced macrophages and enhanced protein signal of M2 marker CD163 (Fig-
ure 2c, d). 
CECR1 expression induces the M2-like macrophage phenotype in vitro  
Effective siRNA mediated silencing of CECR1 was validated by qPCR, Western blotting 
and immunofluorescent staining (Figures 2e and f, and Supplementary Figure 7a and b) 
as compared to non-targeting siRNA treated controls (siSham).  
In THP-1 macrophage with siCECR1 condition, lower protein levels of M2 marker 
CD163 compared to siSham conditions was detected, as observed by qPCR, Western 
blot analysis and cell immunostaining (Supplementary Figure 7c and Figure 2g, h, i), and 
mRNA level of M2 marker IL-10 and M1 marker CD86 were significantly decreased and 
increased upon CECR1 silencing, respectively (Figure 2i). Stimulation with rhCECR1 
raised CD163 transcript and protein levels in THP-1 macrophages in a dose responsive 
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manner (Figure 3a and b). Similar observations were made at the protein level using the 
M-CSF induced 
 
Figure 2. CECR1 is highly expressed in M2-like, U87 stimulated macrophage 
 
(a) Western blot of CECR1 protein in GM/M-CSF induced macrophages (MΦ) with/without U87-CM from 
three experiments. Numbers above bands indicate quantified levels normalized to -actin. (b) Western blot of 
CECR1 protein in THP-1 derived macrophages (MΦ) in response to RPMI-1640, LPS-INF (M1), IL-4 (M2a), IL-
10 (M2b), and U87-CM from three experiments. Numbers above bands indicate quantified levels normalized 
to β-actin. (c) Representative staining of CECR1 and CD163 in GM-CSF and M-CSF induced macrophages 
with/without U87 stimulation for 96 hours. (scale bar: 20 µm). (d) Quantification of fluorescent signal of 
CECR1 per cell in different groups. Data are presented as mean ± S.E.M. and were obtained of three inde-
pendent experiments. *P<0.05, **P<0.01, *** P<0.005. (e) qPCR of CECR1 in macrophages with CECR1 
knockdown and control were obtained from three experiments and presented as mean ± S.E.M. *P<0.05. (f) 
Western blot of CECR1 protein in THP-1 macrophages with siCECR1, siSham, and non-transfected control. (g) 
CD163 immunostaining in siCECR1 and sisham transfected THP-1 macrophages. (scale bar: 20 µm). (h) Quanti-
fied CD163 signal per cell in siCECR1 and siSham control groups are presented as mean ± S.E.M. and were 
obtained of three independent experiments. ** P<0.01. (i) IL-10, CD163, and CD86 expression in siCECR1, 
siSham, and non-transfected THP-1 macrophages as measured by RT-qPCR. Data are presented as mean 
±S.E.M. and obtained from three experiments. *P<0.05. 
 
(M2-like) macrophages (Figure 3c-e). FACs further confirmed that cell surface expres-
sion of CD163 increased in M-CSF induced macrophages following treatment with 
rhCECR1 during M2 macrophage differentiation (Supplementary Figure 7d). Enrichment 
of CD163+ cells was observed in the GBM samples with high CECR1 signal (>5% CECR1+ 
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area per image view), as compared to those with low CECR1 signal (<5% CECR1+ area 
per image view) (Supplementary Figure 7e and f). More CD204+ (M2-like) cells were 
detected in the samples with high CECR1 signal (Supplemental Figure 8a, b). 
 
Figure 3 CECR1 promotes macrophage towards a M2-like phenotype 
 
(a) Western blot of CD163 in THP-1 derived macrophages treated with rhCECR1 for 96 hours. Numbers above 
bands indicate quantified protein levels normalized to -actin. (b) QPCR analysis of CD163 expression in THP-1 
macrophages treated with rhCECR1. Data are from three experiments, normalized to β-actin, presented as 
mean ± S.E.M. *P<0.05, ***P<0.005. (c) Representative CD163 immunostaining of M-CSF induced macro-
phages with or without stimulation with CECR1 (100 nM), for 96 hours. Experiments were repeated three 
times independently. (scale bar: 100 µm) (d) Representative western blot of CD163 in M-CSF induced macro-
phages with or without CECR1 stimulation for 96 hours from three experiments. Numbers above bands indi-
cate quantified protein normalized to β-actin. (e) Quantified CD163 intensity in M-CSF induced macrophages 
with or without CECR1 (100nM) stimulation is shown in mean ± S.E.M. ***P<0.005. (f) QPCR analysis of M2-
macrophage associated genes; IL-10, CXCL12, CCL18, CCL22, IL-6 and inflammatory gene IL-12p35 in THP-1 
derived macrophages treated with CECR1 for 96 hours. Data normalized to β-actin are of three independent 
experiments and shown as mean ± S.E.M. *P<0.05 **P<0.01. (g) QPCR analysis of IL-10, CXCL12, CCL18, IL-6, 
IL-12p35 in M-CSF induced macrophages treated by CECR1(100nM) for 96 hours. Data are of three experi-
ments and shown as mean ± S.E.M. in fold change compared to the CECR1 free condition. *P<0.05 **P<0.01. 
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Cytokines specifically expressed by M2-like TAMs or M1-like macrophage were se-
lected for qPCR analysis. In response to rhCECR1, THP-1 macrophages demonstrated a 
dose responsive up-regulation of CD163, IL-10, CXCL12, CCL18, and CCL22. Increased IL-
6 was only observed in response to the highest concentration of rhCECR1 (Figure 3f). 
RhCECR1 stimulation of M-CSF induced macrophages also induced expression of CD163, 
IL-10, CXCL12, CCL18 and IL-6 (Figure 3g), but suppressed expression of CCL22 (Figure 
3g). The difference in CCL22 may be the result of intrinsic differences between THP-1 
derived macrophages and M-CSF induced macrophages
14
. In contrast, rhCECR1 lowered 
expression of M1 cytokine IL-12p35 in both THP-1 and peripheral M2 macrophages 
(Figure 3f, g). 
CECR1 regulates proliferation and migration of glioma cells via M2-like 
macrophages  
In malignant tumors, macrophage leads to tumor progression
15
. We first confirmed the 
effects of conditioned medium derived from THP-1 macrophages on the proliferation 
rate of three commonly used GBM cell lines
16-18
, U87, U373, and U251 cells.  These cell 
lines have been previously used in macrophage studies
19,20
. GBM cells that received 
conditioned medium from rhCECR1 treated THP-1 macrophages presented higher pro-
liferation rates (Supplementary Figure 9a and b and Supplementary Figure 10a and b).  
GBM cells treated by MФ-CM from THP-1 macrophage with CECR1 silencing (siCECR1 
CM) showed a significant lower proliferation rate than cells stimulated with MФ-CM 
from THP-1 macrophage with siSham treatment (siSham CM) (Figure 4b, Supplementary 
Figure 10a and b). A significant reduction in Ki67 was observed in U87 and U251 ex-
posed to siCECR1 CM in comparison to those exposed to siSham CM (Figure 4d and f; 
Supplementary Figure 10c and d). U87 and U251 cells treated with medium from THP-1 
macrophages exposed to rhCECR1 resulted in rising levels of Ki67 (Figure 4d and f; Sup-
plementary Figure 10c and f). Direct stimulation with rhCECR1 without macrophages did 
not affect the proliferation rate of U87 cells (Supplementary figure 13a). 
Next, all three GBM cell lines were exposed to siCECR1 CM to assess the effects on 
cell migration. SiCECR1 CM induced a weaker migration response than exposure to 
siSham CM (figure 4c). Medium derived from rhCECR1 treated THP-1 macrophages 
enhanced migration of GBM cells (Supplementary Figure 9c and d; Supplementary Fig-
ure 11 and 12).  
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Figure 4 CECR1 in macrophages regulates proliferation and migration of U87 cells 
 
(a) Representative images of U87 cells with/without treatment of macrophage conditioned medium (MΦ-
CM) at day 1,3 post stimulation of three experiments. (scale bar: 200 µm). Data are obtained from three 
experiments (n=6 each) and presented as mean ± S.E.M. in fold change compared to MΦ-CM free condition. 
*P<0.05 ***P<0.005. (b) Representative figures of U87 cells with treatment of MΦ-CM from non-targeting 
sisham or siCECR1 transfected macrophages. Pictures were taken at day 1, 3, 5 post stimulation (scale bar: 
200 µm). Data are represented of three experiments (n=6 for each), and presented as mean ± S.E.M. in fold 
change compared to U87 cells exposed to MΦ-CM of siSham treated macrophages. *P<0.05 ***P<0.005. (c) 
Left panel: representative pictures of U87 migration into the detection zone (indicated by the white circle) 
after stimulation with MΦ-CM from macrophage with sisham and siCECR1 (scale bar: 200 µm). Right panel: 
Quantification of fluorescent cells in the migration zones in sisham and siCECR1 MΦ-CM conditions. Data are 
represented of three experiments and presented as mean ± S.E.M. *P<0.05. (d) Representative images of Ki67 
staining in U87 cells, which were treated with MΦ-CM from siSham and siCECR1 transfected macrophages 
for 48 hours (scale bar: 100 µm). (e) Representative pictures of Ki67 staining in U87 cells, which were treated 
with MΦ-CM for 48 hours from macrophages treated with rhCECR1 for 96 hours (scale bar: 100 µm). (f) 
Quantification of Ki67 staining in U87 cells treated with different MΦ-CM for 48 hours. Left graph: Ki67 signal 
distribution of U87 cells treated with MΦ-CMs of sisham and siCECR1 macrophages. Right graph: Ki67 signal 
distribution of U87 cells treated with MΦ-CMs of macrophages that were stimulated by CECR1. Data are of 
three experiments. Chi-square test was for analysis. ***P<0.005. 
Chapter 3 
50 
CECR1 expression in macrophages mediates paracrine activation of the MAPK 
signaling in U87 and U373 glioma cells  
The mitogen activated protein kinase (MAPK) pathway, consisting of ERK 1/2, JNK/SAPK 
and P38 signaling, are the most recognized and important signaling pathways for the 
modulation of key cancer cell responses
21
. It plays crucial roles in tumor cell survival and 
motility
22
.  
Serum-free medium starved glioma cells (U87 and U373) were stimulated for 10 and 
20 minutes by siCECR1 CM or siSham CM.  Phospho-ERK1/2/ total ERK1/2 and phospho-
JNK/SAPK /total JNK/SAPK ratios decreased in U87 and U373 cells exposed to THP-1 
siCECR1 CM (Figure 5a-d and Supplementary 14 a-d). The transcription factor c-Jun is a 
potential downstream target of JNK/SAPK. Phospho-c-Jun (Ser73)/total c-Jun ratio was 
reduced in the U87 and U373 cells exposed to THP-1 siCECR1 CM (Figure 5e-f, and Sup-
plementary Figure 14e-f). Immunostaining for phospho-c-Jun showed a reduced signal 
in U87 with THP-1 siCECR1 CM treatment (Figure 5g and h).  
In contrast, medium derived from THP-1 macrophages treated with rhCECR1 in-
creased phospho-protein/total protein ratios of both ERK1/2 and JNK/SAPK (Supplemental 
Figure 15c and d) in U87 cells. Direct rhCECR1 treatment of U87 cells without macrophage 
mediation did not increase phospho-ERK1/2 and phospho-JNK/SAPK ratios (Supplemen-
tary Figure 13b). These data indicate that the MAPK signaling pathways in U87 and U373 
cells are activated by CECR1-mediated paracrine effect from macrophages. 
Expression of CECR1 correlates with increased levels of Ki67 positive cells and 
phosphorylation of ERK1/2 and JNK/SAPK in patient GBM samples 
Thirty-three GBM surgical samples were selected for immunohistochemical evaluation 
and divided into two groups based on the median of the percentage of CECR1+ area per 
image view in all samples (Figure 6a-c). The number of Ki67 positive cells and percentage 
of positive areas for phospho-ERK1/2, phospho-JNK/SAPK, and phospho-c-Jun(ser73) 
proteins were analyzed and compared between the two groups (Figure 6a-c). A signifi-
cant higher number of Ki67+ cells were counted in the samples with high CECR1 signal 
(Figure 6c). The number of Ki67 positive cells is positively correlated with the percentage 
of CECR1+ area (Figure 6d). In addition, phospho-ERK1/2, phospho-JNK/SAPK, and phos-
pho-c-Jun signals were significantly higher in the CECR1 high group. The ratios of the 
phospho-ERK1/2/total ERK1/2, phospho-JNK/SAPK/total JNK/SAPK and phospho-c-
Jun/total c-Jun signals correlated positively with the percentage of CECR1+ area in GBM 
samples (Figure 6d). In addition, phospho-ERK1/2/total ERK1/2, phospho-JNK/SAPK/total 
JNK/SAPK, and phospho-c-Jun/total c-Jun signals were positively correlated with the 
number of Ki67 positive cells in GBM specimens (Supplementary Figure 16). 
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Figure 5 CECR1 function in macrophages activates the MAPK pathway in U87 cells 
 
(a) Western blot of phospho-ERK1/2 and total ERK1/2 in U87 cells at 10 and 20 minutes after stimulation with 
MΦ-CM from siSham and siCECR1 transfected macrophages. (b) Phospho-ERK/Total ERK ratios are presented 
as mean ± S.E.M. in fold change compared to MΦ-CM derived of macrophages with non-targeted siRNA 
(siSham) and siRNA targeting CECR1 (siCECR1) from five experiments. *P<0.05. (c) Western blot of phospho-
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JNK/SAPK and total JNK/SAPK protein in U87 cells at 10 and 20 minutes after stimulation with MΦ-CM de-
rived from siSham and siCECR1 transfected macrophages. (d) Phospho-JNK/Total JNK ratios are presented as 
mean ± S.E.M. in fold change compared to MΦ-CM derived of macrophages with non-targeted siRNA (si-
Sham) and siRNA targeting CECR1 (siCECR1) from three experiments. *P<0.05. (e) Western blot of phospho-/ 
total c-Jun in U87 cells at 10 and 20 minutes after stimulation with MΦ-CM derived from siSham and siCECR1 
siRNA transfected macrophages. (f) Phospho-c-Jun/Total c-Jun ratios are presented as mean ± S.E.M. in fold 
change compared to MΦ-CM derived of macrophages with non-targeted siRNA (siSham) and siRNA targeting 
CECR1 (siCECR1) from three experiments. *P<0.05. (g) Representative immunostainings of phosphor-c-Jun in 
U87 cells of two experiments. U87 were stimulated with MΦ-CM derived from siSham and siCECR1 trans-
fected macrophages for 15 and 30 minutes (scale bar: 100 µm). (h) Quantified phosphor-c-Jun in U87 cells 
were obtained from 200 randomly selected cells and presented as mean ± S.E.M in each condition. **P<0.01, 
***P<0.005. 
 
Figure 6 CECR1 correlates with Ki67, MAPK signals in GBM samples 
 
(a) (b) Representative figures of GBM samples immunostained for CECR1, Ki67, phospho-/total ERK1/2, phos-
pho-/ total JNK, phospho-/ total c-Jun are shown (scale bar: 100 µm). (c) Left graph: Quantificatified CECR1 
staining level (%CECR1+ area per image view) in CECR1 high and low groups are presented as mean ± S.E.M. 
***P<0.005. Middle graph: Quantificatified Ki67 in CECR1 high and low group are presented as mean ± S.E.M. 
***P<0.005. Right panel: Ratios of phospho-ERK/total ERK, phospho-JNK/total JNK and phospho-c-Jun/total c-
Jun. Data are presented as mean ± S.E.M. ***P<0.005. (d) Correlation between %CECR1+ area with ratios of 
phospho-ERK/total ERK, phospho-JNK/total JNK, phospho-c-Jun/total c-Jun and numbers of Ki67+ cells. 
Spearman correlation co-efficient and P value are shown. 
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DISCUSSION 
The main findings of the current study are: (a) CECR1 is highly expressed in GBM. (b) 
CECR1 expression is enhanced in M2-like TAMs compared to M1-like TAMs. (c) CECR1 
induces macrophage differentiation towards a M2-like phenotype. (d) CECR1 activity in 
TAMs mediates tumor glioma cell proliferation and migration, possibly by activating the 
MAPK pathway in tumor cells.   
The main function of CECR1 is the conversion of extracellular adenosine to inosine 
by removing an amino-group and replacing it with a hydroxyl group
23
. CECR1 was re-
ported to bind to and activate adenosine receptors A2AR and A2BR
24
. Adenosine is well 
known for its anti-inflammatory effect on classical M1 activation, limiting the produc-
tion of pro-inflammatory factors as TNF, and IL12, and increasing the production of 
anti-inflammatory cytokines including IL10
25,26
. LPS stimulation of Macrophage upregu-
lates adenosine receptor A2AR, which probably increases the sensitivity of M1 macro-
phages to adenosine. This further amplifies the anti-inflammatory effect of adenosine 
and mediates a switch towards a more “mild” M2 phenotype
27
. In addition, in line with 
the present findings, monocytes from patients with CECR1 deficiency were able to dif-
ferentiate into M1-, but not M2 macrophages. Therefore, the intrinsic (genetic or epi-
genetic) ability of monocyte/macrophages to produce high or low levels of CECR1, could 
be an important determinant for M2 or M1 polarization capacity. Especially, in GBM. we 
hypothesized that low levels of CECR1 produced by M1-like macrophages are not able 
to reduce local GBM extracellular adenosine levels, thus a predominant M2-like pheno-
type would be induced by adenosine. Alternatively, higher level of CECR1 produced by 
M2-like macrophages could amplify the signaling of A2AR and A2BR
28
 in both M1/M2-like 
macrophages, further promoting a predominant M2-like macrophage population. 
The effects of CECR1 knockdown in vitro were modest, contrasting to the strong cor-
relation between CECR1 protein expression levels and phospho-JNK and phospho-
ERK1/2 levels found in the tumor samples. This discrepancy could be explained by the 
isolated conditions in our experimental set-up in vitro. We designed the study to inves-
tigate the direct paracrine effects of CECR1 modulation in macrophages on GBM cells 
response, and chose to use conditioned medium derived from the siCECR1 treated 
macrophages to stimulate GBM cells. In vivo, direct interaction with CECR1
high
 express-
ing macrophages with the surrounding tumor environment, including tumor cells and 
other (inflammatory) cells such as subsets of CD3+ T cells
29
, microglia
2
, and neutro-
phils
30
, could further enhance JNK and ERK signaling. 
The immune modulating function of CECR1 discovered in the study is underscored 
by other data on CECR1. Schep at al. demonstrated that a CECR1 heterozygous muta-
tion is associated with respiratory infections and common variable immunodeficiency 
(CVID) in an index patient with immune dysregulation
31
. Recessively inherited CECR1 
mutations that were deleterious for protein function have also been shown to cause 
systemic vasculopathy and early-onset of lacunar strokes in affected patients
9,10
. This 
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phenotype was further validated in zebrafish models in which knockdown of the 
zebrafish homologue of CECR1 caused intracranial hemorrhages and neutropenia. The 
link between immune modulation and the vasculopathy phenotype was further 
strengthened by a report on two patients with biallelic CECR1 mutations and histories of 
vasculitis and intracranial hemorrhages
32
. In the present study CECR1 expressing im-
mune cells were observed at the perivascular areas of the lower-graded gliomas, while 
in the GBMs CECR1 expressing cells were also found further away from the vasculature 
in the tumor parenchyma. These findings possibly reflect the modulation of immune 
cells by CECR1 leading to a progressive defect of the endothelial barrier function in 
glioma vasculature. Taken together, the influence of CECR1 on immune cells, and on 
macrophage polarization in particular, seems to impact the cerebral vasculature of 
normal brain and brain tumors. 
The fraction of resident microglia and TAMs reportedly constitute up to 30% of the 
total cell population of GBM
33
. The glioma cells are capable of actively reprogram the 
TAMs in order to support tumor progression
5
. Based on expression profiling of mouse 
gliomas, subtyping beyond the classic M1 and M2 poles has been introduced and M2a 
(Th2, anti-pathogens response), M2b (Th2, immune regulatory), and M2c (immune 
modulatory and tissue remodeling) TAMs are now being recognized
34
. Expression analy-
sis of typical M2a, b, and c subtype markers validated the presence of the TAM sub-
types in human gliomas, with in particular enrichment of M2b and M2c cells in GBM. 
It remains unclear if the glioma TAMs constitute a unique phenotype that is not 
found in macrophage populations in non-neoplastic tissues – which would make them a 
potential therapeutic target. Investigations of the influence of CECR1 on the expression 
of the M1, M2a, b, and c markers may further reveal its regulatory function TAM polari-
zation. 
In conclusion, the current study has demonstrated a new CECR1-mediated cross-talk 
mechanism between macrophages and glioma cells. Continuous CECR1 autocrine stimu-
lation of macrophages enables M2-like TAMs to stimulate MAPK and c-Jun signaling in 
glioma cells via paracrine activation, leading to higher proliferation and motility rates in 
tumor glioma cells. Based on our findings, CECR1 could become a suitable drug target 
for selective modulation of the M2-like TAMs in glioma. 
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SUPPLEMENTARY DATA 
Supplemental Figure 1 CECR1 is highly enriched in GBM. 
 
(a) Analysis of two different GEO datasets shows CECR1 transcript level in glioblastoma. Shown are median 
values of CECR1 levels. * P<0.05; ** P<0.01. Left panel: AII: Astrocytoma grade II, AIII: Astrocytoma grade III. 
Right panel: OG II: Oligodentroglioma grade II, AO: Anaplastic Oligodentroglioma, AOA: Anaplastic Oligoastro-
cytoma. (b) QPCR analysis of macrophage markers CD16, CD204, and IL-10 in grade II, III and IV human glio-
mas. Results are shown in mean ± S.E.M.; * P<0.05; ** P<0.01. Grade II, N=19; Grade III, N=5; Grade IV, N=19. 
QPCR results of human glioma lysates showing (c) the mRNA expression levels of iNOS and IL-12p35 in glioma 
grades II, III and IV (Mean ± S.E.M), (d) the mRNA expression levels of CD68, CD86, and CD206 between the 
different grades  (mean ± S.E.M). Displayed values were normalized with the  actin housekeeping gene. 
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Supplemental Figure 2 CECR1 co-localized with CD16 expression in autopsy brain, astrocytoma grade II and GBM 
 
(a) Immunohistochemistry for CECR1 and CD16 in autopsy brain, astrocytoma grade II and GBM (scale bar: 
200 µm). (b) Percentages of CD16 positive areas in autopsy brains, AII and GBM. Mean values of CD16 are 
shown. * P<0.05, ***P<0.005. (c) Confocal microscope images showing co-localization of CECR1 with CD16 in 
GBMs (scale bar: 50 µm for upper panel; 10 µm for lower panel). (d) Confocal microscope images showing co-
localization of CD204 with CD16 in GBMs (scale bar: 50 µm for upper panel; 10 µm for lower panel). 
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Supplemental Figure 3 CECR1 is expressed by microglia and perivascular macrophages in autopsy brain sam-
ples and low-grade astrocytomas  
 
Representative pictures of CD68 and CECR1 double immunostaining from four cases of autopsy brain samples 
and three low-grade astrocytomas. In autopsy brain tissue, showing (a) CECR1 co-localization with CD68 in 
parenchyma (scale bar: 20 μm), (b) co-localization of CECR1 and CD68 in a single cell structure (scale bar: 10 
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μm), (c) CECR1 co-localization with CD68 in perivascular macrophages (scale bar: 20 μm). (d) Co-localization of 
CD68 and CECR1 in a single perivascular macrophage(scale bar: 10 μm). (e) In low-grade astrocytomas, CECR1 
co-localized with CD68 in macrophages at perivascular sites (scale bar: 20 μm). (f) High magnification of the 
selected area (scale bar: 10 μm). 
 
Supplemental Figure 4 Co-localization of CECR1 with CD163 in perivascular macrophages in autopsy brain 
tissue and low-grade astrocytomas  
 
Representative pictures of CD163 and CECR1 double immunostaining from four autopsy brain samples and 
three low-grade astrocytomas. Co-localization of CECR1 with CD163 in (a) perivascular macrophages in autop-
sy brains (scale bar: 20 μm); (b) high magnification view of select area (scale bar: 10 μm). Co-localization of 
CECR1 with CD163 in (c) astrocytomas grade II (scale bar: 20 μm); (d) high magnification view of select area 
(scale bar: 10 μm).    
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Supplemental Figure 5 M-CSF induced macrophages from peripheral monocytes express higher levels of M2-
like macrophage markers 
 
Peripheral monocytes were differentiated into M1 and M2-like macrophages by GM-CSF (10 ng/ml) and M-
CSF (10 ng/ml) stimulation respectively for 7 days.  
(a, b left panel) Bright field examination show typical morphological features for M1 and M2-like macrophages 
as a result of GM-CSF and M-CSF induced differentiation respectively. (a, b middle panel) Immunofluorescent 
signal of CD68 of GM-CSF and M-CSF induced macrophages (scale bar: 50 µm). (a, b right panel) Immunofluo-
rescent signal of CD204 (scale bar: 20 µm). (c) Representative Western blot of three independent experiments 
showing typical CD163 and CD80 protein expression levels for GM-CSF and M-CSF induced macrophages. (d) 
IL-10 and CXCL12 transcript levels as measured by qPCR. Mean ± S.E.M, *P<0.05, N=3. 
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Supplemental Figure 6 
 
(a) Representative cell immunostaining of CECR1 staining in THP-1 macrophages with CECR1 knockdown 
versus sisham transfected controls of three experiments. (scale bar: 10 µm). (b) Quantification of the fluores-
cent intensity of CECR1 signal per cell in CECR1 knockdown and sisham. Data are presented as mean ± S.E.M., 
of 3 independent experiments. Five image fields were randomly selected for quantification of each experi-
ment group. *** P<0.005. (c) Western blot of CD163 in siCECR1 and sisham transfected THP-1 macrophages. 
Numbers above bands indicate quantified protein normalized to β-actin control. Represented figures are of 
three experiments. (d) Flow cytometry shows percentage of CD163+ cells in M-CSF induced macrophages with 
and without rhCECR1 for 96 hours. Most left graph: Negative control only stained with the secondary anti-
body conjugated with Alexa Fluor 555. Data are of three experiments; data are in mean values ± S.D. (e) GBM 
immunostained for CECR1 and CD163. Tumors were divided in a CECR1-low and high group based 
on %CECR1+ area per image view (scale bar: 100 µm). (f) Comparison of %CD163+ areas in CECR1 expression 
low and high GBM samples. Each scatter dot represents one individual sample. Medians are indicated 
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(P=0.057). 
 
Supplemental Figure 7 GBM with higher CECR1 levels show higher numbers of CD204 positive macrophages 
 
GBM samples were divided into two groups based on CECR1 level. (a) Representative figures of immunostain-
ing for CD204 in GBM cross-sections of CECR1 high and low groups. (scale bar: 100 m). (b) Quantification of 
the CECR1 and CD204 signal in CECR1 high group compared to samples with lower CECR1 levels. **P<0.01. 
 
Supplemental Figure 8 RhCECR1 stimulation of macrophages regulates proliferation and migration of U87 cells  
(a) Representative figures of U87 cells with treatment of MΦ-CM derived from macrophages treated with a 
range of rhCECR1 concentrations for 96 hours. Pictures were taken at day 1, day 3 and day 5 post MФ-CM 
stimulation. (scale bar: 200 µm). (b) Quantification of MTT reaction. Data are represented of three experi-
ments. Six replicated wells of each condition were used. Data are in mean ± S.E.M. in fold change compared to 
MΦ-CM derived of macrophages without rhCECR1 treatment. *P<0.05 ***P<0.005. (c) Representative pic-
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tures of U87 migration into the detection zone after stimulation with MΦ-CM of macrophages treated with 
different concentrations of rhCECR1 for 96 hours. Pictures were taken at 0 hour and 24 hours after start of 
migration experiment (scale bar: 200 µm). Detection zone is indicated by a white circle. (d) Quantification of 
fluorescent cells in migration zones in MΦ-CM conditions in which macrophages were stimulated with differ-
ent rhCECR1 concentrations for 96 hours. Data are represented of three experiments and presented as mean 
± S.E.M. *P<0.05, **P<0.01, ***P<0.005. 
 
Supplemental Figure 9 CECR1 activation in macrophages regulates parachrine-mediated proliferation in U373 
and U251 cells 
 
(a) Left panel: Quantification of MTT reaction of U373 with treatment of MΦ-CM from siCECR1, siSham and 
non-transfected THP-1 macrophages. Right panel: Quantification of MTT assay of U373 with/without treat-
ment of MΦ-CM from THP-1 macrophages with rhCECR1 treatment for 96 hours. (b) Left panel: Quantifica-
tion of MTT reaction of U251 with treatment of MΦ-CM from siCECR1, siSham and non-transfected THP-1 
macrophages. Right panel: Quantification of MTT assay of U251 with/without treatment of MΦ-CM from 
THP-1 macrophages with rhCECR1 treatment for 96 hours.  Data are represented of three experiments. Six 
replicated wells of each condition were used. Data are in mean ± S.E.M. in fold change compared to MΦ-CM 
derived of macrophages without rhCECR1 treatment. *P<0.05, **P<0.01, ***P<0.005. (c) Representative 
pictures of Ki67 staining in U251 cells treated with/without MΦ-CM from non-transfected, siSham, and 
siCECR1 transfected macrophages (scale bar: 50 µm). (d) Quantification of Ki67 in U251 cells treated with 
different MΦ-CMs for 48 hours. Data are obtained from three experiments. * P<0.05,  **P<0.01. (e) Repre-
sentative pictures of Ki67 staining in U251 cells treated with/without MΦ-CM and MΦ-CM with treatment of 
RhCECR1 50nM for 48 hours. (scale bar: 50 µm). (f) Quantification of Ki67 in U251 cells treated with different 
MΦ-CMs for 48 hours. Data are obtained from three experiments. ***P<0.005. 
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Supplemental Figure 10 CECR1 activation in macrophages regulates parachrine-mediated migration in U373 
cells 
 
(a) Representative pictures of U373 migration into the detection zone after stimulation with MΦ-CM of 
macrophages with non-transfection, sisham and siCECR1 transfection (Scale bar: 200 µm). Right lower panel: 
Quantification of fluorescent cells in migration zones in different MΦ-CM conditions. Data are represented of 
three experiments and presented as mean ± S.E.M. **P<0.01, ***P<0.005. (b) Representative pictures of 
U373 migration into the detection zone after stimulation with MΦ-CM of macrophages treated with different 
concentrations of rhCECR1 for 96 hours (scale bar: 200 µm). Right lower panel: Quantification of fluorescent 
cells in migration zones in different MΦ-CM conditions. Data are represented of three experiments and 
presented as mean ± S.E.M. **P<0.01. 
 
Chapter 3 
66 
Supplemental Figure 11 CECR1 activation in macrophages regulates parachrine-mediated migration in U251 
cells 
 
(a) Representative pictures of U251 migration into the detection zone after stimulation with MΦ-CM of 
macrophages with non-transfection, sisham and siCECR1 transfection (Scale bar: 200 µm). Right lower panel: 
Quantification of fluorescent cells in migration zones in different MΦ-CM conditions. Data are represented of 
three experiments and presented as mean ± S.E.M. **P<0.01. (b) Representative pictures of U251 migration 
into the detection zone after stimulation with MΦ-CM of macrophages treated with different concentrations 
of rhCECR1 for 96 hours (scale bar: 200 µm). Right lower panel: Quantification of fluorescent cells in migration 
zones in different MΦ-CM conditions. Data are represented of three experiments and presented as mean ± 
S.E.M. *P<0.05. 
 
CECR1 in M2-like TAMs promotes glioma progression 
67 
Supplemental Figure 12 Direct stimulation with rhCECR1 does not influence proliferation of U87 cells and 
activation of MAPK in U87 cells. 
 
(a) Quantification of the absorbance of the end product of the MTT assay, measured in U87 cells stimulated 
with different concentrations of rhCECR1. (b) Upper panel: Representative pictures of Western blots measur-
ing phosphor-ERK1/2 and total ERK1/2 in U87 directly treated with rhCECR1 for 10 and 20 minutes. Lower 
panel: Representative pictures of Western blots measuring phosphor-JNK and total JNK in U87 directly treated 
with rhCECR1 for 10 and 20 minutes. 
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Supplemental Figure 13 CECR1 function in macrophages activates the MAPK pathway in U373 cells 
 
(a) Western blot of phospho-ERK1/2 and total ERK1/2 protein in U373 cells at 10 and 20 minutes after stimu-
lation with MΦ-CM from siSham and siCECR1 transfected macrophages. Representative figures are shown of 
three experiments. (b) Western blot quantification shows  phospho-ERK1/2/total ERK1/2 ratio. Data are of 
three observations at different time points. Phospho-ERK/Total ERK ratios are presented as mean ± S.E.M. in 
fold change compared to MΦ-CM derived of macrophages with non-targeted siRNA (siSham) and siRNA 
targeting CECR1 (siCECR1). (c) Western blot of phospho-JNK/SAPK and total JNK/SAPK protein in U373 cells at 
10 and 20 minutes after stimulation with MΦ-CM derived from siSham and siCECR1 transfected macrophag-
es. Representative figures are shown from three experiments. (d) Quantified Western blot results showing 
phospho-JNK/SAPK/total JNK/SAPK ratios. Data was obtained from three experiments at different time points. 
Quantified Phospho-JNK/Total JNK ratios are presented as mean ± S.E.M. in fold change compared to MΦ-CM 
derived of macrophages with non-targeted siRNA (siSham) and siRNA targeting CECR1 (siCECR1). *P<0.05. (e) 
Western blot of phospho-c-Jun and total c-Jun in U373 cells at 10 and 20 minutes after stimulation with MΦ-
CM derived from siSham and siCECR1 siRNA transfected macrophages. (f) Quantified Western blot results 
showing phospho-c-Jun/total c-Jun ratios. Data was obtained from two experiments, shown individually. 
Quantified Phospho-c-Jun/Total c-Jun ratios are presented as mean ± S.E.M. in fold change compared to MΦ-
CM derived of macrophages with non-targeted siRNA (siSham) and siRNA targeting CECR1 (siCECR1). 
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Supplemental Figure 14 RhCECR1 stimulation of macrophages activate MAPK pathways in U87 cells 
 
(a) Representative Western blot of two independent experiments, showing phospho-ERK1/2 and ERK1/2 in 
U87 cells at 10, 20, and 30 minutes after stimulation with mediums derived from macrophages treated with 
different concentration of rhCECR1 (MΦ-CM). (b) Graph showing quantified Western blot results of phospho-
ERK1/2/total ERK1/2 ratios in response to conditioned mediums derived from macrophages treated with 
different concentration of rhCECR1. (c) Representative Western blot of two independent experiments, show-
ing phospho-JNK/SAPK and total JNK/SAPK in U87 cells at 10, 20, 30 minutes after stimulation with mediums 
derived from macrophages treated with different concentration of rhCECR1 (MΦ-CM). (D) Graph showing 
quantified Western blot results of phospho-JNK/SAPK/total JNK/SAPK ratios in response to conditioned medi-
ums derived from macrophages treated with different concentration of rhCECR1.   
 
Supplemental Figure 15 Ki67 correlated positively with phosphor-ERK,JNK and c-Jun in GBM samples 
 
Correlation between numbers of Ki67+ cells with ratios of phospho-ERK/total ERK, phospho-JNK/total JNK, 
and phospho-c-Jun/total c-Jun. Spearman correlation co-efficient and P value are shown. 
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ABSTRACT: 
Introduction: Glioblastomas (GBM) are most malignant brain tumors characterized by 
profound vascularization. Activation of macrophages strongly contributes to tumor 
angiogenesis during GBM development. Previously, we showed that extracellular aden-
osine deaminase protein Cat Eye Syndrome Critical Region Protein 1(CECR1) is highly 
expressed by M2-like macrophages in GBM where it defines macrophage M2 polariza-
tion and contributes to tumor expansion. In this study, the effect of CECR1 in macro-
phages on tumor angiogenesis was investigated.  
Methods and Results: Immunohistochemical evaluation of GBM tissue samples showed 
that the expression of CECR1 correlates with microvascular density in the tumors, con-
firming data from the TCGA set. In a 3D co-culture system consisting of human peri-
cytes, HUVECs and THP1-derived macrophages, CECR1 knockdown by siRNA and CECR1 
stimulation of macrophages inhibited and promoted new vessel formation respectively. 
Loss and gain of function studies demonstrated that PDGFB mRNA and protein levels in 
macrophages are modulated by CECR1. The pro-angiogenic properties of CECR1 in mac-
rophages were partially mediated via paracrine activation of pericytes by PDGFB-
PDGFRβ signaling. CECR1-PDGFB-PDGFRβ crosstalk between macrophages and peri-
cytes promoted pericyte migration, shown by transwell migration assay, and enhanced 
expression of periostin, a matrix component with pro-angiogenic properties. 
Conclusions: CECR1 function in (M2-like) macrophages mediates crosstalk between 
macrophages and pericytes in GBM via paracrine PDGFB-PDGFRβ signaling, promoting 
pericyte recruitment and migration, and tumor angiogenesis. Therefore, CECR1 offers a 
new target for anti-angiogenic therapy in GBM.  
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INTRODUCTION 
Glioblastoma multiform (GBM) represents the highest grade of glioma and carries a 
dismal prognosis of merely 12-15 months, even after current standard chemo-
radiotherapy and tumor resection regimes (1). Presently, our understanding of the 
exact mechanisms driving GBM pathogenesis remains limited and further research is 
essential for the design of more effective therapies. GBMs are highly vascularized tu-
mors that are hall marked by vascular hyper-proliferative capacity (2) and vast myeloid 
infiltration (3).  
So far, the therapeutic effects of anti-angiogenic regimes targeting VEGF were 
shown to be limited, due to rapid acquirement of resistance by the tumor cells (4). It 
has been proposed that the drug-resistance may be related to the activation of alterna-
tive angiogenic pathways such as FGF2-mediated and HIF1-independent mechanisms 
that bypass the need for VEGFA regulation of tumor angiogenesis (5). In addition, the 
recruitment and activation of bone marrow derived circulatory cells, including macro-
phages, could rescue tumor angiogenesis by secretion of these alternative pro-
angiogenic factors (6).  
Previous studies have well established the involvement of resident macrophages 
(microglia) and infiltrated macrophages, also called glioma-associated macrophages 
(GAMs), in tumor angiogenesis of GBM (7, 8). Although GAMs can produce VEGFA, 
alternative mechanisms including GAMs-induced RAGE (9), CXCL2 (10), and IGFBP1 (11) 
mediated regulation of tumor angiogenesis, have also been demonstrated. In addition 
to regulating angiogenesis, GAMs actively promote glioma growth, migration and inva-
sion (12), and help maintain a glioma stem cell niche (13). Furthermore, findings of 
clinical studies imply an important functional contribution of GAMs to prognosis or 
recurrence of GBM (3, 8, 14, 15). Macrophages are classically distinguished into M1 and 
M2 phenotypes. M1 macrophages are primarily associated with a pro-inflammatory 
state, whereas M2 macrophages are associated with immune modulation and wound 
healing. Compared to M1 macrophages, M2 macrophages have been shown to act pro-
angiogenic, both in vitro and in vivo (16-18). In line with these observations, recent 
studies have indicated that mainly tumor-associated macrophages with a M2-like phe-
notype can act as pro-angiogenic modulators, stimulating expansion of disorganized 
neovessels by e.g. paracrine release of PIGF (19) and CCL18 (20). In GBM, M2-like GAMs 
have been mainly described for their immune suppressive and tumor supportive func-
tion. As the majority of GAMs in GMB are known to have a M2-like phenotype, specific 
drug-targeting of M2 macrophages could become a viable alternative therapy for the 
inhibition of tumor angiogenesis in GBM (6).  
Recently, the extracellular adenosine deaminase protein Cat Eye Syndrome Critical 
Region Protein 1(CECR1) has been shown to regulate macrophage maturation. In previ-
ous studies we demonstrated that CECR1 is consistently highly expressed by M2-type 
GAMs, particularly in high-grade glioma. In line with the findings presented by Zhou et 
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al (21), we could validate that CECR1 is an important promoter of GAM polarization 
towards M2-like macrophages. Our previous study also demonstrated that CECR1-
mediated paracrine activation of M2-like GAMs directly affected the GBM cells, promot-
ing tumor cell proliferation and migration. However, the effect of CECR1 regulation of 
GAMs on tumor angiogenesis remains to be investigated. Considering the important 
role that CECR1 plays in M2-like macrophage polarization, and the general pro-
angiogenic function of GAMs, we hypothesize that CECR1 contributes to the paracrine 
pro-angiogenic function of (M2-like) GAMs. 
In the present study we demonstrated that CECR1 expression correlated with micro-
vascular density in GBM samples based analysis. Using a well-validated 3D co-culture 
system consisting of human pericytes, HUVECs and THP1-derived macrophages, we 
further demonstrated that gain and loss of function of CECR1 activity in macrophages 
inhibited and promoted new vessel formation respectively. Further investigation re-
vealed that CECR1 modulated pericyte function (mainly migration), a process that was 
mediated by CECR1-PDGFB-PDGFRβ paracrine crosstalk between macrophages and 
pericytes. 
RESULTS 
CECR1 levels correlate with microvascular density in human GBM 
Immuno-histochemisty analysis of human GBM samples indicated strong CECR1 intensi-
ty in GBM samples with high microvascular density, as shown by CD31+ staining of vas-
cular endothelium (Figure 1a). The high level of CECR1 coincided with a strong signal of 
CD204+ M2 macrophages. In contrast, regions in GBM samples with weak CECR1 im-
munostaining showed limited numbers of CD204+ cells, and low microvascular density 
(Figure 1a). Quantitative analysis using ImageJ software confirmed the conclusions of 
the initial visual evaluation, with the mean percentage of CD31+ area per image field 
per GBM sample being significantly higher in the group of samples with high versus low 
CECR1 levels (Figure 1b). Further analysis revealed a significant positive correlation 
between the CD31 and CECR1 in the collection of GBM samples (Figure 1b). These data 
were in line with the findings obtained by data mining in the TCGA data set: significant 
positive correlations were identified between PECAM1 (endothelial cell marker), En-
doglin (endothelial (progenitor) cell marker) and CECR1 expression in a set of 166 sam-
ples (Figure 1c, d). The findings were validated in a second TCGA GBM set (22) of 154 
GBM samples (Figure 1c, d). Taken together, these observations indicate that high 
CECR1 levels in GBM relate to high microvascular density and the presence of CD204+ 
M2 macrophages.   
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Figure 1 CECR1 levels correlates with microvascular density in human GBM 
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(a) Immuno-histological staining of human GBM cross-sections for CD31, CECR1 and CD204, in samples with 
high CECR1 signal (column High) and low CECR1 signal (column Low) (Scale bar: 200 µm). (b) Upper graph 
shows the results of a quantitative analysis using ImageJ software of the mean percentage of CD31+ cells per 
image field per GBM patient in CECR1 low and high signal groups. Lower graph shows the correlation between 
mean %CD31+ cells and %CECR1+ cells per image field per GBM patient. (c) Left graph: Correlation between 
PECAM1 and CECR1 mRNA levels in a set of 166 TCGA-dataset derived GBM samples. Right graph: Correlation 
between PECAM1 and CECR1 mRNA levels in a second set of 154 TCGA-dataset derived GBM samples. (d) Left 
graph: Correlation between Endoglin and CECR1 mRNA levels in a set of 166 TCGA-dataset derived GBM 
samples. Right graph: Correlation between Endoglin and CECR1 mRNA levels in a second set of 154 TCGA-
dataset derived GBM samples. ***P<0.01.  
CECR1 promotes the pro-angiogenic paracrine action of M2 macrophages 
Previously we have identified M2-like macrophages as the main cell type in GBM to pro-
duce high levels of CECR1. We also showed that CECR1 promotes M0 to M2 macrophage 
polarization and determined M2 paracrine activity. Here we investigated the function of 
CECR1 in macrophage-mediated angiogenesis in a GBM-like environment. Angiogenesis 
was assessed in a 3D co-culture assay consisting of a collagen matrix in which GFP labeled 
HUVECs directly interact with dsRed labeled human-derived pericytes. This complex sys-
tem mimics the complete sequence of events in microvasculature formation, allowing us 
to study vessel sprouting, vascular cell migration through a 3D matrix environment, multi-
cellular vessel formation, lumenization, pericyte recruitment, perivascular coverage, and 
microvascular stabilization, all within a 5-day time range. To assess CECR1 function in 
GAMs in a GBM environment, THP1 monocytic cells were maturated by stimulation with 
PMA for 48 hours, before transfection with CECR1 targeting siRNA to obtain CECR1 si-
lenced macrophages. These siCECR1 macrophages were further stimulated for 48 hours 
with or without U87 derived medium to assess the effect of a GBM paracrine environ-
ment. To assess the paracrine effect of the modified macrophages on angiogenesis, the 
THP1-derived macrophages were harvested and seeded on top of the co-culture system 
(Figure 2a). Stimulation of the co-cultures with THP1 macrophages significantly increased 
microvascular density, as observed by quantitative analysis of the number of tubules, total 
tubule length and number of junctions at day 5 (Figure 2b, c, f). Successful siRNA mediat-
ed knockdown CECR1 in THP1 macrophages, as validated by western blot and qPCR (Fig-
ure 2e), significantly reduced the response of the co-culture to the macrophages, as 
shown by a reduction in total tubule length compared to treatment with sisham and con-
trol macrophages. These effects were further amplified when the co-cultures were treat-
ed with THP1 macrophages stimulated with U87 supernatant during maturation, with 
CECR1-silenced + U87 supernatant-treated THP1 cells reducing the number of tubules and 
junctions and decreasing the total tubule length in the exposed co-cultures compared to 
the control groups (Figure 2d, f). In contrast, stimulation of co-cultures with the superna-
tant of THP1 macrophages that were stimulated with human recombinant CECR1 during 
maturation, showed a significant increase in all assessed vascular parameters (Supple-
mentary figure 1a, b), demonstrating a dose-response relation.   
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Figure 2 CECR1 promotes the pro-angiogenic paracrine action of M2 macrophages 
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(a) Diagram showing the experimental setup of testing paracrine angiogenic activation of vascular cells in 3D co-
cultures by THP1 macrophages. (b) Low and high magnification fluorescent images of neo-vessel formation by 
HUVECs (GFP-marked) and human derived pericytes (dsRed-marked) without THP1 marcrophage stimulation. (c) 
Low and high magnification fluorescent images of neo-vessel formation by HUVECs (GFP-marked) and human 
derived pericytes (dsRed-marked) with stimulation of non-treated (control), and sisham or siCECR1 treated THP1 
macrophages. (d) Low and high magnification fluorescent images of neo-vessel formation by HUVECs (GFP-marked) 
and human derived pericytes (dsRed-marked) with stimulation of non-treated (control), and sisham or siCECR1 
treated THP1 macrophages with U87 stimulation. (Scale bar: 100 µm for b, c, and d). (e) Upper image: Western blot 
of CECR1 protein and  actin loading control in THP1 macrophages. Blot represents results from three observa-
tions. Lower graph: QPCR results of CECR1 mRNA levels normalized to housekeeping genes in non-treated (con-
trol), and sisham or siCECR1 treated THP1 macrophages, without and with U87 stimulation. *P<0.05; **P<0.01. (f) 
Quantified results of the co-culture experiment. No. of junctions, tubules, and total tubule length data are shown. 
*P<0.05; **P<0.01. Representative graphs were taken from at least three experiments. Six wells were analyzed in 
each experiment.   
 
Our previous studies demonstrated that M2 macrophages were the main producers 
of CECR1 in GBM. Here we investigated if the paracrine pro-angiogenic effects could be 
partially mediated by direct stimulation of vascular cells by CECR1. Indeed, stimulation 
of the co-cultures with recombinant CECR1 increased the number of junctions, tubules, 
and total tubule length, demonstrating that vascular cells can be directly stimulated by 
CECR1  
(Supplemental figure 2a,b). Combined these data indicate that CECR1 plays an im-
portant role in regulating the pro-angiogenic function of macrophages. 
PDGFB expression correlates with M2 GAMs and is enhanced by CECR1 
In order to identify which particular known pro-angiogenic molecules are related to the 
expression of CECR1, qPCR was carried out on 6 common pro-angiogenic genes (VEGFA, 
TIE1, TIE2, ANGPT1, ANGPT2, PDGFB). QPCR analysis of macrophages silenced for CECR1 
showed a significant decrease in PDGFB levels (Figure 3a), while expression levels of 
other pro-angiogenic genes were not affected (VEGFA, TIE1, TIE2, ANGPT1, ANGPT2, 
data not shown). Visa versa, stimulation of macrophages with recombinant human 
(rh)CECR1 significantly increased PDGFB in a dose-responsive manner (Figure 3b). These 
data were further validated by immuno-fluorescent staining of cytospin THP1 macro-
phages, showing a reduction in PDGFB signal that coincided with a reduction in CD163 
(M2) marker signal in the CECR1 silenced versus control macrophages and sisham treat-
ed macrophages (Figure 3c). This effect was CECR1 knockdown specific, as knockdown of 
PDGFB in THP1 macrophages did not reduce the CD163 M2 marker signal, while the 
PDGFB signal was clearly decreased (Figure 3c). In contrast, treatment of macrophages 
with rhCECR1 increased both CD163 and PDGFB mean intensity signals (Figure 3e). 
Quantification of the mean intensity levels of PDGFB of the different groups confirmed  
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Figure 3 PDGFB expression correlates with M2 GAMs and is enhanced by CECR1 
 
(a) QPCR analysis of PDGF mRNA levels normalized to housekeeping genes in non-treated (control), and 
sisham or siCECR1 or siPDGFB treated THP1 macrophages. *P<0.05; ***P<0.005. Experiments were repeated 
at least three times. (b) QPCR analysis of PDGFB mRNA levels normalized to housekeeping genes in THP1 
macrophages treated with different concentrations of rhCECR1 from three experiments. *P<0.05; 
***P<0.005. (c) Image panel shows immuno-fluorescent staining of PDGFB and CD163, and merged images of 
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cytospin non-treated (control), and sisham or siCECR1 or siPDGFB treated THP1 macrophages (Scale bar: 10 
µm). (d) Graph shows mean PDGF intensity of each treatment group. **P<0.01; ***P<0.005. Experiments 
were repeated at least three times. (e) Image panel shows immuno-fluorescent staining of PDGFB and CD163, 
and merged images of cytospun non-treated (control), and rhCECR1 treated THP1 macrophages (Scale bar: 10 
µm) (f) Image panel shows immuno-fluorescent staining of PDGFB (green) and CD163 (red), and merged 
images of cytospin non-treated controls with exposure to U87 supernatant U87 conditioned medium (CM), 
and THP1 macrophages treated with sisham + U87 supernatant or siCECR1 + U87 supernatant. Graph shows 
mean PDGFB intensity of each treatment group from at least three experiments.  **P<0.01; ***P<0.005. (g) 
Low and high magnification confocal images of double immuno-fluorescent staining of CD68, CD163 and 
PDGFB, CECR1 in human GBM sections (scale bar: Left panel, 50 µm, Right upper panel, 5 µm, right lower 
panel 10 µm). (h) Upper graph: Correlation between PDGFB and CECR1 mRNA levels in a set of 166 TCGA-
dataset derived GBM samples. Right graph: Correlation between PDGFB and CECR1 mRNA levels in a second 
set of 154 TCGA-dataset derived GBM samples.  
 
that PDGFB was decreased and increased by CECR1 silencing, and rhCECR1 stimulation, 
respectively (Figure 3d). Stimulation of THP1 macrophages with U87 derived supernatant 
showed upregulation of PDGF signal in cytospin samples. This effect was significantly 
reduced in siCECR1 versus sisham treated THP1 macrophages (Figure 3f). A correlation 
between CECR1 and PDGFB levels was also found by analysis of TCGA datasets, which 
showed a positive correlation between PDGFB and CECR1 expression levels in a provi-
sional set of 166 GBM samples, and was subsequently validated in a second set of 154 
GBM samples (Figure 3h). Similar to CECR1, immunostaining of GBM samples revealed 
that PDGFB+ cells were mainly GAMs that express pan macrophage and M2 markers 
such as CD68 and CD163 (Figure 3g). 
CECR1-mediated paracrine activation of macrophages promotes pericyte 
recruitment via PDGFB/PDGFR signaling in GBM  
To assess the role of PDGFB in CECR1 regulation of macrophages in angiogenesis, we 
conducted co-culture experiments with macrophages silenced for PDGFB. Co-cultures 
with PDGFB silenced macrophages seeded on top mimicked the phenotype of co-
cultures that were treated by CECR1 silenced macrophages, demonstrating a general 
decrease of all parameters of active angiogenesis (Figure 4a b). Co-culture analysis of 
siPDGFB macrophages that differentiated with exposure to U87 supernatant showed a 
similar negative effect on angiogenic parameters (Supplemental data Figure 3a, b). This 
reduction was partially rescued by treating siPDGF macrophages with rhCECR1 
(siPDGFB versus siPDGFB + rhCECR1, total tubule length), indicating that the paracrine 
pro-angiogenic effect of CECR1 in macrophages is partially mediated via PDGFB (Figure 
4a, b). PDGFB mediates its activity via PDGF receptor (PDGFR) signaling. In GBM sam-
ples, immuno-staining revealed that PDGFR+ cells are mainly perivascular mural cells 
that are closely located near CD163+ M2 macrophages (Figure 5a, b). QPCR analysis of 
different in vitro human cell types that have equivalents in GBM in vivo, including HU-
VECs, pericytes, U87, U251, and THP1 macrophages, demonstrated that PDGFR was  
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Figure 4 CECR1-mediated macrophage paracrine activation of angiogenesis is partially regulated via PDGFB 
 
(a) Low and high magnification fluorescent images of neovessel formation by HUVECs (GFP-marked) and 
human derived pericytes (dsRed-marked) without THP1 marcrophage stimulation, and with stimulation of 
non-treated (control), and sisham or siPDGFB treated THP1 macrophages, without or with rhCECR1 rescue. (b) 
Quantified results of the co-culture experiment. No. of junctions, tubules, and total tubule length data are 
shown. *P<0.05; **P<0.01 ***P<0.005.  Scale bar: 100 µm. N>10 cocultures in total. 
 
mainly expressed by pericytes (Figure 5c). Confocal imaging combined with double 
immuno-staining further confirms mural cell expression of PDGFR and the close locali-
zation of CD163+ GAMs in human GBMs (Figure 5d). The PDGFB/PDGFRβ lig-
and/receptor signaling mechanism is well-known to promote mural cell proliferation 
and is critical for mural cell recruitment to newly formed vessels to ensure vascular 
coverage and stabilization. Next, we investigated the CECR1-mediated effects of THP1 
macrophages on pericyte recruitment. Pericytes were evaluated for their migratory 
capacity in a transwell migration assay in response to paracrine factors that are present 
in macrophage-derived supernatants of the different groups (Figure 5e). Pericyte migra-
tion increased upon stimulation by supernatant of  THP1 macrophages (Figure 5f, g). 
Pericyte migration significantly decreased in response to supernatant derived from 
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CECR1 silenced THP1 macrophages (Figure 5e-g). This effect was mimicked by PDGFB 
silencing in THP1 macrophages in normal medium (Figure 5f, g). The data imply that 
CECR1-enhanced release of PDGFB by M2-like GAMs promotes pericyte recruitment to 
inflammatory pro-angiogenic sites via PDGFRβ signaling in GBM.  
 
Figure 5 CECR1-mediated paracrine activation of macrophages may promote pericyte recruitment via 
PDGFB/PDGFRβ signaling in GBM 
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(a) Low (right panel) and high (left panel) immunohistological staining of PDGFR and CD163 in human GBM 
sections. Black arrows indicate pericytes and endothelial cells (EC) forming blood vessels (BV). White arrow 
indicates macrophages (M)  (Scale bar: Left panel, 200 µm, right panel, 40 µm). (b) High magnification image 
of PDGFR immunohistological staining in human GBM sections. (c) QPCR analysis of PDGFR mRNA expres-
sion levels normalized to housekeeping genes in HUVECs, pericytes, U87, U251, and THP1 macrophages from 
three experiments. *** P<0.001 (Pericyte versus other cell types ). (d) Confocal images of CD163 and PDGFR 
double immuno-fluorescent staining in human GBM sections. White arrows indicate pericytes, endothelial 
cells (EC), and macrophages (M). Scale bars: left panel, 50µm; right panel, 20 µm. (e) Diagram of the experi-
mental setup of the transwell migration assay of pericytes (dsRed marked) seeded on top of the transwell. Cell 
migration aws towards a lower chamber with DMEM medium only, or with supernatant derived from non-
treated (control) macrophages, and sisham or siCECR1 treated macrophages. (f) Panel of fluorescent images 
of dsRed marked pericytes that have migrated through the transwell setting in response to the different 
conditions (DMEM only, or in response to supernatant of non-treated macrophages (control), or sisham, 
siCECR1, or siPDGFR treated macrophages). (g) Quantified results of the transwell migration assay. **P<0.01; 
***P<0.005, N>6 migration assays per condition.  
CECR1 activation in THP1 macrophages promotes paracrine activation of 
periostin protein production in pericytes  
Further confocal immuno-histochemical analysis of human GBM samples revealed colo-
calization of PDGFRβ+ perivascular mural cells with the extra cellular matrix component 
periostin (Figure 6a). Previously, we have detected enrichment of periostin in the mi-
crovasculature of GBMs using a proteomics screen (23). Work by others revealed an 
important role for periostin in recruitment of M2-like tumor associated macrophages 
and subsequent support of malignant growth (13). In line with these reports, periostin 
deposition was detected in close proximity of CD163+ M2 GAMs (Figure 6b). A signifi-
cant positive correlation was also identified between CD163 and periostin expression in 
a set of 154 samples using the TCGA GBM database (Figure 6c). Similarly to PDGFRβ, 
qPCR analysis of different in vitro human cell types that can be found in GBM, including 
HUVECs, pericytes, U87, U251, and macrophages, demonstrated that periostin was 
mainly expressed by pericytes (Figure 6d). Paracrine stimulation of pericytes by THP1 
macrophages enhanced periostin protein levels in the co-culture setup (Figure 6e, f). 
THP1 macrophages stimulated with U87 supernatant during maturation further en-
hanced periostin protein levels (Figure 6e, f), indicating that GAMs can significantly 
promote periostin protein production in pericytes.  
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Figure 6 CECR1 activation in THP1 macrophages promotes paracrine activation of periostin protein production 
in pericytes  
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(a, b) Confocal images of imunohistological stainings of periostin, PDGFR, and CD163 in human GBM sec-
tions. Scale bar: 50 µm. (c) Correlation between CD163 and periostin mRNA levels in a set of 154 TCGA-
dataset derived GBM samples. (d) QPCR analysis of periostin mRNA expression levels normalized to house-
keeping genes in HUVECs, pericytes, U87, U251, and THP1 macrophages from three experiments. *** P<0.001 
(Pericyte versus other cell types ). (e) Diagram showing experimental setup with pericytes (green) cocultured 
with macrophages without (light blue) and with U87 pre-stimulation (dark blue) seeded in filter insert. West-
ern blot shows periostin and  actin protein levels in pericytes of the different treatment groups. (f) Quantita-
tive results of Western blot analysis normalized to  actin loading control from four experiments. *P<0.05; 
***P<0.005. (g) Correlation between periostin and CECR1 mRNA levels in a set of 205 TCGA-dataset derived 
GBM samples. (h) Western blot shows periostin and  actin protein levels in pericytes treated with no macro-
phages, with non-transfected macrophages (control), and macrophages transfected with sisham, siCECR1, or 
siPDGFR. Graph shows quantitative results of Western blot analysis normalized to  actin loading control 
from four experiments. *P<0.05. (i) Western blot shows periostin and  actin protein levels in pericytes treat-
ed with macrophages with and without pre-treatment with rhCECR1. Graph shows quantitative results of 
Western blot analysis normalized to  actin loading control of at least four experiments. *P<0.05. (j) Western 
blot shows periostin and  actin protein levels in pericytes treated with different concentrations of PDGFB. 
Graph shows quantitative results of Western blot analysis normalized to  actin loading control from at least 
three experiments. ** P<0.01; ***P<0.005. (k) Representative western blot of three independent experi-
ments, showing periostin and  actin protein levels in pericytes treated with rhCECR1. (l) Panel of fluorescent 
images of dsRed marked pericytes that have migrated through the transwell setting in response to the differ-
ent conditions (in response to supernatant of non-treated macrophages (control), or sisham, or siperiostin 
treated macrophages), with and without PDGFB stimulation (Scale bar: 50 μm). (m) Quantified results of the 
transwell migration assay from three experiements. **P<0.01; ***P<0.005. 
 
Periostin expression correlates (r=0.3015; p<0.0001) with CECR1 expression levels in a 
set of 205 samples derived from the TCGA GBM database (Figure 6g). The periostin 
protein levels of pericytes exposed to the paracrine activity of THP1 macrophages 
dropped significantly following silencing the macrophages for CECR1 (Figure 6h). Simi-
larly, silencing of PDGFB in the THP1 macrophages resulted in decreased periostin pro-
duction by pericytes (Figure 6h). In support of these findings, THP1 macrophages that 
were treated with rhCECR1 during maturation, increased periostin protein levels pro-
duced by pericytes (Figure 6i). Similarly, periostin production by pericytes that were 
directly stimulated with physiological levels of PDGFB was significantly increased (Figure 
6j). However, direct stimulation of pericytes with rhCECR1 did not enhance their perios-
tin production (Figure 6k), indicating that the CECR1-mediated macrophage activation 
of periostin expression in pericytes is indirect and requires an intermediate paracrine 
factor, such PDGFB. In line with these findings, direct stimulation of pericytes with 
PDGFB promoted their migration, and silencing of periostin in pericytes inhibited this 
response (Figure 6l, m). Further evidence for the involvement of periostin in angiogene-
sis and cell migration is provided by correlation analysis of periostin expression in three 
different TCGA derived human GBM data sets (Supplementary Figure 4a). Overlap anal-
ysis identified a set of 139 genes that was significantly correlated with periostin expres-
sion in the three GBM gene sets (Supplemental Figure 4b). Functional annotation of the 
139 genes identified the top 20 of the significant biological processes including angio-
genesis related GO terms such as “blood vessel morphology”, “angiogenesis”, “blood 
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vessel development”, and “cardiovascular system development” (Supplemental Figure 
4c). Furthermore, GO terms associated with cell migration such as; “cell adhesion”, and 
“extracellular matrix disassembly” were also identified (Supplemental Figure 4c). Taken 
together, the data reveal a link between periostin expression by pericytes and CECR1-
mediated macrophage paracrine activity.  
DISCUSSION 
The main findings of this study are: a) Expression of CECR1 is positively correlated with 
microvascular density in glioblastoma. b) CECR1 expression by GAMs promotes angio-
genesis in a 3D co-culture assay. c) The level of CECR1 regulates PDGFB production in 
GAMs. d) The CECR1-PDGFB mediated cross-talk between macrophages and pericytes 
promotes migration of pericytes and contributes to new vessel formation. e) Macro-
phage-pericyte CECR1-PDGFB-PDGFRβ signaling upregulates the expression of the pro-
angiogenic extracellular matrix component periostin in pericytes.  
Current knowledge of the proangiogenic capacities of GAMs mainly concerns the ef-
fects of these cells on vascular endothelial cells (24). The regulation of perivascular cells, 
such as pericytes, by GAMs, is rarely studied. In this study we describe the proangiogenic 
role of CECR1 that is mediated via an autocrine feedback loop in which CECR1 production 
in (M2) GAMs enhances PDGFB expression and secretion. PDGFB/PDGFRβ signaling is 
crucial for the vascular maturation process in angiogenesis, during which newly formed 
microvessels secrete PDGFB to guide perivasular coverage by pericytes. PDGFB secreted 
by (M2) GAMs promote both pericyte migration and angiogenesis, as shown by our mi-
gration and 3D co-culture data respectively. Periostin is an extracellular matrix protein 
that is specifically present in the basal membrane of the microvasculature of GBMs [19]. 
In the present study we identified periostin as a potent down-stream target of the mac-
rophage CECR1-PDGFB paracrine signaling cascade (See Supplemental data Figure 5). 
Pericytes are defined by their singular perivascular position, their remarkable dendrite-
like morphology and their expression of PDGFRβ and NG-2 (25), Pericytes are multifunc-
tional cells (26), being vital cells  for vessel construction, maintenance, and the regulation 
of the vascular physiology (27). Pericyte dysfunction could lead to delay in blood vessel 
maturation, and contributes to vascular instability and leakage (28). Pericytes also con-
tribute to recruitment of immune cells, including monocytes, during inflammation (29). A 
process of mutual activation between GAMs and pericytes during tumorangiogenesis has 
been previously identified. In tumors the paracrine influence of GAMs leads to activation 
of the PDGFB-SOX17 axis, which is initiated by tumor cells and leads to pericyte produc-
tion of IL-33 (30). In addition, tumor associated macrophages secrete MMP-9, which has 
been shown to enhance the recruitment of pericyte precursor cells into the tumor mi-
croenvironment (31). The present data demonstrate the pro-angiogenic function of 
CECR1 in macrophages, mediated via paracrine regulation of PDGFB. The relation be-
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tween CECR1 and angiogenesis and vascular density is reflected by the hyper-
inflammatory response in patients with a CECR1 loss of function mutation (32). One of 
the most prominent symptoms displayed by these patients was early-onset stroke and 
profound vasculopathy. Similarly, vascular instability was observed in zebrafish with 
CECR1 knockdown. In previous studies we pointed out that CECR1 in GBM is mainly ex-
pressed by M2-like GAMs. We also discovered that CECR1 acts as a potent polarizing 
factor in GAMs differentiation towards the M2-like phenotype. CECR1 activity also in-
creased the pro-tumoral function of M2 macrophages in a paracrine fashion(33). In the 
current study, we have shown that CECR1 activity in GAMs enhances PDGFB mRNA and 
protein production levels. In line with these findings, PDGFB was previously reported not 
only to be expressed by activated endothelial cells, but also by M2-like GAMs (34). Ele-
vated levels of PDGFB produced in malignant cancers upregulate erythropoietin expres-
sion in stromal cells via activation of PDGRB that accelerates tumor angiogenesis (35). 
The CECR1-PDGFB-PDGFRβ axis that is revealed in this study points to a putative CECR1-
mediated functional cross-talk between macrophages and pericytes, guiding the process 
of vascular maturation and development. This process may be involved in the vascular 
symptoms observed in patients with CECR1 mutations (21).   
Aberrant vessel morphology with abnormal pericyte coverage is considered as one 
of the classical hallmarks of tumor vasculature in malignant tumors including GBM. 
Recent studies in pericytes have revealed hyperplasia of this cell type in GBM (36). The 
function of pericytes in malignant tumors is not only restricted to support vascular 
growth. As a potent producer of VEGFA, perivascular pericytes protect the tumor mi-
crovasculature against disintegration during anti-VEGFA therapy by elevating local VEG-
FA levels (26). Furthermore, pericytes in glioma were shown to produce other angiogen-
ic molecules like HGF, TGFβ1 and Prostaglandins. Pericytes also inhibit the activation of 
T cells and thereby induce immunosuppression in glioma (37), while expressing plas-
minogen urokinase in support of the self-renewal and invasion of glioma initiating cells 
(38). Based on these reports, we can conclude that pericytes play many significant roles 
in promoting angiogenesis and tumor progression in glial tumors. 
In this study we have identified periostin as a down-stream target of PDGFB signal-
ing in pericytes. Periostin was identified as a pro-angiogenic extracellular matrix com-
ponent in glioma (23). As a multifunctional protein it is involved in various carcinogenic 
processes such as the regulation of cell migration and the epithelial-mesenchymal tran-
sition in cancer cells, mainly via activation of cell focal adhesion kinases through cell 
binding to integrins (39). Recently, periostin was shown to play a role in the recruitment 
of M2-like GAMs in GBM (13) and to mediate the resistance  to anti-VEGFA therapy by 
increasing expression of caveolin-1, HIF-1α, and VEGFA (40). In addition, periostin is 
expressed by mammary stromal cells in breast cancer where it is involved in actively 
maintaining a breast cancer stem cell niche via the canonical WNT signaling pathway 
(41). In pancreatic carcinoma the expression of periostin was found upregulated in 
response to PDGFB stimulation (42). Our data provides evidence that the modulation of 
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CECR1 in macrophages influences the expression of periostin in pericytes via PDGFB-
mediated paracrine signaling.  
In conclusion, this study demonstrates that in glioblastoma CECR1 produced by M2-
like GAMs regulates the cross-talk between macrophages and pericytes via paracrine 
PDGFB-PDGFRβ signaling, promoting pericyte recruitment and migration, and tumor 
angiogenesis. The pro-angiogenic function of the CECR1-PDGFB-PDGFRβ signaling cas-
cade is related to the expression of periostin by pericytes. This new knowledge on com-
plex interaction between immuno cells and vascular cells, in the process of tumor neo-
angiogenesis could lead to better immune-modulatory and anti-angiogenic strategies 
for treatment of GBM in the future.    
MATERIAL AND METHODS 
Patient samples 
Patient samples of glioblastoma were collected from the Department of Pathology, 
Erasmus Medical Center with the approval of committee of research ethics. All the 
samples were diagnosed as glioblastoma by a board certificated pathologist (J.M.K). 
Cell culture 
Human monocytic cell line THP-1, obtained from Department of Hematology, Erasmus 
Medical Center, was maintained in culture in RPMI-1640 (Lonza, Breda) supplemented 
with 10%FBS and 1% Penicillin/Streptomycin. THP-1 cells were differentiated into mac-
rophage-like cells by PMA (Sigma, Sweden) at concentration of 100ng/ml for 48 hours. 
Recombinant human CECR1 protein (rhCECR1) was added to the macrophage cultures 
at a concentration gradient of 0, 12.5, 25, 50, 100, 200 nM for 96 hours. 
Human umbilical vein endothelial cells (HUVECs) (Lonza, Breda) and HUVECs trans-
fected with a lentiviral vector encoding GFP were cultured in EGM-2 endothelial medi-
um (Lonza, Breda) with 1% Penicillin/Streptomycin.  
Human brain vascular pericytes (HBVP) with and without lentiviral transfection of a 
vector encoding for dsRed, and GBM cell lines; U87, and U251 were maintained in 
DMEM (Lonza, Breda) with 10% FBS and 1% Penicillin/Streptomycin. Pericytes were 
treated with recombinant human PDGFΒ (Sigma, Sweden) at different concentrations 
according to the specifications of the different assays.  
siRNA transfection 
siCECR1(5’-GUGCCAAAGGCUUGUCCUA-3’,5-CUUCCACGCCGGAGAAACA-3’,5’-GCCCAA 
AGCUAGUUAGUAC-3’;5’-UCGCAGAAUCCAUCCGAAU-3’); siPDGFΒ(5’-CCGAGGAGCUU 
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UAUGAGAU-3’, 5’-GAAGAAGGAGCCUGGGUUC-3’,5’-GCAAGCACCGGAAAUUCAA-3’, 5’-
GGGCCGAGUUGGACCUGAA-3’), siPOSTN(5’-CCGAAGCUCUUAUGAAGUA-3’), and 
scrambled siRNA (5’-UGGUUUACAUGUCGACUAA-3’,5’-UGGUUUACAUGUUGUGUGA-
3’,5’-UGGUUUACAUGUUUUCUGA-3’, UGGUUUACAUGUUUUCCUA-3’) (siSham) were 
purchased from Dharmacon (GE health care, the Netherlands). Macrophages were 
transfected with SiCECR1 and siPDGFΒ using transfection buffer 2 (Dharmacon, GE, The 
Netherlands); pericytes or pericytes-dsRed were transfected with siPOSTN using trans-
fection buffer 1 (Dharmacon, GE, the Netherlands) according to manufactural instruc-
tions (See supplementary material and methods for details).   
RNA isolation and RT-qPCR 
Total RNA was isolated from macrophages and pericytes using RNA isolation kit (Bio-
line, UK) and cDNA was synthesized by sensi-fast cDNA synthesis kit (bio-line, UK). Tran-
scripts of CECR1, PDGFΒ, and POSTN were measured and normalized to β-actin in mac-
rophages and pericytes (For primers sequences see supplementary Table 1). 
Trans-well co-culture 
Macrophages were seeded in 0.4μm trans-well insert (Fisher scientific, USA) and were 
treated with U87-derived conditioned medium or recombinant human (rh)CECR1 pro-
tein for 48 hours followed by co-culture with pericytes for extra 72 hours. Pericytes 
were harvested afterwards for performing downstream assays. 
Western blot 
20 μg of total protein lysate derived from macrophages and pericytes was loaded onto 
10% SDS-PAGE gel and blotted to Nitro cellulous membranes followed by blocking and 
incubation of primary antibody. Protein levels were assessed by immunoblotting using 
specific antibodies against CECR1 (Sigma, 1:200), Periostin (R&D, 1:200), PDGFRβ 
(Abcam, 1:10000), and β-actin (Abcam, 1:500) as a loading control, followed by incuba-
tion with secondary antibodies (IRdye 680 CW, IRDye 800 CW, Licor Bioscience, USA) 
and detection of signals using the Odyssey imaging system (Licor Bioscience, USA). 
Immunostaining 
4 μm of adjacent sections were used for immunohistochemical and immunofluores-
cence analysis. Immunostaining and slide scanning were performed according to the 
protocol described previously (43). Macrophages were fixed using 4% PFA/PBS, fol-
lowed by antibody incubation. All fluorescence labeled samples was analyzed under the 
confocal microscope LSM 700 (Zeiss, The Netherlands). Five areas in high magnification 
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field were randomly selected from each slide and quantified using Image J (Antibodies 
applied were listed in supplementary table2). 
Transwell migration assay 
7,000 Pericytes-dsRed with transfected with siPOSTN, siSham and non-transfected con-
trols were seeded into the top compartment of the Fluor block 8 μm transwell inserts 
(Fisher Scientific, USA). Recombinant PDGFΒ protein was added in the lower chamber 
with serum free DMEM medium. Serum free macrophage conditioned medium from 
sisham, siCECR1, siPDGFΒ, and non-transfected control macrophages was added into 
the lower chamber. After 24 hours of migration, pictures from five randomly selected 
areas under 10x view were taken under a fluorescent microscope for image quantifica-
tion by image J. 
3D collagen tubule formation assay 
HUVEC-GFP and Pericyte-dsRed were co-cultured in 96-well plate at 5:1 ratio within a 
3D culture environment of bovine collagen type I (Gibco, USA) supplemented with SCF-
1, SDF-1α, and IL-3, as described previously (44). 300 macrophages with different condi-
tions were seeded on top of collagen gel and maintained for 5 days. At the 5
th
 day, tu-
bule formation was captured by fluorescent microscope and quantified by Angiosys 1.0. 
TCGA Database 
Three GBM datasets were obtained from TCGA via the c-Bioportal provided by the Me-
morial Sloan Kettering Cancer Center. Genes that positively correlated with POSTN 
expression (cut off point: spearman r>0.4) in all three GBM database were selected for 
pathway analysis by String. 
Statistics 
Data from clinical samples were analyzed by Mann-Whitney U test and Spearman Corre-
lation using SPSS 21.0. All in vitro data were tested using unpaired two-tailed student’s T 
test (Significance levels P<0.05). All data are presented in Mean ± S.E.M. unless other-
wise stated. 
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SUPPLEMENTAL FIGURES 
Supplemental Figure 1 Macrophage Stimulated with rhCECR1 promotes angiogenesis in 3D coculture assays  
 
(a) Low and high magnification fluorescent images of neovessel formation by HUVECs (GFP-marked) and 
human derived pericytes (dsRed-marked) with no macrophage stimulation (no M), with macrophage stimu-
lation (M CECR1 0 nM), and with stimulation of macrophages that were exposed to different concentrations 
of CECR1 during maturation (M CECR1 12.5, 50 and 200 nM). (b) Quantified results of the co-culture experi-
ment. No. of junctions, tubules, and total tubule length data are shown. Represented graphs were taken from 
at least three experiments. Six wells per condition were conducted in each experiment. * P<0.05. (Scale bar: 
100 µm).  
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Supplemental Figure 2 Stimulation with rhCECR1 promotes angiogenesis in 3D coculture assays  
 
(a) Low and high magnification fluorescent images of neovessel formation by HUVECs (GFP-marked) and 
human derived pericytes (dsRed-marked) with stimulation of different concentrations of rhCECR1. (b) Quanti-
fied results of the co-culture experiment. No. of junctions, tubules, and total tubule length data are shown. * 
P<0.05 ***P<0.005. 
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Supplemental Figure 3 PDGFB silencing decreases macrophage paracrine activation of angiogenesis in 3D 
coculture assays  
 
(a) Low and high magnification fluorescent images of neovessel formation by HUVECs (GFP-marked) and 
human derived pericytes (dsRed-marked) without macrophage stimulation, or with macrophage stimulation 
(non-treated control, sisham, or siPDGFB treated) that were pre-treated with or without U87 supernatant 
during differentiation. (b) Quantified results of the co-culture experiment from three times. No. of junctions, 
tubules, and total tubule length data are shown. *P<0.05 **P<0.01  ***P<0.005. (Scale bar: 100 µm).  
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Supplemental Figure 4 Periostin expression in TCGA human GBM samples correlates with a genetic profile that 
is associated with angiogenesis and cell migration  
 
(a) Correlation analysis of periostin mRNA levels with gene sets of three different TCGA human GBM data files. 
Graphs show r values on y-axis, and individual genes that significantly correlate with periostin on x-axis. (b) 
Venn graph demonstrating the overlap between the genes that significantly correlate with periostin expres-
sion in the three data sets. (c) Functional annotation of the 139 overlapping genes produced a list of top 20 
significant biological processes. GO terms are shown on the y-axis. No. of input genes per GO term are indi-
cated on the x-axis.    
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Supplemental Figure 5 Proposed working mechanism of CECR1 in the cross-talk between (M2-like) macro-
phages and pericytes  
 
The GBM environment promotes CECR1 production in (M2) TAMs, which enhances PDGFB expression and 
secretion. PDGFB/PDGFRβ signaling is crucial for the vascular maturation process in angiogenesis, during 
which newly formed microvessels secrete PDGFB to guide perivasular coverage by pericytes. PDGFB secreted 
by (M2) GAMs at perivascular locations activate PDGFRβ signaling and promote both pericyte migration, and 
periostin production in support of angiogenesis. Therapeutic agents (indicated in the diagram as a grey cross) 
that target CECR1, PDGFB, PDGFRβ, or periostin, could interfere with macrophage-pericyte cross-talk and 
subsequently counter tumor-angiogenesis.  
 
Supplementary Information accompanies the paper on the Oncogene website 
(http://www.nature.com/onc) 
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ABSTRACT 
In a previous study we found specific overexpression of periostin in glioma blood ves-
sels.  
Recently, in a murin glioma model periostin expression was linked to glioma stem 
cells and associated with glioma progression. The aim of this study was to identify the 
cellular source of periostin expression in human gliomas, its expression levels in the 
various glioma grades and to study the effect of periostin on glioma angiogenesis. To 
this aim, we compared human glioma samples of various malignancy grades for the 
expression of periostin and sought the cellular source of its expression by confocal mi-
croscopy using multiple markers and in situ RNA to tissue samples. By silencing POSTN 
expression in an in vitro model for angiogenesis we studied the effects of periostin on 
angiogenesis. 
We found that the expression of periostin is exclusively by PDGFRbeta positive cells, 
of which only few cells appeared positive for the glioma stem cell markers SOX-2 and 
olig 2. Silencing of POSTN in pericytes in the in vitro angiogenesis model resulted in 
attenuation of the number and length of the tubules formed, and the number of junc-
tions the vessels formed. The results identify the pericytes as the main source of perios-
tin in human glioma, and highlight the importance of periostin for the formation of 
angiogenesis, thereby proposing periostin as a novel target for developing new anti-
angiogenic strategies for glioma.   
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INTRODUCTION 
In order to find new targets for effective anti-angiogenic therapy for gliomas, the identi-
fication of molecules that play key roles in neovascularization is crucial. In spite of the 
fact that gliomas are among the tumors with highest degree of vascularization, anti-
angiogenic therapies have not yielded major improvements in clinical outcome [1]. It 
remains unclear why anti-angiogenic therapies largely fail, and whether the currently 
used drugs address all players in the complex process of angiogenesis. Notorious 
changes in protein expression patterns of the vessel walls of incipient gliomas have 
been recorded [2, 3]. The blood vessels in high-grade gliomas / glioblastomas (GBM) 
show proliferation of endothelial cells, pericytes and other mural cells, altogether des-
ignated as microvascular proliferation (MVP). Because VEGF levels are associated with 
hypoxia and it is generally assumed that along with tumor progression hypoxia increas-
es, VEGF inhibitors like bevacizumab are only used in patients with high-grade gliomas. 
Given the notion that shifts in protein expression patterns have been recorded in the 
vasculature of low-grade gliomas, new targets for anti-angiogenic therapies, targeting 
early events of angiogenesis in glioma, need to be explored.   
In a previous study we identified some proteins that are specifically upregulated in 
tumor angiogenesis [2]. Among the matricellular proteins αV-integrin and tenascin-C we 
most prominently identified periostin. Matricellular proteins are expressed during de-
velopment, tissue repair and cancer and contribute to angiogenesis by making the ex-
tracellular matrix permissive for new vascular sprouts [4-10]. In various epithelial tu-
mors increased levels periostin were found [4, 11-14] and a prominent role of periostin 
at sites of metastasis was reported [15]. Periostin has only recently been associated 
with glioma invasion and vasculature[2, 16-18]. However, most data were obtained in 
mice models and data on the expression site of POSTN in human glioma are still largely 
missing. In addition, the effects of periostin expression on glioma angiogenesis have not 
been investigated so far. 
In the present study we explored the expression of periostin in human glioma sam-
ples by immunohistochemical detection of co-expression patterns and in situ RNA de-
tection and found expression of periostin by PDGFRβ+ pericytes, with only limited over-
lap with SOX-2+/olig-2+ glioma stem cells (GSC). Silencing of the POSTN gene in cultured 
pericytes in the presence of glioma cells, resulted in a reduction of angiogenic capacity, 
pointing to the importance of periostin for glioma angiogenesis. The results of this work 
highlight the importance of periostin to glioma angiogenesis, and present a plea for its 
candidacy as new target for anti-angiogenic therapeutic strategies in gliomas.   
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MATERIALS AND METHODS 
Tissue samples 
Tissue samples of 12 GBM, 10 PA, 10 grade II and III astrocytoma were selected. In or-
der to make comparisons with normal brain and non-neoplastic lesions in which angio-
genesis takes place, 8 arteriovenous malformations, 5 cavernous hemangiomas, 9 he-
mangioblastomas and 8 samples of normal brain were included for comparison. The age 
and gender distributions of the patients from whom the tumors and lesions were used 
are shown in Table 1.  
 
Table 1 Tissue types, ages and sexes of the patients and relative RNA expression for tenascin-C, periostin and 
Integrin-αV. 
 
n (male / 
female) 
Median age 
(range) POSTN 
 
TNC Integrin-αV 
Glioblastoma 12 (10/2) 47 (14/58) Z=-3.0 p=0.003 Z=-3.7 p=0.0002 Z=-3.7 p=0.0002 
Pilocytic astrocytoma 10 (3/7) 20 (4-51) Z=-3.3 p=0.0004 Z=-3.6 p=0.0004 Z=-3.6 p=0.0004 
Astrocytoma (WHO grade II/III) 10 (5/5) 44 (32-59) Z=-0.9 p=0.4 Z=-2.8 p=0.005 Z=-3.1 p=0.002 
Arteriovenous malformation 8 (7/1) 41 (11/65) Z=-2.2 p=0.03 Z=-2.4 p=0.015 Z=-2.8 p=0.004 
Cavernous hemangioma 5 (1/4) 22 (7/34) Z=-2.4 p=0.02 Z=-2.9 p=0.003 Z=-2.9 p=0.003 
Hemangioblastoma 9 (5/4) 31 (13/82) Z=-3.6 p=0.0004 Z=-3.3 p=0.001 Z=-3.1 p=0.002 
Control brain 8 (5/3) 48 (28/62)    
TNC = tenascin-C; POSTN = periostin. 
The Z-values are calculated by the Mann Whitney U test and are relative to the expressional levels in normal 
brain. 
 
All patients had given consent for using their biomaterials and the study was approved 
by the medical ethical committee of the Erasmus Medical Center. Part of each tissue 
sample was freshly-frozen and stored at -80ºC for RNA isolation while another part was 
formalin-fixed and embedded in paraffin for immunohistochemistry. 
Immunohistochemistry 
For immunohistochemistry we used formalin-fixed, paraffin-embedded material corre-
sponding to the same sample used for RNA isolation. After deparaffinization with xylene 
four adjacent sections for each sample were stained with the following antibodies and 
dilutions: tenascin-C (Abcam, Cambridge, UK, 1:100), Periostin (Sigma Life Science, 
HPA012306, 1:50), integrin-αV, and CD31, (DAKO, Denmark, 1:40). Samples were incu-
bated with primary antibodies for 30 minutes at room temperature, and washed with 
PBS. Next, the samples were incubated with alkaline phosphatase conjugated secondary 
antibodies for 30 minutes at room temperature. Consequently, the slides were washed 
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with Tris/HCl buffer, and developed for 30 minutes using New Fuchsin Alkaline Phos-
phatase Substrate solution. Finally, the slides were rinsed with tapwater, and counter-
stained with haematoxylin. Immunohistochemical stainings were evaluated and scored 
by the neuropathologist (JMK).  
Triple Labeling Immunofluorescence 
Four-µm-thick paraffin sections were cut from formalin-fixed paraffin-imbedded blocks 
of one GBM and one PA sample. Deparaffinized sections were pretreated for antigen 
retrieval by microwave in an EDTA-HCl retrieval solution buffer (Klinipath, 43979001, ph 
9). Slides were washed in PBS/tween 0.1% and incubated overnight at 4ºC with a mix-
ture of the following primary antibodies: Mouse monoclonal integrin-αV (Santa Cruz sc-
9969, 1: 40) and rabbit polyclonal periostin (Atlas antibodies HPA012306, 1:100). Slides 
were washed twice with PBS/tween 0.1%, and incubated for two hour at room temper-
ature with a mixture of the following two secondary antibodies: goat anti-mouse Cy3 
(Biolegend, 405309, 1:200 ) and donkey anti-rabbit Cy5 (Jackson, 711-175-152, 1:50). 
After washing, the slides were incubated for one hour at room temperature with 
normal mouse serum (Jackson, 015-000-120, 1:20). The purpose of this step was to 
saturate the open binding sites on the goat anti-mouse secondary antibody with IgG. 
The slides were incubated for one hour at room temperature with unconjugated Fab 
goat anti-mouse IgG (H+L) (Jackson, 115-007-003). This step covers the remaining se-
rum-derived mouse IgG binding sites. The slides were washed and incubated overnight 
at 4ºC with monoclonal primary antibody against tenascin–C (Abcam, Ab 58954, 1: 100). 
Washed slides were incubated for two hours at room temperature with secondary anti-
body (goat anti-mouse-FITC conjugated, Biolegend, 405305, 1: 100). The slides were 
stained for 5 minutes with 0.1% solution of Sudan Black (Sigma, 199.664) in ethanol 70 
%. The sudan black step is included to diminish autofluorescence of lipofuscin. Slides 
were stained with DAPI and mounted with coverslips. 
RNA isolation and RT-PCR 
For each sample, 10-15 sections of 20 µm thickness were cut by cryostat. Sections were 
collected in RNase free Eppendorf tubes, snap frozen on dry ice, and stored at -80ºC 
until RNA isolation. To verify the presence of tumor in all the sections used for RNA 
isolation, we cut 5 µm sections before and after sampling for RNA isolation and verified 
content of lesional tissues in H&E stained sections. Total RNA was isolated using RNA-
Bee (Campro, Veenendaal, The Netherlands) according to the instructions supplied by 
the manufacturer. Following isolation, RNA samples were diluted in nuclease-free wa-
ter, snap frozen on dry ice and subsequently stored at -80ºC. Total RNA quantity was 
determined by Nanodrop and RNA integrity was checked using gel electrophoresis. To 
generate cDNA, 1 µg of total RNA was reverse transcribed using the RevertAid cDNA 
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synthesis kit (Fermentas). cDNA samples were dissolved in 20 µl nuclease-free water, 
and stored at -20ºC until analysis by RT-PCR.  
Samples were analyzed in the Applied Biosystems 7500 Fast Real-Time PCR System. 
We used the following commercially available exon-spanning TaqMan Gene Expres-
sion Assays (Applied Biosystems): Periostin, exon 3-4 (Hs00170815_m1), Hypoxanthine 
phosphoribosyltransferase 1 (HPRT1), exon 1-2 (Hs01003267_m1) and beta-Actin, exon 
1-1 (Hs99999903_m1). Four µl of each cDNA sample was amplified for 40 rounds, in a 
reaction volume of 20 µl. Maximal reliable Ct levels were set at 35. For Ct values ex-
ceeding 35, the ΔCt levels were replaced by the lowest ΔCt value minus one for each 
target (corresponding with 50% of the lowest detected level of expression). Since 
GeNorm and NormFinder analysis recognized HPRT1 as the most stable reference gene 
among all tissue groups, we used HPRT1 as our reference gene. We quantified the rela-
tive expression level for each gene by calculating ΔCt values: ΔCt = Ct (HPRT1) – Ct (tar-
get). 
Statistics 
Using the Mann-Whitney U test in SPSS 17.0.2, ΔCt values were compared between 
PAs, grade II/III astrocytomas, GBMs, arteriovenous malformations, cavernous heman-
giomas, hemangioblastomas and normal brain. All glioma subgroups were compared to 
each other. Due to multiple testing, P-values < 0.01 were considered statistically signifi-
cant.  
In situ RNA hybridization 
In situ hybridization was performed using the RNAscope1 2.0 HD Brown Chromogenic 
Reagent Kit according to the manufacturer’s instructions (Advanced Cell Diagnostics, 
Hayward, CA). Hs-POSTN probe (Advanced Cell Diagnostics #409181) was used follow-
ing the manual protocol. Briefly, prepared slides were baked for 1 h at 60°C prior to use. 
After deparaffinization and hydration, tissues and cells were air-dried and treated with a 
peroxidase blocker before heating in a target retrieval solution (pretreatment 2 solution 
as part of the RNAscope1 kit; Advanced Cell Diagnostics #320043) for 20 min at 95–
100°C. Protease (pretreatment 3 solution of the RNAscope1 kit; Advanced Cell Diagnos-
tics #320045) was then applied for 30 min at 40°C. Target probes were hybridized for 2 
h at 40°C, followed by a series of signal amplification and washing steps. Hybridization 
signals were detected by chromogenic reactions using DAB chromogen followed by 1:1 
(vol/vol)-diluted hematoxylin (Fisher Scientific, Pittsburg, PA) counterstaining.  
POSTN in various cell types   
The expression of the POSTN gene was measured by RT-PCR in HUVECs (ScienCell-
1800), pericytes (ScienCell-1200) and human astrocytes (scienCell-8000). The POSTN 
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protein expression is measured by Western Blotting in cell lysates of HUVECs, pericytes 
and astrocytes. 
HUVECs and pericytes were co-cultured for 3 days by using DMEM media + SCF, 
SDF-1α and IL-3 and the protein expression of POSTN is measured in both cell types and 
in their media. Subsequently, HUVECs and pericytes were co-cultured (DMEM media + 
SCF, SDF-1α and IL-3) and stimulated by adding conditioned media of glioma cells (U87).  
Silencing of POSTN 
POSTN in pericytes was silenced by using two different siRNA sequences (Supplemental 
Figure 1).  POSTN was successfully downregulated using siPOSTNs2 (n= 3).  
Angiogenesis model 
HUVECs were labeled with GFP and pericytes with DsRed. The HUVECs and pericytes 
were mixed at ratio 5:1 and cultured in medium consisting of DMEM + SCF; SDF-1
α
 and 
IL-3. To create 3D angiogenesis model, bovine collagen type 1 was mixed with pericytes 
and added to a 96-well plate. HUVEC were placed on top of the collagen 1. Parameters 
of angiogenesis (i.e., number and lengths of tubules and number of junctions) were 
measured up to 5 days as described previously [19]. The experiments were repeated 6 
times in 6 wells. The angiogenesis experiments were repeated by using U87 conditioned 
media. 
RESULTS 
Immunohistochemistry & RT-PCR 
In PA and GBM, expression of periostin was present in the perivascular area of hyper-
trophic and glomeruloid vessels (Figure 1A). In PA expression was exclusively found 
around the blood vessels, while in GBM, periostin was also markedly present in areas 
away from the blood vessels. In grade II/III astrocytomas that have by definition no 
MVP, little expression around the blood vessels was seen. The  
Results of immunohistochemistry corresponded to those of RT-PCR; periostin ex-
pression was low in normal brain and in grade II/III astrocytomas, as opposed to the 
expression in PA, GBM and the vascular malformations (arteriovenous malformations, 
cavernous hemangiomas) and hemangioblastomas, where periostin was strongly ex-
pressed (Figure 1B).  
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Figure 1 
 
Figure 1A:POSTN is expressed in the perivascular area in both glioblastoma (GBM) and pilocytic astrocytoma 
(PA). Unlike the expression in PA, in GBM POSTN is also expressed in areas away from the blood vessels. In 
astrocytoma grade II / III and normal brain samples scarce cells express POSTN. (H&E, x 200). Figure 1B: 
POSTN expression in various types of brain tumors was confirmed by RT-PCR. POSTN is expressed at a high 
level in GBMs and Pas. In contrast, POSTN was expressed at a low level in astrocytoma grade II /III, and normal 
brain samples (showing limited or no angiogenesis). 
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Confocal microscopy to periostin and PDGFRβ expression demonstrated co-localization 
of these two proteins (Figure 2), indicative of periostin expression by pericytes. 
 
Figure 2 
 
Confocal images of blood vessels in GBMs. PDGFRβ is a marker for (cerebral) pericytes. POSTN is expressed by 
PDGFRβ+ cells. Blue=DAPI (nuclear staining); Red=POSTN; Green= PDGFRβ (pericytes); merged images show 
that POSTN expression is localized in the pericytes.   
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Immunohistochemistry to the glioma stem cell markers olig-2 and Sox-2 and periostin 
showed only few cells positive for periostin and any of the two stem cell markers. (Fig-
ure 3). 
 
Figure 3 
 
Immunohistochemical staining of GBM samples for the glioma stem cell markers Olig-2 and Sox-2 show that 
POSTN is not expressed by Olig-2+ / Sox-2+ cells. Very limited POSTN+ cells express either oligo-2 or Sox-2, 
showing that POSTN is not expressed by stem cells in human GBMs.   
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In situ hybridization RNA 
In situ RNA expression of periostin was found in PDGFRβ-positive cells (pericytes, Figure 
4A ). 
 
Figure 4A 
 
In situ RNA expression of periostin was found in the PDGFRβ+ pericytes. Few POSTN+ cells were found scat-
tered outside the endothelial layer. 
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These cells were found scattered outside the endothelial layer and no co-localization of 
RNA in situ signal with GFAP+ astrocytic cells, or CD31+ endothelial cells was seen (Fig-
ure 4B).  
 
Figure 4B 
 
POSTN RNA in situ expression overlaps with the periostin protein (left lower and upper panels) but there is no 
co-localization with CD31+ endothelial cells or GFAF+ astrocytic (tumor) cells (right lower and upper panels).   
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Pericytes are the main source of POSTN; in vitro results  
Measurements of the expression of POSTN by RT-PCR in HUVEC, pericytes and astro-
cytes revealed that periostin is expressed mainly in pericytes. Based on RT-PCR results 
and western plot, no periostin expression was detected in HUVECs while pericytes ex-
pressed high levels of POSTN. Periostin was expressed in astroctyes but the level of 
expression was lower than that in pericytes (Figure 5A). 
 
Figure 5 
 
A. Western blot results: HUVECs do not express POSTN at all. The same results are confirmed by IHC and RNA 
in situ hybridization. β-actin was used as control to normalize POSTN expression. 
B. Conditioned media of glioma cells stimulate pericytes to express higher levels of POSTN: the expression of 
POSTN in pericytes has increased after adding condition media of glioma cells (U87). Conditioned media of 
glioma cells did not stimulate HUVEC’s to express POSTN: the expression of POSTN in HUVEC cells was not 
affected after adding condition media of glioma cells (U87) (data not shown). 
 
Following co-culturing HUVECs and pericytes POSTN gene, and protein expression was 
low in the HUVECs, while the gene was upregulated in pericytes without protein 
change. However, following stimulating the co-cultures with condition media of glioma 
cells (U87), pericytes expressed higher levels of periostin (Figure 5B). 
POSTN supports angiogenesis 
Because pericytes expressed the highest level of periostin, we proceeded to silence 
periostin in pericytes. Silencing of POSTN was achieved by two different si RNA se-
quences. POSTN was successfully downregulated using siPOSTN for both sequences 
(n=3; mean ± S.E.M.; p , 0.005) (Suppl. Figure 1). The efficient downregulation of POSTN 
in cell lysates and pericyte-conditioned medium was achieved for sequence #2. Efficient 
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downregulation of periostin protein by using sequence #1 was only achieved in the 
conditioned medium, not the cell lysates. 
The successful silencing of POSTN in pericytes resulted in significant attenuation of 
the number and length of the tubules formed, and the number of junctions the vessels 
formed (Figure 6A and B).  
 
Figure 6A 
 
 
Figure 6B  
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A. Silencing POSTN has a significant effect on the number and lengths of tubules and number of junctions 
formed in the In vitro 3D angiogenesis model. Green=HUVEC; Red=Pericytes; siSham=negative control for 
silencing; siPOSTN1 &2= Silencing POSTN in pericytes by using 2 different sequences. B. Angiogenesis parame-
ters are affected by silencing POSTN: silencing POSTN affected the number of tubule formation and the length 
of the tubules more significantly than the number of junctions. 
DISCUSSION 
Periostin is a member of the TGF family of which the expression is induced by TGF-β and 
BMP-2 [20]
.
. Periostin is a multifunctional matricellular protein that regulates the for-
mation of the peridontal ligaments, the cardiac valves and acts in bone morphogenesis 
[21]. Further, Periostin interacts with other ECM components like tenascin-C [22] and 
the bone morphogenic proteins 1/2 (BMP1/2) that promote the remodeling of the ex-
tracellular matrix by promoting the secretion of fibronectin and collagen [23,24]. Perios-
tin has been associated with cancers of the GI tract [25-27] and breast cancer. In breast 
and colon cancer it was shown that the expression of periostin in stromal cells is in-
duced by tumor cells and is associated with cell proliferation, immune evasion, migra-
tion and genomic instability and decreases apoptosis of cancer cells [13, 28, 29]. Among 
other extracellular matrix proteins, periostin also plays a role in regulating the epitheli-
al-mesenchymal transition (EMT) of tumor cells [30]. In breast cancer, periostin is re-
portedly expressed by tumor-associated fibroblast residing in the microenvironment 
and enhances the metastatic potential of the tumor cells [31]. Interaction between 
periostin and Wnt3/4 and LRP5/6 activates canonical Wnt signaling. In breast cancer 
periostin also promotes the resuscitation and proliferation of perivascular located tu-
mor stem cells [32]. The N-terminal region binds to the integrins αVβ+3,αVβ5, α6β4 
through its FAS domain [30] thereby stimulating the migration of tumor associated 
endothelial cells and tumor cells via the activation of Akt/PKB and Focal Adhesion Ki-
nase(FAK)-mediated signaling pathways [13]. The intracellular domain of pre-NOTCH1 is 
recognized by periostin causing the activation of the Notch pathway [33]. Loss of Postn 
in the ErbB2/Neu-driven murin breast tumor model results in reduced activity of the 
Notch signaling pathway and deceleration of tumor growth [34].  
To date, only few studies have focused on the expression of periostin in glial neo-
plasms [2, 35]. In a study based on data from the cancer genome atlas, upregulation of 
periostin expression in GBMs was associated with tumor progression and shortened 
survival rates [36]. Periostin secretion has been associated with human glioma cell inva-
sion, adhesion, migration and stem cell survival, and correlates directly with glioma 
grade [37]. The expression of periostin in GBM is reversely related to clinical outcome 
(Disease free survival and overall survival). The association between the expression 
levels of periostin on the one hand, and glioma grade and patient survival on the other, 
may well be explained by the increase in angiogenesis during glioma progression. Peri-
ostin expression was reportedly found in cells of astrocytic lineage and “vascular ele-
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ments” but no double labeling for GFAP or other markers was provided [37]. Although 
we found expression of periostin in cultured astrocytes we were unable to detect any 
expression in astrocytic tumor cells in the human glioma samples.  
In the present study we demonstrate the specific link between periostin expression 
and glioma angiogenesis. Periostin has been associated with invasion of glial tumor cells 
and was not specifically linked to angiogenesis [16, 38]. However, periostin was associ-
ated with angiogenesis previously: it promotes angiogenesis in wound healing, vascular 
heart disease, and also in neoplasia [39-44]. The elevated expression levels are due to 
hypoxia and VEGF-driven angiogenesis [45-47]. Under hypoxic circumstances periostin 
promotes the incorporation of tenascin-C into the extracellular matrix serving various 
reparative processes [48, 49]. In addition, during breast cancer-associated angiogenesis 
the so-called tip cells (endothelial cells that navigate the branching of newly formed 
vessels) also transiently express periostin. In the GBMs included in this study we found 
the expression of periostin concentrated around the blood vessels and variable expres-
sion in the neuropil. The marked expression of periostin around vessels suggests that its 
upregulation is mediated by hypoxia, which is supported by the results of several stud-
ies [50, 51]. The extravascular expression of periostin in GBM in the present study is 
reminiscent of findings in ovarian carcinoma [11, 13, 14, 52], colon cancer [11, 53], 
pancreas carcinoma [14], breast cancer [28] and neuroblastoma [54]. The expression of 
periostin in GBM and PA is suggestive of involvement in the formation of vessel hyper-
trophy underlying vascular dysfunction. The significant difference in the expressional 
levels of periostin in astrocytomas grades II and III on the one hand, and GBM on the 
other hand, suggests that periostin plays a specific role in the genesis of vascular hyper-
trophy. 
There is interesting recent data on the expression of periostin in a murin glioma 
model. It was shown that SOX-2+/Oligo-2+ glioma stem cells express periostin that, by 
interaction with Integrin αVβ3 recruit peripheral monocytes to the perivascular spaces 
where these cells subsequently differentiate into M2-like macrophages [55]. In this 
study we confirm predominant expression around the blood vessels. In addition, we 
identified the PDGFRβ+ pericytes as the source of periostin production. Although we 
found overlap of the immunophenotypes of these cells with the glioma stem cell profile 
(SOX2+/olig2+), the majority of cells producing periostin are not immunopositive for the 
stem cell profile. Therefore, the data indicate that the situation of periostin expression 
in mice is only partly recapitulated in man. In previous work [56] we found that TAMs 
with M2 profiles present in gliomas contribute to glioma angiogenesis by the production 
of CECR1. The present results obtained in the in vitro angiogenesis model reveals a role 
of periostin, produced by pericytes (not TAMs), in human glioma angiogenesis. The in 
vitro experiments show that silencing for periostin in pericytes have a negative effect on 
the number and length of the vascular tubules and the formation of junctions. Studies 
in mice have shown that by periostin secretion pro-tumoral macrophages are recruited 
and that periostin propagates tumor growth by suppressing the anti-tumoral functions 
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of the T lymphocytes [55]. Taken together, the available data point to cellular and mo-
lecular interactions in the perivascular niche that involve GSCs, pericytes, TAMs and 
other cells, that mediate glioma growth and angiogenesis. 
Similar to periostin, integrin-αV is another molecule that not only plays a role in an-
giogenesis, but also in the proliferation, migration and invasion of the tumor cells [57]. 
In the central nervous system VEGF triggers the expression of integrin-αV by activated 
endothelial cells, pericytes and glial cells. The expression of integrin-αVβ3 and integrin-
αVβ5 also parallels the progression from low-grade to high-grade tumors [4, 58-60]. 
Schnell et al. found elevated levels of integrin-αV β3 in GBM but not in low-grade glio-
mas[58]. Because of their prominent expression in tumor tissue and minimal expression 
in normal brain, tenascin-C and integrin-αV have served as therapeutic targets in phase 
I and II trials in GBM patients, in which blocking antibodies and RNAi have yielded mod-
est improvements in survival [4, 61, 62]. Because of the functional connection between 
tenascin-C and periostin, considering the latter in the development of anti-glioma ther-
apeutic strategies seems legitimate. 
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SUPPLEMENTAL FIGURES 
Suppl. Figure 1 
 
(upper part): RT-PCR results of siPOSTN: The differences of the expression levels of POSTN in the cell lysates 
indicate successful silencing at the RNA level for both probes used. (lower part): Western blotting of the cell 
lysates for periostin following siPOSTN shows that probe #2 yielded better silencing results than probe #1d.   
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Suppl. Figure 2 
 
(Upper panel): RT-PCR results of siPOSTN: The differences of the expression levels of the secreted POSTN in 
the supernatant show a successful silencing at the RNA level for both probes used.  (Lower panel): Western 
blotting results of siPOSTN: The secreted protein expressions of POSTN reveal successful silencing using both 
siPOSTN probes.  
  
Proteome analysis of the CECR1 mediated response of TAMs in glioma 
121 
Chapter 6 
Proteome analysis of the CECR1 mediated response of TAMs in glioma 
Chapter 6 
Proteome analysis of the CECR1 mediated 
response in tumor associated macrophages 
identifies key pathways and molecules in the 
immune response regulation of glioma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Changbin Zhu, M.D. M.Sc.; Dana Mustafa, Ph.D; Ihsan Chrifi B.A.Sc., Lennard Dekker, 
Ph.D.; Pieter J.M. Leenen, Ph.D.; Dirk J. Duncker, M.D., Ph.D.; Theo M. Luider, Ph.D.; 
Johan M. Kros, M.D., Ph.D.
*
; Caroline Cheng Ph.D.
*
 (* equal contribution of last authors) 
 
(Submission in prep.) 
Chapter 6 
122 
  
Proteome analysis of the CECR1 mediated response of TAMs in glioma 
123 
ABSTRACT  
Introduction: Tumor associated macrophages (TAMs) promote tumor development, 
angiogenesis and distal metastasis. In previous studies, we showed that Eye Syndrome 
Critical Region Protein 1(CECR1) is expressed by M2-like TAMs in glioma and promotes 
M2 TAMs differentiation, affecting tumor cell proliferation and migration. Here we 
investigated the proteomic profile of TAMs expressing CECR1. 
Methods: THP-1 macrophages were siRNA silenced for CECR1 in vitro, with or without 
stimulation  by glioma (U87) cells. Lysates were analyzed by (nano)LC-MS. Significant 
altered protein levels were identified (P<0.05), followed by pathway annotation 
(STRING, IPA and Cytoscape). 
Results: CECR1 silencing upregulated 67 proteins in THP1-derived macrophages. Path-
way annotation mapped this set to 3 major pathways relevant to macrophage func-
tions, including MHCI antigen presentation, phagosome maturation and endocytosis. 
Stimulation by U87 cells attenuated the changes that were observed on protein and 
mRNA levels in response to CECR1 silencing. LAT2 was upregulated by CECR1 knock-
down in U87 co-cultured macrophages and was associated with a IL-10
low
, IL-12
high
 M1-
like phenotype. CECR1 silencing also downregulated S20 proteasome complex proteins 
PSMA5, PSMA7, PSMC6 and PSMD8 in the U87 coculture conditions. This protein profile 
was linked to a low proliferation rate of CECR1-silenced TAMs. Overlap analysis identi-
fied S100A9 and PLAU as CECR1-related proteins that were significantly correlated with 
expression of CECR1 and macrophage lineage markers in three large public GBM da-
tasets.  
Conclusion: This study reports the molecular pathways and key molecules that are me-
diated by CECR1 function in macrophages and TAMs in glioma.  
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INTRODUCTION 
Glial tumors are highly heterogeneous in cell composition and are located in the im-
mune privileged environment of the central nervous system, limiting effective thera-
pies. In glioblastoma multiforme (GBM), mesenchymal cells with macrophage or micro-
glia characteristics can comprise up to 40% of all local cells (REF: PMC4373835). Macro-
phages are a major component of the innate immune system
1
, contributing to early 
pathogen recognition, removal and presentation
2,3
. Displaying relatively high plasticity, 
macrophages can adapt to the local microenvironments by differentiating into sub-
phenotypes with various functions
5,6
. In classic immunology, for simplicity of study, 
phenotypes of macrophages are usually put into the perspective of the M1 and M2 
spectrum
7
. In the microenvironment of malignant tumors, recruited monocytes pre-
dominantly differentiate into tumor-associated macrophages (TAMs), that typically 
exhibit an M2-like macrophage phenotype. M2-like TAMs  are characterized by higher 
expression levels of cell surface markers CD163, CD204, CD206, and CSFR1. In addition, 
M2-like TAMs secrete higher levels of IL-10, CCL18, TGF-β, and COX-24. This paracrine 
profile mainly induces local immune-suppression by inhibiting infiltration of CD8+ T cells 
and promoting activation of the regulatory T cells population
11
. TAMs also promote 
tumor angiogenesis via secretion of pro-angiogenic factors and enzymes like VEGFA, 
VEGFC, PDGFB, PDGFC, uPA, FGF, Cathepsin and MMPs
12,13
. In breast, prostate, bladder  
and cervical cancers, the presence of M2-like TAMs tumors is therefore  strongly associ-
ated with immunosuppressive action and dismal prognosis
8-10
. In glioma a significant 
higher number of TAMs are observed in high-grade tumors that is associated with in-
creased vascular density  of the tumor tissue.  
An improved understanding of the molecular regulators of M2-like TAMs will ease 
the identification of new drug targets in the treatment of GBM and other types of ma-
lignant tumors. In previous studies on diffuse gliomas we have examined the function of 
cat eye syndrome critical region 1 (CECR1), a conserved molecule that is highly ex-
pressed in the macrophage lineage
15
. CECR1 reportedly functions as a growth factor 
and immune regulator through its adenosine deaminase enzymatic activity as well as by 
direct binding to adenosine receptors in invertebrate and vertebrate
16,17,18
. More specif-
ically, CECR1 binds with adenosine receptors and functions as a growth factor for mon-
ocytes and T lymphocytes via autocrine and paracrine stimulation
19
. In monocytes, 
CECR1 was also shown to promote monocyte differentiation (PMID:20453107). In a 
recent genetic study, loss-of-function mutations in CECR1 were shown to be associated 
with a range of vascular and inflammatory phenotypes in patients with syndromic 
presentations of early-onset stroke, systemic vasculopathy and auto-inflammatory dis-
eases (PMID 24552284). The cytokine profile of patient-derived CECR1 gene deficient 
macrophages demonstrated a  predominant M1-like pro-inflammatory phenotype
20,21
. 
Our previous findings reported increased expression of CECR1 in TAMs of gliomas, and 
provided causal evidence that CECR1 is vital for promoting TAM differentiation towards 
Proteome analysis of the CECR1 mediated response of TAMs in glioma 
125 
an M2-like (immune-suppressive) phenotype (REF). Furthermore, we demonstrated that 
CECR1 functions as an oncogenic molecule that enhances glioma proliferation, migra-
tion and angiogenesis via direct crosstalk between TAMs, glial cells and vascular cells.  
Although these studies have improved our understanding of CECR1 function in 
TAMs, the complex intracellular molecular mechanisms in macrophages that are medi-
ated by CECR1 remain to be further elucidated. In this study we aimed to define the 
function of CECR1 in TAMs by a proteomics approach. We identified key CECR1 regulat-
ed molecules and pathways in normal macrophages and TAMs that are activated by glial 
tumor cells.       
MATERIAL AND METHODS 
Cell Culture 
The human monocytic cell line, THP-1 cells were obtained from the department of He-
matology, Erasmus Medical Center, Rotterdam.  THP-1 cells were cultured in RPMI-1640 
medium supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin/Strepto-
mycin. THP-1 macrophage differentiation was induced by stimulating with PMA (Sigma, 
Sweden) for 48 hours at the concentration of 100 ng/ml. The human GBM cell line U87 
was purchased from ATCC (USA) and maintained in DMEM with 10% FBS and 1% Penicil-
lin/Streptomycin.  
siRNA Transfection 
A mix of four siRNA sequences that target CECR1 mRNA (5’-GUGCCAAAGGCUUGU 
CCUA-3’,5-CUUCCACGCCGGAGAAACA-3’, 5’-GCCCAAAGCUAGUUAGUAC-3’, 5’-UCGCA 
GAAUCCAUCCGAAU-3’) and scrambled non-targeting siRNAs (5’-UGGUUUACAUGUCG 
ACUAA-3’, 5’-UGGUUUACAUGUUGUGUGA-3’, 5’-UGGUUUACAUGUUUUCUGA-3’, UGGU 
UUACAUGUUUUCCUA-3’) were obtained from Dharmacon (GE health care, Nether-
land). THP-1 derived macrophage cultures were transfected after 48 hours of PMA 
treatment, following the manufacture’s protocol (using Dharmacon transfection rea-
gent). Efficiency of CECR1 knockdown was assessed after 24 and 48 hours at transcrip-
tional level and protein level. For co-culture experiments siRNA transfected cells were 
used 24 hours post transfection. 
Co-Culture 
100,000 U87 cells were seeded on top of the culture inserts with a pore size of 0.4µm 
(Fisher Scientific, USA). SiRNA transfected macrophages were seeded into the lower 
chamber in 6-well plates. Macrophages were co-cultured with U87 cells in serum-free 
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RPMI-1640 medium for 48 hours and 96 hours for RNA and protein isolation respective-
ly. Real-time qPCR and proteomic analysis were performed after 48 hours and 96 hours 
post co-culturing respectively. Macrophages without U87 cell co-culture were harvested 
48 hours and 96 hours post transfection for qPCR and proteomic measurement respec-
tively (Figure 1). 
 
Figure 1 Schematic illustration of study design and work flow 
 
Human monocytic cell line THP-1 cells were differentiated into macrophage by PMA (100ng/ml) for 48 hours 
followed by siRNA transfection, non-targeted, scramble siSham as transfection control. At the same time, 
glioblastoma cell line U87 was co-cultured with macrophage with/without CECR1 silencing. After 96 hours’ 
incubation, cell lysates of these macrophages were harvested and analyzed by nano-LC/MS. Raw data was 
imported into Scafford 4 and further exported into Excel sheet for further analysis. 
Proteomics analysis  
Macrophage cell pellets were harvested and 150 µl of RapiGest (Waters Corporation, 
Milford, MA) in 50 mM NH4HCO3 was added to each sample. Samples were sonificated 
for 4 min at 70% amplitude at a maximum temperature of 25 °C (Branson, Ultrasonic, 
Danbury, CT). The proteins were reduced with 10 mM dithiothreitol (DTT) at 60°C for 30 
min. After the mixture was cooled down to room temperature, it was alkylated in the 
dark with 50 mM iodoacetamide at ambient temperature for 30 min, and digested 
overnight with 5 µl trypsin (Promega, Madison, WI). To inactivate trypsin and to de-
grade the RapiGest, 2 µl of 50% TFA was added and samples were subsequently incu-
bated for 30 minutes at 37°C. Samples were centrifuged at maximum speed for 15 min 
at 4°C and the supernatants were transferred to LC vials to be measured on the LC-MS. 
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The digested samples were measured on a nano-LC (Thermo Fisher Scientific, Ger-
mering, Germany). 
Raw data from proteomics measurements was imported into Scaffold 4 followed by 
export in Excel sheet format. Total unique peptide count per peptide in each group was 
compared by student’s T-Test. Proteins were considered differentially expressed when 
P<0.05. 
RNA isolation and Real time qPCR  
Total RNA was isolated from macrophages using RNA isolation kit (bio-line, USA) and 
reversely synthesized into cDNA using Sensi-fast cDNA synthesis kit (Bio-line, USA) fol-
lowing manufacture’s protocol. QPCR was performed by assessment of Syber Green 
signal using CFX96 Touch™ Real-Time PCR Detection System (Bio-rad, USA). Transcripts 
of CECR1, S100A9, PLAU, CTSH, HLA-A, HLA-C, ITGB7, WDFY, EVL, SEPT7, IL-10, IL-12p35 
were measured and normalized to β-actin (Primers for all targets are shown in Supple-
mentary table 1) 
MTT Assay 
THP-1 macrophages were transfected with siSham and siCECR1. The following day 
transfected macrophages were seeded in 96-well plates at a density of 5000 cells/well.    
Macrophages were treated by U87 derived conditioned medium. Macrophages without 
U87 conditioned medium treatment were measured at the same day as a reference 
measurement. Macrophage proliferation was monitored for the next five days using 
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma, Sweden), 
which was added at a concentration of 0.45 mg/ml to each well. After 4 hours of incu-
bation, the MTT signals were measured by spectrometry at the 570 nm absorbance 
wave length. 
Western Blot 
20 µg of total protein was loaded onto a 10% SDS-PAGE gel and blotted to Nitro cellu-
lose membranes followed by incubation with block buffer (Licor Bioscience, USA). Pro-
tein levels were assessed by immunoblotting using specific antibodies against LAT2 (Cell 
Signaling Technology, 1:1000), and β-actin (Abcam, 1:500) as a loading control, followed 
by incubation with secondary antibodies (IRdye 680 CW, IRDye 800 CW, Licor Biosci-
ence, USA) and detection of signals using the Odyssey imaging system (Licor Bioscience, 
USA). 
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Immunofluorescent staining 
Macrophages silenced for CECR1 versus sisham-transfected controls were treated with 
U87 conditioned medium for 48 hours. Macrophages were fixed in 4%PFA for 15 min. 
Cells were permeabilized followed by a blocking step. Primary antibodies against 
CECR1(Sigma, 1:200), Ki67(Dako 1:200), and secondary antibodies were applied to de-
tect expression of target proteins. 10 areas were randomly selected and pictures were 
taken under the confocal microscope (Zeiss, The Netherlands). The number of Ki67 
positive cells was counted in each image view. 
Bioinformatics  
Raw data generated by Scaffold 4 was exported into Excel. Significantly expressed pro-
teins were enriched in biological process pathways and KEGG pathways by STRING da-
tabase(http://string-db.org/). Proteins that were not significantly changed were import-
ed as background molecules and mapped into canonical pathways together with signifi-
cantly expressed proteins using Ingenuity Pathway Analysis (Qiagen, USA). Proteins 
mapped into Canonical Pathways were exported, and networks were generated by 
STRING online software. Information from each network were exported and visualized 
using Cytoscape 3.3. Mutual expressed proteins were identified and visualized by Venne 
Graph (http://bioinformatics.psb.ugent.be/webtools/Venn/). Correlation analysis was 
performed using the TCGA GBM database via the c-Bioportal provided by the Memorial 
Sloan-Kettering Cancer Center. Calculated Pearson and Spearman correlation co-
efficiencies were used to generate Heat maps using Excel. 
Statistics  
Unique peptides from the proteomic analysis were compared per group in each exper-
iment and analyzed using unpaired two-tailed students’ T-Test. Proteins were consid-
ered significantly differentially expressed when P<0.05. All in vitro data were tested 
using unpaired two-tailed student’s T test (Significance levels P<0.05). All data are pre-
sented in Mean ± S.E.M. unless otherwise stated. 
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RESULTS 
Changes in proteomic profile of THP-1 macrophages in response to CECR1 
silencing   
For proteomics analysis, CECR1 was silenced in THP-1 macrophages for 96 hours. The 
efficiency of CECR1 silencing was assessed by immunofluorescence of the CECR1 signal 
in siCECR1 treated macrophages compared with non-targeting scrambled siRNA (si-
sham) transfected control macrophages (Supplementary figure 1). Protein lysates de-
rived from CECR1-silenced versus sisham treated macrophages were analyzed by mass 
spectrometry (Figure 2a). In total, protein levels of 102 proteins were affected by CECR1 
silencing (Supplementary table 2,3). 35 proteins were down-regulated (more enriched 
in sisham group), and 67 proteins were upregulated in the CECR1-silenced group (more 
enriched in the siCECR1 group (Figure 2b).  
Gene ontology analysis indicated that these 35 down-regulated proteins were en-
riched in pathways like “protein folding”, “translation”, and “peptide metabolic process” 
(Figure 2c). The 67 proteins upregulated were enriched in several Gene Ontology and 
KEGG pathways and cell mechanisms including ”Antigen processing and presentation of 
exogenous peptide antigen via MHC class I”, “type I interferon signaling pathway” as 
well as “Phagosome” (Figure 2d, e).  
For more in depth analysis, proteins which were not significantly affected by CECR1 si-
lencing were analyzed together with the 67 upregulated proteins, using Ingenuity Path-
way Analysis (IPA). Retrieved networks include “MHC I Antigen Presenting”, “Phagosome 
maturation” and “Caveolin mediated endocytosis”. These networks and detailed infor-
mation of protein components of each network of are presented in Figure 3a, b, c; Table 
1-3. Among the 67 proteins that were upregulated in the CECR1 silenced condition, 15 
proteins including HLA-A, B, C, TAPBP, TAP1, ISG15, ELAVL1 and CTSS were predicated to 
be downstream targets of IFN-γ signaling (Figure 3d). Together these data indicate that 
CECR1 in normal macrophages are involved in regulating MHCI antigen presentation, 
phagosome maturation, caveolin mediated endocytosis, and IFN regulated signaling.    
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Table 1.  Proteins in MФ siCECR1 mapped to Antigen Presenting Pathway by IPA 
UniProt Symbol  Entrez Gene Name Location Type(s) Fold Change P-Value 
P30501 HLA-C major histocompatibility complex. class I. C Plasma Membrane other 8 0.001 
Q03518 TAP1 major transporter 1. ATP- binding cassette. sub-family B (MDR/TAP) Cytoplasm transporter 1.500038989 0.006 
P01892 HLA-A histocompatibility complex. class I. A Plasma Membrane other 1.2397077 0.007 
Q03519 TAP2 transporter 2. ATP- binding cassette. sub-family B (MDR/TAP) Cytoplasm transporter 1.500038989 0.008 
P27797 CALR calreticulin Cytoplasm transcription regulator 1.135242102 0.01 
O15533 TAPBP TAP binding protein (tapasin) Cytoplasm transporter 1.333298677 0.023 
P10319 HLA-B major histocompatibility complex. class I. B Plasma Membrane transmembrane receptor 1.275444392 0.035 
P28062 PSMB8 proteasome subunit beta 8 Cytoplasm peptidase 1.143138335 0.067 
P28065 PSMB9 proteasome subunit beta 9 Cytoplasm peptidase 0.833353207 0.37 
P61769 B2M beta-2- microglobulin Plasma Membrane transmembrane receptor 1 0.42 
P30101 PDIA3 protein disulfide isomerase family A member 3 Cytoplasm peptidase 1.07549439 0.43 
P28072 PSMB6 proteasome subunit beta 6 Nucleus peptidase 0.799960128 0.52 
P27824 CANX calnexin Cytoplasm other 0.967947027 0.6 
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Table 2 
UniProt  Symbol Entrez Gene Name Location Type(s) Fold Change P-Value 
P30501 HLA-C major histocompatibility complex. class I. C Plasma Membrane other 8.33 0.001 
P54920 NAPA NSF attachment protein alpha Cytoplasm transporter 1.83 0.005 
Q03518 TAP1 transporter 1. ATP-binding cassette. sub-family B (MDR/TAP) Cytoplasm transporter 1.50 0.006 
P01892 HLA-A major histocompatibility complex. class I. A Plasma Membrane other 1.24 0.007 
Q13488 TCIRG1 T-cell immune regulator 1. ATPase H+ transporting V0 subunit a3 Plasma Membrane enzyme 1.33 0.007 
P27797 CALR calreticulin Cytoplasm transcription regulator 1.14 0.01 
Q06830 PRDX1 peroxiredoxin 1 Cytoplasm enzyme 0.91 0.029 
P46459 NSF N-ethylmaleimide sensitive factor Cytoplasm transporter 1.17 0.031 
P10319 HLA-B major histocompatibility complex. class I. B Plasma Membrane transmembrane receptor 1.28 0.035 
P51148 RAB5C RAB5C. member RAS oncogene family Cytoplasm enzyme 1.33 0.055 
P20645 M6PR mannose-6-phosphate receptor. cation dependent Cytoplasm transporter 2.00 0.089 
P11279 LAMP1 lysosomal associated membrane protein 1 Plasma Membrane other 1.20 0.12 
P30041 PRDX6 peroxiredoxin 6 Cytoplasm enzyme 0.85 0.12 
Q71U36 TUBA1A tubulin alpha 1a Cytoplasm other 0.81 0.12 
Q93050 ATP6V0A1 ATPase H+ transporting V0 subunit a1 Cytoplasm transporter 2.64 0.13 
P38606 ATP6V1A ATPase H+ transporting V1 subunit A Plasma Membrane transporter 0.85 0.18 
Q14204 DYNC1H1 dynein cytoplasmic 1 heavy chain 1 Cytoplasm peptidase 0.79 0.19 
Q13509 TUBB3 tubulin beta 3 class III Cytoplasm other 0.95 0.19 
Q9UI12 ATP6V1H ATPase H+ transporting V1 subunit H Cytoplasm transporter 0.81 0.23 
Q13409 DYNC1I2 dynein cytoplasmic 1 intermediate chain 2 Cytoplasm other 0.70 0.25 
P36543 ATP6V1E1 ATPase H+ transporting V1 subunit E1 Cytoplasm transporter 1.83 0.28 
Q9BUF5 TUBB6 tubulin beta 6 class V Cytoplasm other 1.57 0.34 
Q15904 ATP6AP1 ATPase H+ transporting accessory protein 1 Cytoplasm transporter 0.60 0.37 
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UniProt  Symbol Entrez Gene Name Location Type(s) Fold Change P-Value 
P63167 DYNLL1 dynein light chain LC8-type 1 Cytoplasm other 0.50 0.37 
P13473 LAMP2 lysosomal associated membrane protein 2 Plasma Membrane enzyme 0.90 0.37 
Q15836 VAMP3 vesicle associated membrane protein 3 Plasma Membrane other 0.50 0.37 
P68371 TUBB4B tubulin beta 4B class IVb Cytoplasm other 0.96 0.41 
P61769 B2M beta-2-microglobulin Plasma Membrane transmembrane receptor 1.00 0.42 
P21283 ATP6V1C1 ATPase H+ transporting V1 subunit C1 Cytoplasm transporter 0.86 0.52 
Q9BQE3 TUBA1C tubulin alpha 1c Cytoplasm other 0.98 0.52 
P07437 TUBB tubulin beta class I Cytoplasm other 0.96 0.59 
P27824 CANX calnexin Cytoplasm other 0.97 0.6 
P68366 TUBA4A tubulin alpha 4a Cytoplasm other 0.97 0.62 
P30044 PRDX5 peroxiredoxin 5 Cytoplasm enzyme 1.00 0.64 
P61421 ATP6V0D1 ATPase H+ transporting V0 subunit d1 Cytoplasm transporter 1.06 0.74 
P51149 RAB7A RAB7A. member RAS oncogene family Cytoplasm enzyme 1.06 0.91 
P21281 ATP6V1B2 ATPase H+ transporting V1 subunit B2 Cytoplasm transporter 1.05 1 
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Table 3 
UniProt  Symbol Entrez Gene Name Location Type(s) Fold Change P-Value 
P30501 HLA-C major histocompatibility complex. class I. C Plasma Membrane other 8.33 0.001 
P26010 ITGB7 integrin subunit beta 7 Plasma Membrane transmembrane receptor 4.33 0.001 
P01892 HLA-A major histocompatibility complex. class I. A Plasma Membrane other 1.24 0.007 
P10319 HLA-B major histocompatibility complex. class I. B Plasma Membrane transmembrane receptor 1.28 0.035 
P05556 ITGB1 integrin subunit beta 1 Plasma Membrane transmembrane receptor 1.19 0.05 
P51148 RAB5C RAB5C. member RAS oncogene family Cytoplasm enzyme 1.33 0.055 
P11215 ITGAM integrin subunit alpha M Plasma Membrane transmembrane receptor 1.29 0.074 
P35606 COPB2 coatomer protein complex subunit beta 2 Cytoplasm transporter 1.50 0.081 
P20702 ITGAX integrin subunit alpha X Plasma Membrane transmembrane receptor 1.17 0.1 
P53621 COPA coatomer protein complex subunit alpha Cytoplasm transporter 1.25 0.12 
P38570 ITGAE integrin subunit alpha E Plasma Membrane other 2.33 0.12 
P61923 COPZ1 coatomer protein complex subunit zeta 1 Cytoplasm transporter 0.43 0.13 
O14579 COPE coatomer protein complex subunit epsilon Cytoplasm transporter 0.77 0.19 
Q9Y678 COPG1 coatomer protein complex subunit gamma 1 Cytoplasm transporter 1.00 0.23 
P18031 PTPN1 protein tyrosine phosphatase. non-receptor type 1 Cytoplasm phosphatase 1.18 0.23 
O75955 FLOT1 flotillin 1 Plasma Membrane other 1.43 0.24 
P60709 ACTB actin. beta Cytoplasm other 0.96 0.26 
P63267 ACTG2 actin. gamma 2. smooth muscle. enteric Cytoplasm other 1.03 0.29 
P06756 ITGAV integrin subunit alpha V Plasma Membrane ion channel 0.69 0.33 
P18084 ITGB5 integrin subunit beta 5 Plasma Membrane other 0.50 0.33 
P50570 DNM2 dynamin 2 Plasma Membrane enzyme 0.78 0.37 
Q14254 FLOT2 flotillin 2 Plasma Membrane other 1.67 0.37 
P61769 B2M beta-2-microglobulin Plasma Membrane transmembrane receptor 1.00 0.42 
P08648 ITGA5 integrin subunit alpha 5 Plasma Membrane transmembrane receptor 1.10 0.47 
P48444 ARCN1 archain 1 Cytoplasm other 0.90 0.61 
P53618 COPB1 coatomer protein complex subunit beta 1 Cytoplasm transporter 1.00 0.64 
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Figure 2 CECR1 silencing in THP-1 macrophages influenced various functions of macrophages 
 
a. Schematic illustration displayed comparison of proteins from macrophage with siSham and siCECR1  
b. Volcano blot showing differentially expressed proteins in macrophage with siSham and macrophage with 
siCECR1. Proteins were considered as differentially expressed when p value<0.05  
c. Bar graph displaying the annotation of Gene Ontology with FDR (False Discovery Rate) <0.05 enriched in 
macrophage with siSham compared with macrophage transfected by siCECR1 
d. Bar graph displaying the top 10 annotations of Gene Ontology with FDR (False Discovery Rate) <0.05 en-
riched in macrophage with siCECR1 compared with macrophage transfected by siSham control. 
e. Bar graph showing the result of proteins in macrophage with siCECR1 from top 5 KEGG pathway.  
Changes in proteomic profile of U87 stimulated THP-1 macrophages in response 
to CECR1 silencing  
THP-1 macrophages treated with CECR1 silencing were co-cultured with U87 cells to 
mimic TAMs differentiation conditions and were compared with U87 co-cultured mac-
rophages treated with siSham (Figure 4a). In total, 47 proteins were significantly affect-
ed by CECR1 silencing (Figure 4b); 18 proteins were upregulated, and 29 proteins were 
downregulated by CECR1 silencing in U87 co-cultured THP-1 macrophages (Supplemen-
tary table 4,5). Gene ontology analysis could not identify a pathway that was significant-
ly annotated to the 18 upregulated proteins. The majority of pathways that were signifi-
cantly linked to the 29 downregulated proteins were based on four proteasome pro-
teins, PSMC6, PSMA7, PSMA5, and PSMD8 (Figure 4c, d). The most relevant pathways 
were all mainly involved in regulation of cell cycle (Figure 4d). In line with these findings, 
the proliferation rate of U87-stimulated THP-1 macrophage with CECR1 silencing was 
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lower than U86-stimulated sisham control macrophages, as shown by MTT assay (Figure 
4e). In addition, the number of cells positive for Ki67 (a marker for cell proliferation) in 
U87-stimulated THP-1 macrophages with CECR1 silencing was significantly lower than in 
siSham-treated control macrophages (Figure 4f, g).  
Although these four proteins were involved in antigen presentation, other proteins 
that are vital for the proteosome step in this pathway such as TAP, TAPBP and HLA-A, B, 
C are not enriched in CECR1 silenced THP-1 macrophages (Supplementary figure 2), 
indicating that this process is not affected in by CECR1 under U87 coculture conditions.   
 
Figure 3 CECR1 silencing in THP-1 macrophages enhanced MHC I Antigen Presenting, Phagosome maturation, 
Caveolin mediated endocytosis and IFN-γ responsive signaling.  
 
a. Network generated by Cytoscape presenting MHC I antigen presenting pathway from IPA analysis. Nodes 
with red color indicated proteins significantly enriched in macrophage with siCECR1 (P<0.05). Green nodes 
indicated proteins equally enriched in macrophage with sisham and siCECR1.  
b. Network generated by Cytoscape presenting Phagosome maturation pathway from IPA analysis. Nodes with 
red color indicated proteins significantly enriched in macrophage with siCECR1 (P<0.05). Green nodes indicat-
ed proteins equally enriched in macrophage with sisham and siCECR1.  
c. Network generated by Cytoscape presenting Phagosome maturation pathway from IPA analysis. Nodes with 
red color indicated proteins significantly enriched in macrophage with siCECR1 (P<0.05).  Green nodes indi-
cated proteins equally enriched in macrophage with sisham and siCECR1.  
d. Upstream prediction of significantly expressed proteins in macrophage with CECR1 silencing from IPA.  
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Figure 4 CECR1 silencing leads a limited response in U87 co-cultured THP-1 macrophage 
 
a. Schematic illustration displayed comparison of proteins from U87 co-cultured macrophage with siSham and 
siCECR1  
b. Volcano blot showing differentially expressed proteins in U87 co-cultured macrophage with siSham and 
macrophage with siCECR1. Proteins were considered as differentially expressed when P value<0.05  
c. Network generated by Cytoscape of proteasome proteins PSMC6, PSMA5, PSMA7 and PSMD8. Raw data of 
network was exported from STRING. 
d. Table listing 13 pathways mostly related to proteasome network with FDR<0.05 from Gene Ontology.  
e. MTT assay assessing proliferation of U87 co-cultured macrophage for continuous five days. Data were 
shown as mean± S.E.M. Two-way anova was used to test the difference of U87 co-cultured macrophage with 
siSham and siCECR1. ***P<0.005    
f. Ki67 staining of U87 co-cultured macrophage with siSham and siCECR1. Scale bar: 50µm 
g. Quantification of Ki67 positive cells per image view in U87 co-cultured macrophage with siSham and 
siCECR1. Data were shown as mean± S.E.M. ***P<0.005    
Stimulation by U87 cells attenuates the changes that occur at protein and mRNA 
level in response to CECR1 silencing in THP-1 macrophages.  
As only a very limited effect of CECR1 silencing on immune response was observed in 
CECR1 silenced U87 THP-1 macrophages, a comparison of CECR1 silenced macrophage 
with/without U87 co-culture was conducted (Figure 5a). 57 proteins were downregulat-
ed in U87 co-cultured macrophages with CECR1 silencing compared to macrophages 
with CECR1 silencing without U87 stimulation (Figure 5b). The annotation of Gene On-
tology analysis using the downregulated proteins as input, indicated “endocytosis”, 
Proteome analysis of the CECR1 mediated response of TAMs in glioma 
137 
“phagocytosis”, “immune response” as well as “phagolysosome assembly” may be af-
fected (Figure 5c). To assess whether protein levels were downregulated on mRNA 
level, transcripts of key molecules involved in above pathways like HLA-A, C, ITGB7, EVL, 
WDFY, SEPT7 were evaluated in macrophages with/without U87 co-culture. CECR1 
silencing increased gene expression of these molecules. However, U87 stimulation at-
tenuated this upregulation of target genes in response to CECR1 silencing (Figure 5d). 
Thus, the changes observed on protein level in response to CECR1 silencing on THP-1 
macrophages is regulated on gene expression level, but U87 stimulation diminishes this 
response.  
 
Figure 5. U87 cells attenuated CECR1 Silencing mediated response in macrophage 
 
a. Schematic illustration displayed comparison of proteins from macrophage with siCECR1 with/without U87 
co-culture. 
b. Volcano blot showing differentially expressed proteins in macrophage with siCECR1 with/without U87 co-
culture. Proteins were considered as differentially expressed when P value<0.05  
c. Table listing top 10 pathways with FDR<0.05 related to downregulated proteins in U87 co-cultured macro-
phage with CECR1 knockdown 
d. Real time PCR validation of HLA-A, C, ITGB7, WDFY, EVL, SEPT7 in macrophage with siCECR1 knockdown and 
with/without U87 co-culture. Data were shown as mean± S.E.M. * P<0.05, **P<0.01, ***P<0.005   
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Overlap analysis identifies S100A9 and PLAU as two CECR1-related proteins that 
are significantly correlated with expression of CECR1 and macrophage lineage 
markers in three large public GBM datasets.  
As shown in our previous study, CECR1 was highly expressed in macrophages stimulated 
by U87 cells. Proteins that are enriched in U87 treated macrophages may thus be puta-
tively regulated by CECR1. Next we compared the list of proteins that were upregulated 
in U87-stimulated THP-1macrophages versus macrophages without U87 treatment 
(Supplementary table 6) with the list of proteins that were downregulated in THP-1 
macrophages with CECR1 silencing compared to sisham treated THP-1 macrophages 
(Supplementary table 2). This overlap analysis retrieved three common proteins, which 
are EEF1G, S100A9 and DNAJC10 (Figure 6a). Similarly, the comparison of enriched 
proteins in U87-stimulated macrophages versus macrophages without U87 treatment 
(Supplementary table 6) with proteins that were downregulated in U87 co-cultured 
macrophages with CECR1 silencing versus U87 co-cultured sisham treated macrophages 
(Supplementary table 5) resulted in 9 common proteins (Figure 6d). QPCR analysis vali-
dated the downregulation of S100A9 and PLAU expression in CECR1 silenced macro-
phage with/without U87 co-culture compared to their related sisham controls. U87 
stimulation significantly increased expression of S100A9 and PLAU in macrophages 
(Figure 6 b, e). Analysis of S100A9 and PLAU in the TCGA GBM database using 3 large 
public GBM datasets demonstrated that both S100A9 and PLAU expression levels are 
positively correlated with CECR1 and other monocyte/macrophage lineage markers 
(Figure 6c, f). Although the overlap analyses indicated that DNAJC10 is the most rele-
vant molecule under regulation of CECR1, the analysis of DNAJC10 using the same pub-
lic GBM datasets did not show any correlation with CECR1 as well as other markers of 
monocytes/macrophages (data not shown). 
LAT2 was upregulated by CECR1 knockdown in U87 co-cultured macrophages. 
Further overlap analysis identified LAT2 as a CECR1-related protein (Figure 7a) via com-
parison of downregulated proteins in U87-stimulated THP-1 macrophages versus mac-
rophage without U87 treatment (Supplementary table 7) with proteins upregulated in 
U87 co-cultured macrophages with CECR1 silencing versus sisham treated controls 
(Supplementary table 4). LAT2 was validated to be upregulated in U87 co-cultured mac-
rophages by CECR1 silencing by western blot analysis (Figure 7b, c). In line with this 
finding, CECR1-silenced U87 co-cultured macrophages displayed a IL-10 low and IL-
12p35 high expression profile, which implied a more pro-inflammatory phenotype (Fig-
ure 7d, e). 
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Figure 6. S100A9, PLAU are two mostly CECR1-related molecules in macrophage 
 
a. Venn graph showing the overlapped proteins from proteins enriched in U87 co-cultured macrophage with 
siSham(versus macrophage with siSham) and proteins enriched in macrophage with siSham (versus macro-
phage with siCECR1) 
b.  Real time PCR validation of S100A9 expression in macrophage with siCECR1 knockdown and with/without 
U87 co-culture. Data were shown as mean± S.E.M. * P<0.05, ***P<0.005    
c.  Heat map showing correlation co-efficiency from both pearson and spearman analysis of S100A9 with 
CECR1 and monocyte/macrophage markers from three TCGA GBM database.  
d.  Venn graph showing the overlapped proteins from proteins enriched in U87 co-cultured macrophage with 
siSham (versus macrophage with siSham) and proteins enriched in U87 co-cultured macrophage with siSham 
(versus macrophage with siCECR1) 
e.  Real time PCR validation of PLAU expression in macrophage with siCECR1 knockdown and with/without 
U87 co-culture. Data were shown as mean± S.E.M. ** P<0.01, ***P<0.005    
f.   Heat map showing correlation co-efficiency from both pearson and spearman analysis of PLAU with CECR1 
and monocyte/macrophage markers from three TCGA GBM database.  
 
Chapter 6 
140 
Figure 7 LAT2 was upregulated by CECR1 knockdown in U87 co-cultured macrophage 
 
a. Venn graph showing the overlapped proteins from proteins downregulated in U87 co-cultured macrophage 
with siSham(versus macrophage with siSham) and proteins downregulated in macrophage with siSham (ver-
sus macrophage with siCECR1) 
b. Western blot analysis of LAT2 expression in U87 co-cultured macrophage with siSham and siCECR1 
c. Quantification of LAT2 protein band in U87 co-cultured macrophage with siSham and siCECR1 
d. Real time PCR measurement of IL-10 expression in U87 co-cultured macrophage with/without CECR1 
silencing. Data were shown as mean± S.E.M. * P<0.05 
e. Real time PCR measurement of IL-12p35 expression in U87 co-cultured macrophage with/without CECR1 
silencing. Data were shown as mean± S.E.M. * P<0.05 
DISCUSSION 
Recent studies have highlighted the importance of CECR1 in the regulation of the innate 
immune response
19
. In vitro, monocytes-derived from patients with deleterious CECR1 
mutations showed diminished capacity of M2 macrophage differentiation, whereas M1 
macrophage differentiation remained unaffected (PMID 24552284). The TAM popula-
tion in glial tumors exhibits a mainly M2-macrophage like phenotype. We previously 
reported that CECR1 was strongly expressed in high-grade gliomas by M2-like TAMs. In 
line with the results of the genetic study, CECR1 proved vital for differentiation of mon-
ocytes towards M2-like TAMs in a glial tumor paracrine environment (U87 supernatant 
stimulation) (REF). CECR1 activity in M2-like TAMs promoted paracrine stimulation of 
glial tumor cell migration and proliferation (REF). In addition, CECR1 function facilitated 
paracrine crosstalk of M2-like TAMs with perivascular pericytes, contributing to tumor 
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angiogenesis (REF). Although these studies provide direct evidence for the significant 
role of CECR1 in TAM regulation, the molecular mechanisms that drive the CECR1-
mediated function of TAMs remain to be elucidated. A genome-wide “omics” approach 
could help reveal the CECR1 mechanisms. A genome-wide transcriptome dataset of 
peripheral blood mononuclear cells (PBMCs) derived from patients with CECR1 muta-
tions has been published, showing marked increased expression of neutrophil-
associated genes in the disease condition
27
. Another case-report study did not detect 
upregulation of neutrophil-associated genes in the patient’s BPMCs, but demonstrated 
an increase in IFN-γ response genes
28
. In line with this report, patients with CECR1 ge-
netic mutations that received anti-TNF-α antibody treatment reached complete remis-
sion or partially recovered from their autoimmune disease-like symptoms
26
. The latter 
clearly demonstrates the potential value of in depth analysis of CECR1 mediated mech-
anisms in identifying new drug targets for therapy development. As most molecular 
data on CECR1 function in immune cells were obtained from the mixed PBMC popula-
tion, these findings remain difficult to extrapolate to aid in our understanding of the 
CECR1 working mechanism of local TAMs in glial tumors. The general working mecha-
nism of CECR1 in monocytes/macrophages also requires further exploration.    
In this study we conducted proteomics analysis of siRNA mediated CECR1 silencing 
in macrophages that were stimulated with or without glial tumor cells (U87) in co-
culture. In the absence of U87 stimulation, CECR1 silencing in macrophages   showed a 
protein profile that is related to key mechanisms in macrophage immune response 
regulation, including “MHC I antigen presenting” and “Phagosome maturation”, “Caveo-
lin mediated endocytosis” and “Type I interferon signaling pathway”. These pathways 
are mostly involved in pro-inflammatory responses and anti-pathogen defense, and are 
more in line with M1-macrophage function. Among these three pathways, “MHC I Anti-
gen Presenting” and “Phagosome maturation” have been reported to be regulated via 
IFN- signaling 
29
. IFN- has been recognized as the main cytokine that is associated to 
induction of the M1 response (PMC:3944738). Our data showed upregulation of pro-
teins mapping into interferon responding pathway in response to CECR-1 silencing of 
macrophages, including ISG15, HLA-A, HLA-B, HLA-C, TAP1, TAP2, TAPBP, and TIMP-1. 
Furthermore, several proteins that are recently reported to be involved in immune 
response like WDFY1, a regulator of the Toll-like receptor signaling pathways
30
 and 
SEPT7 involved in phagosome assembly and vesicle transport
29
 were also enriched in 
CECR1-silenced macrophages. WDFY1 is as an adaptor protein anchored on the mem-
brane of early endosomes. It participates in Toll like receptor pathways and activates 
NF-κB signaling pathway in macrophages, which in turn, activates the transcription of 
type I interferons as well as other inflammatory factors including key proteins of the M1 
macrophage cytokine release repertoire such as TNF-α, IL-6 and CXCL10
30
 
(PMID:24013843). Moreover, CECR1 silencing in macrophages promotes higher levels of 
proteins that are associated with the MHC I antigen presenting function. This would 
trigger imply enhanced CD8+ T cell activation, a feature that is more associated with 
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M1-macrophages
31
. Thus, in line with present literature and our previous studies, cur-
rent data shows that CECR1 function in macrophages is indeed important to endorse 
M2 macrophage function, as made evident by the shift towards a more M1 macro-
phage-like proteosome profile that is observed in response to CECR1-silencing.     
Malignant tumor including glial tumors are known to influence the local immune re-
sponse including hampering vital macrophage functions like antigen presenting and 
phagocytosis
33
. In this study, we observed a general inhibitory effect of U87 cell on the 
CECR1-silencing response in macrophages: Coculture with U87 cells reversed the 
CECR1-silencing induced pro-inflammatory M1-like protein profile in macrophages. No 
upregulation of proteins involved in “MHC I antigen presenting” and “Phagosome matu-
ration”, “Caveolin mediated endocytosis” and “Type I interferon signaling pathway” was 
observed. In contrast, CECR1 silencing in macrophages under U87 costimulation mainly 
downregulated proteins that were part of cell cycle regulation. In line with this proteo-
me profile, CECR1 silenced macrophages with U87 stimulation indeed showed a lower 
proliferation capacity compared to sisham treated controls. Macrophage proliferation 
has been reported to be activated by paracrine stimulation of malignant tumor cells, 
mainly via secretion of various cytokines and growth factors like M-CSF
34'35
. Numerous 
studies have indicated that reduction of the number of immuno-suppresive (M2) mac-
rophages in tumors could be an effective therapeutic approach
35,36
. Our proteomics 
analysis revealed downregulation by CECR1 silencing of the proteasome proteins 
PSMA5, PSMA7, PSMC6 and PSMD8 in the U87 coculture conditions. PSMA5 and 
PSMA7 are essential subunits of the complete assembly of the 20S proteosome core 
complex, whereas PSMC6 and PSMD8 are essential subunits of the 19S regulatory parti-
cle. Together, 1 20S core and 2 19S regulator particles form the functional 26S proteo-
some complex (PMC:2902798). The 26S proteasome complex participates in various 
critical cell pathways including DNA synthesis, repair, transcription, translation and cell 
signal transduction (PMC:2902798) as well as antigen presentation
37
 and regulation of 
cell cycle transition
38
. Cell proliferation and cell cycle is mainly regulated by 26S proteo-
somes by targeting p53
39
 and inhibitors of cell cycle dependent kinase, like p21
40
, p27
41
, 
for ubiquitin-mediated degradation. Inhibition of S26 proteasome activity led to cell 
cycle arrest and induced apoptosis by increasing levels of p53, p21 and p27
42
. Our find-
ings indicate that CECR1 silencing may contribute to low proliferation rate of TAMs via 
downregulation of essential protein components of the S26 proteosome complex. Thus, 
CECR1 depletion may be considered as a novel approach in targeting TAM proliferation 
in gliomas.  
Overlap analysis of our data identified S100A9 and PLAU as two CECR1-related pro-
teins that are significantly correlated with expression of CECR1 and macrophage lineage 
markers in GBMs. These two molecules were previously shown to be highly expressed in 
myeloid cells
12,43
. S100A9 was also shown to promote glioma growth and angiogenesis 
by interaction with the PAGE receptor on the surface of glioma cells
44
, a process medi-
ated via activation of MAPK and NF-κB pathways
45
. PLAU is one of the proangiogenic 
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factors that can be produced TAMs
12
. It was shown to aid the invasion and metastasis of 
various types of cancer cells via binding to PLAUR, subsequently activating downstream 
pathways like ERK1/2
46
, PI3K/Akt
47
. Moreover, the interaction of PLAU-PLAUR raised 
plasmin levels, contributing to the activation of matrix metalloproteinases
48
.  
In U87 co-cultured macrophages CECR1 silencing upregulated protein levels of LAT2. 
Coincidently, U87 treatment decreased the LAT2 expression in sisham treated macro-
phages. Previous studies pointed to the immune modulatory function of LAT2 via com-
peting with TREM-2/LAT signaling pathway, which resulted in upregulation of IL-12 and 
downregulation of IL-10 in LPS stimulated macrophages
49
. Indeed, CECR1-silenced mac-
rophages in U87 coculture conditions displayed an decrease in IL-10/IL-12p35 ratio.  
In conclusion, in this study we have identified, for the first time to our knowledge, 
the molecular pathways and key molecules that are mediated by CECR1 function in 
macrophages and glial tumor associated macrophages. Our proteome dataset could 
provide the basis for the development of interesting drug targets for future immuno-
therapy development in the treatment of malignant (glial) tumors as well as auto im-
mune disease.     
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SUPPLEMENTARY DATA 
Supplementary Figure 1 
 
(A) Transcript of CECR1 was assessed by real time qPCR. Data were shown as Mean ± SEM. *** P<0.005 based 
on student’s T-test. N=3 
(B) Representative figure of CECR1 immunostaining of macrophages with siSham and siCECR1 transfection. 
Experiments were repeated three times with similar read out. Scale bar: 50µm 
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Supplementary Figure 2 
 
Schematic diagram of IPA data showing involvement of PSMA5, 7, PSMC6, PSMD8 in S20 proteasome complex 
related pathways. 
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Supplementary table 1: Sequence of Primers for Real time qPCR 
Primers  Oligo Sequence (5'-3') 
CECR1 Forward TGGCGTTAAGCTGCCTTACT 
CECR1 Reverse GCTACAGGGTGGTTCCTCAA 
S100A9 Forward TCCTCGGCTTTGACAGAGTG 
S100A9 Reverse TGCCCCAGCTTCACAGAGTA 
CTSH Forward CCTGTGAAAAATCAGGGTGCCT 
CTSH Reverse TGAAGACAACTGAGGCTGCAA 
PLAU Forward CCCAGGAAATGGGACAGGG 
PLAU Reverse ACAGTTCGCCTGTTCGTATCT 
HLA-A Forward CGACGCCGCGAGCCAGA 
HLA-A Reverse GCGATGTAATCCTTGCCGTCGTAG 
HLA-C Forward GGAGACACAGAAGTACAAGCG 
HLA-C Reverse CGTCGTAGGCGTACTGGTCATA 
ITGB7 Forward GAGGAAGGACTGCTCTGCAC 
ITGB7 Reverse ACCATGCCCGAGATCCCAAG 
WDFY Forward ACGGATATTTGTGGGCCAGG 
WDFY Reverse CGGTTCTGATGAGCTGGGTA 
EVL Forward AGGGTCTGTGGTCCTCTGAT 
EVL Reverse GCAGATACTCTGTTCACTTGTGG 
SEPT7 Forward CACGCTTATGGTAGTGGGTGA 
SEPT7 Reverse TGAGCAGCAACTGAACACCA 
IL-10 Forward GGCACCCAGTCTGAGAACAG 
IL-10 Reverse TGGCAACCCAGGTAACCCTTA 
IL-12p35 Forward GCTCCAGAAGGCCAGACAAA 
IL-12p35 Reverse GCCAGGCAACTCCCATTAGT 
β-actin Forward TCCCTGGAGAAGAGCTACGA 
β-actin Reverse AGCACTGTGTTGGCGTACAG 
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Supplementary Table 2 
UniProt Symbol Entrez Gene Name Location Type(s) Fold Change P-value 
O43312 MTSS1 metastasis suppressor 1 Cytoplasm transporter 4.33 0.001 
Q8IXB1 DNAJC10 DnaJ heat shock protein family (Hsp40) member C10 Cytoplasm enzyme 3.33 0.002 
Q8NE86 MCU mitochondrial calcium uniporter Cytoplasm enzyme 3.33 0.002 
P62899 RPL31 ribosomal protein L31 Cytoplasm enzyme 3.33 0.002 
P63313 TMSB10 thymosin beta 10 Cytoplasm phosphatase 3.33 0.001 
Q99471 PFDN5 prefoldin subunit 5 Nucleus enzyme 3.00 0.001 
 Q9UBQ0 VPS29 VPS29 retromer complex Cytoplasm other 3.00 0.001 
P06702 S100A9 S100 calcium binding protein A9 Cytoplasm enzyme 2.40 0.018 
P62333 PSMC6 proteasome 26S subunit. ATPase 6 Nucleus kinase 1.86 0.035 
Q9BUJ2 HNRNPUL1 heterogeneous nuclear ribonucleoprotein U like 1  Nucleus kinase 1.70 0.035 
Q14643 ITPR1 inositol 1.4.5-trisphosphate receptor type 1 Cytoplasm other 1.60 0.016 
P09668 CTSH cathepsin H Cytoplasm other 1.56 0.007 
Q92974 ARHGEF2 Rho/Rac guanine nucleotide exchange factor 2 Cytoplasm enzyme 1.47 0.033 
P14868 DARS aspartyl-tRNA synthetase Cytoplasm other 1.36 0.034 
 Q15019 SEPT2 septin 2 Cytoplasm enzyme 1.33 0.007 
Q9NSD9 FARSB phenylalanyl-tRNA synthetase beta subunit Cytoplasm enzyme 1.30 0.047 
Q9UHB9 SRP68 signal recognition particle 68 Nucleus other 1.30 0.047 
P27348 YWHAQ tyrosine 3- monooxygenase/ tryptophan 5- monooxygenase 
activation protein theta 
Cytoplasm other 1.28 0.039 
P34910 EVI2B ecotropic viral integration site 2B Plasma Membrane enzyme 1.27 0.016 
Q92598 HSPH1 heat shock protein family H (Hsp110) member 1 Cytoplasm enzyme 1.26 0.004 
P09661 SNRPA1 small nuclear ribonucleoprotein polypeptide A' Nucleus other 1.25 0.007 
P52815 MRPL12 mitochondrial ribosomal protein L12 Cytoplasm enzyme 1.24 0.016 
O43399 TPD52L2 tumor protein D52 like 2 Cytoplasm other 1.23 0.025 
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UniProt Symbol Entrez Gene Name Location Type(s) Fold Change P-value 
Q14697 GANAB glucosidase II alpha subunit Cytoplasm transcription regulator 1.14 0.04 
P08559 PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 Cytoplasm phosphatase 1.11 0.026 
P49368 CCT3 chaperonin containing TCP1 subunit 3 Cytoplasm transcription regulator 1.11 0.033 
P07339 CTSD cathepsin D Cytoplasm peptidase 1.11 0.05 
Q06830 PRDX1 peroxiredoxin 1 Cytoplasm other 1.10 0.029 
Q8TCT9 HM13 histocompatibility (minor) 13 Cytoplasm other 1.06 0.047 
P26641 EEF1G eukaryotic translation elongation factor 1 gamma Cytoplasm enzyme 1.05 0.015 
Q07020 RPL18 ribosomal protein L18 Cytoplasm enzyme 1.05 0.047 
P07355 ANXA2 annexin A2 Plasma Membrane transporter 1.05 0.028 
P14618 PKM pyruvate kinase. muscle Cytoplasm transporter 1.01 0.003 
 
  
Chapter 6 
152 
Supplementary Table 3 
Uniprot  Symbol Entrez Gene Name Location Type(s) Fold Change P-value 
P30501 HLA-C major histocompatibility complex. class I. C Plasma Membrane enzyme 8.33 0.001 
Q16181 SEPT7 septin 7 Cytoplasm transporter 5.33 0.007 
P26010 ITGB7 integrin subunit beta 7 Plasma Membrane transporter 4.33 0.001 
P05161 ISG15 ISG15 ubiquitin-like modifier Extracellular Space enzyme 4.00 0.008 
Q9UI08 EVL Enah/Vasp-like Plasma Membrane enzyme 3.67 0.001 
Q96C23 GALM galactose mutarotase (aldose 1-epimerase) Cytoplasm enzyme 3.67 0.001 
Q53H82 LACTB2 lactamase beta 2 Cytoplasm enzyme 3.67 0.006 
Q8IWB7 WDFY1 WD repeat and FYVE domain containing 1 Cytoplasm other 3.67 0.001 
P00390 GSR glutathione reductase Cytoplasm transcription regulator 3.00 0.029 
Q96N66 MBOAT7 membrane bound O-acyltransferase domain containing 7 Plasma Membrane other 3.00 0.001 
Q9NX40 OCIAD1 OCIA domain containing 1 Cytoplasm other 3.00 0.003 
Q13596 SNX1 sorting nexin 1 Cytoplasm enzyme 3.00 0.026 
Q0VD83 APOBR apolipoprotein B receptor Plasma Membrane enzyme 2.83 0.026 
Q8TCS8 PNPT1 polyribonucleotide nucleotidyltransferase 1 Cytoplasm other 2.75 0.029 
Q92804 TAF15 TATA-box binding protein associated factor 15 Nucleus transcription regulator 2.00 0.047 
P54920 NAPA NSF attachment protein alpha Cytoplasm peptidase 1.83 0.005 
Q15717 ELAVL1 ELAV like RNA binding protein 1 Cytoplasm other 1.78 0.025 
P43304 GPD2 glycerol-3-phosphate dehydrogenase 2 Cytoplasm other 1.75 0.042 
P01137 TGFB1 transforming growth factor beta 1 Extracellular Space translation regulator 1.67 0.008 
Q9NYU2 UGGT1 UDP-glucose glycoprotein glucosyltransferase 1 Cytoplasm translation regulator 1.67 0.011 
Q8NBQ5 HSD17B11 hydroxysteroid (17-beta) dehydrogenase 11 Cytoplasm other 1.64 0.025 
P29218 IMPA1 inositol monophosphatase 1 Cytoplasm translation regulator 1.60 0.035 
Q02543 RPL18A ribosomal protein L18a Cytoplasm enzyme 1.58 0.025 
Q00688 FKBP3 FK506 binding protein 3 Nucleus other 1.56 0.016 
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Uniprot  Symbol Entrez Gene Name Location Type(s) Fold Change P-value 
Q02978 SLC25A11 solute carrier family 25 member 11 Cytoplasm enzyme 1.56 0.047 
O95466 FMNL1 formin like 1 Cytoplasm cytokine 1.50 0.025 
Q9UGP8 SEC63 SEC63 homolog. protein translocation regulator Cytoplasm enzyme 1.50 0.023 
Q03518 TAP1 transporter 1. ATP-binding cassette. sub-family B (MDR/TAP) Cytoplasm other 1.50 0.006 
P11413 G6PD glucose-6-phosphate dehydrogenase Cytoplasm transmembrane receptor 1.48 0.013 
P16435 POR cytochrome p450 oxidoreductase Cytoplasm transmembrane receptor 1.48 0.01 
Q9P2E9 RRBP1 ribosome binding protein 1 Cytoplasm enzyme 1.46 0.016 
P14854 COX6B1 cytochrome c oxidase subunit 6B1 Cytoplasm enzyme 1.45 0.013 
Q03519 TAP2 transporter 2. ATP-binding cassette. sub-family B (MDR/TAP) Cytoplasm other 1.44 0.005 
P04040 CAT catalase Cytoplasm enzyme 1.43 0.002 
P62280 RPS11 ribosomal protein S11 Cytoplasm other 1.42 0.016 
P62820 RAB1A RAB1A. member RAS oncogene family Cytoplasm enzyme 1.41 0.038 
O14950 MYL12B myosin light chain 12B Cytoplasm enzyme 1.38 0.001 
Q9Y3Z3 SAMHD1 SAM domain and HD domain 1 Nucleus enzyme 1.36 0.015 
P27105 STOM stomatin Plasma Membrane enzyme 1.36 0.025 
P07305 H1F0 H1 histone family member 0 Nucleus enzyme 1.33 0.013 
O15533 TAPBP TAP binding protein (tapasin) Cytoplasm kinase 1.33 0.023 
Q13488 TCIRG1 T-cell immune regulator 1. ATPase H+ transporting V0 subunit a3 Plasma Membrane kinase 1.33 0.007 
O75947 ATP5H ATP synthase. H+ transporting. mitochondrial Fo complex subunit D Cytoplasm peptidase 1.31 0.026 
P25774 CTSS cathepsin S Cytoplasm enzyme 1.30 0.025 
P07737 PFN1 profilin 1 Cytoplasm other 1.30 0.018 
P31948 STIP1 stress induced phosphoprotein 1 Cytoplasm ion channel 1.28 0.013 
P23786 CPT2 carnitine palmitoyltransferase 2 Cytoplasm enzyme 1.28 0.021 
P10319 HLA-B major histocompatibility complex. class I. B Plasma Membrane transmembrane receptor 1.28 0.035 
P13804 ETFA electron transfer flavoprotein alpha subunit Cytoplasm enzyme 1.27 0.018 
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Uniprot  Symbol Entrez Gene Name Location Type(s) Fold Change P-value 
O75874 IDH1 isocitrate dehydrogenase (NADP(+)) 1. cytosolic Cytoplasm transcription regulator 1.26 0.005 
P22307 SCP2 sterol carrier protein 2 Cytoplasm transmembrane receptor 1.25 0.033 
P01892 HLA-A major histocompatibility complex. class I. A Plasma Membrane ion channel 1.24 0.007 
Q99536 VAT1 vesicle amine transport 1 Plasma Membrane transporter 1.23 0.024 
P05556 ITGB1 integrin subunit beta 1 Plasma Membrane other 1.19 0.05 
Q9NX63 CHCHD3 coiled-coil-helix-coiled-coil-helix domain containing 3 Cytoplasm enzyme 1.19 0.047 
P46459 NSF N-ethylmaleimide sensitive factor Cytoplasm enzyme 1.17 0.031 
Q99623 PHB2 prohibitin 2 Cytoplasm other 1.15 0.039 
P27797 CALR calreticulin Cytoplasm other 1.14 0.01 
P55265 ADAR adenosine deaminase. RNA-specific Nucleus peptidase 1.13 0.013 
Q15942 ZYX zyxin Plasma Membrane enzyme 1.12 0.006 
P12109 COL6A1 collagen type VI alpha 1 Extracellular Space peptidase 1.10 0.047 
Q02878 RPL6 ribosomal protein L6 Nucleus other 1.10 0.024 
P10599 TXN thioredoxin Cytoplasm other 1.07 0.007 
P07910 HNRNPC heterogeneous nuclear ribonucleoprotein C (C1/C2) Nucleus other 1.06 0.007 
P28799 GRN granulin Extracellular Space other 1.06 0.016 
Q15067 ACOX1 acyl-CoA oxidase 1. palmitoyl Cytoplasm other 1.05 0.047 
P01033 TIMP1 TIMP metallopeptidase inhibitor 1 Extracellular Space other 1.05 0.013 
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Supplementary Table 4 
Uniprot Symbol Entrez Gene Name Location Type(s) Fold Change P-Value 
P49757 NUMB NUMB endocytic adaptor protein Plasma Membrane other 3.665474579 0.001 
Q13231 CHIT1 chitinase 1 Extracellular Space enzyme 3.333412829 0.001 
P01137 TGFB1 transforming growth factor beta 1 Extracellular Space growth factor 3.000077979 0.019 
Q16181 SEPT7 septin 7 Cytoplasm other 2.500124605 0.038 
Q9GZY6 LAT2 linker for activation of T-cells family member 2 Plasma Membrane other 2 0.047 
P40429 RPL13A ribosomal protein L13a Cytoplasm other 1.777685362 0.039 
P30041 PRDX6 peroxiredoxin 6 Cytoplasm enzyme 1.624504793 0.033 
P50281 MMP14 matrix metallopeptidase 14 Extracellular Space peptidase 1.500038989 0.007 
P30520 ADSS adenylosuccinate synthase Cytoplasm enzyme 1.461044379 0.047 
P49327 FASN fatty acid synthase Cytoplasm enzyme 1.382232207 0.006 
Q9BV40 VAMP8 vesicle associated membrane protein 8 Plasma Membrane transporter 1.363202607 0.013 
P08559 PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 Cytoplasm enzyme 1.278099363 0.047 
Q07955 SRSF1 serine/arginine-rich splicing factor 1 Nucleus other 1.266634254 0.016 
P26038 MSN moesin Plasma Membrane other 1.20664392 0.038 
O00567 NOP56 NOP56 ribonucleoprotein Nucleus other 1.17609125 0.026 
P18669 PGAM1 phosphoglycerate mutase 1 Cytoplasm phosphatase 1.135242102 0.016 
P07900 HSP90AA1 heat shock protein 90kDa alpha family class A member 1 Cytoplasm enzyme 1.100378609 0.023 
P62937 PPIA peptidylprolyl isomerase A Cytoplasm enzyme 1.060687741 0.001 
 
  
Chapter 6 
156 
Supplementary Table 5 
Uniprot Symbol Entrez Gene Name Location Type(s) Fold Change P-Value 
Q0VD83 APOBR apolipoprotein B receptor Plasma Membrane transmembrane receptor 0.21 0.002 
O94874 UFL1 UFM1 specific ligase 1 Cytoplasm other 0.25 0.006 
Q8N1F7 NUP93 nucleoporin 93kDa Nucleus other 0.30 0.001 
Q99685 MGLL monoglyceride lipase Plasma Membrane enzyme 0.30 0.001 
P48556 PSMD8 proteasome 26S subunit. non-ATPase 8 Cytoplasm other 0.30 0.006 
P00749 PLAU plasminogen activator. urokinase Extracellular Space peptidase 0.30 0.04 
P54886 ALDH18A1 aldehyde dehydrogenase 18 family member A1 Cytoplasm kinase 0.33 0.002 
Q14011 CIRBP cold inducible RNA binding protein Nucleus translation regulator 0.33 0.002 
P53634 CTSC cathepsin C Cytoplasm peptidase 0.33 0.002 
Q8IXB1 DNAJC10 DnaJ heat shock protein family (Hsp40) member C10 Cytoplasm enzyme 0.40 0.034 
P62979 RPS27A ribosomal protein S27a Cytoplasm other 0.47 0.049 
P28066 PSMA5 proteasome subunit alpha 5 Cytoplasm peptidase 0.59 0.007 
Q96JJ7 TMX3 thioredoxin related transmembrane protein 3 Cytoplasm enzyme 0.64 0.001 
Q5JRX3 PITRM1 pitrilysin metallopeptidase 1 Cytoplasm peptidase 0.65 0.025 
O94925 GLS glutaminase Cytoplasm enzyme 0.70 0.016 
O96008 TOMM40 translocase of outer mitochondrial membrane 40 Cytoplasm ion channel 0.72 0.034 
P23284 PPIB peptidylprolyl isomerase B Cytoplasm enzyme 0.73 0.02 
 Q00341 HDLBP high density lipoprotein binding protein Nucleus transporter 0.74 0.024 
P07305 H1F0 H1 histone family member 0 Nucleus other 0.74 0.025 
P00491 PNP purine nucleoside phosphorylase Nucleus enzyme 0.74 0.047 
P62333 PSMC6 proteasome 26S subunit. ATPase 6 Nucleus peptidase 0.75 0.007 
O14818 PSMA7 proteasome subunit alpha 7 Cytoplasm peptidase 0.75 0.007 
P43490 NAMPT nicotinamide phosphoribosyltransferase Extracellular Space cytokine 0.75 0.031 
P10515 DLAT dihydrolipoamide S-acetyltransferase Cytoplasm enzyme 0.79 0.047 
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P99999 CYCS cytochrome c. somatic Cytoplasm transporter 0.80 0.024 
O95571 ETHE1 ETHE1. persulfide dioxygenase Cytoplasm enzyme 0.87 0.033 
Q15942 ZYX zyxin Plasma Membrane other 0.88 0.047 
P61019 RAB2A RAB2A. member RAS oncogene family Cytoplasm enzyme 0.92 0.026 
P62277 RPS13 ribosomal protein S13 Cytoplasm other 0.95 0.025 
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Supplementary Table 6 
UniProt Symbol Entrez Gene Name Location Type(s) Fold Change P-Value 
P01584 IL1B interleukin 1 beta Extracellular Space cytokine 7.00 0.002 
O75431 MTX2 metaxin 2 Cytoplasm transporter 4.33 0.008 
Q9Y2J2 EPB41L3 erythrocyte membrane protein band 4.1 like 3 Plasma Membrane other 3.50 0.009 
Q9ULC5 ACSL5 acyl-CoA synthetase long-chain family member 5 Cytoplasm enzyme 3.33 0.001 
P17813 ENG endoglin Plasma Membrane transmembrane receptor 3.33 0.002 
P00749 PLAU plasminogen activator. urokinase Extracellular Space peptidase 3.33 0.04 
P00390 GSR glutathione reductase Cytoplasm enzyme 3.20 0.008 
P28074 PSMB5 proteasome subunit beta 5 Cytoplasm peptidase 3.00 0.002 
P54886 ALDH18A1 aldehyde dehydrogenase 18 family member A1 Cytoplasm kinase 3.00 0.002 
P06280 GLA galactosidase alpha Cytoplasm enzyme 3.00 0.006 
P49006 MARCKSL1 MARCKS-like 1 Cytoplasm other 3.00 0.029 
Q9HCC0 MCCC2 methylcrotonoyl-CoA carboxylase 2 Cytoplasm enzyme 2.60 0.033 
Q9UNM6 PSMD13 proteasome 26S subunit. non-ATPase 13 Cytoplasm peptidase 2.43 0.006 
P20340 RAB6A RAB6A. member RAS oncogene family Cytoplasm enzyme 2.17 0.024 
Q9Y230 RUVBL2 RuvB like AAA ATPase 2 Nucleus transcription regulator 1.88 0.019 
Q13148 TARDBP TAR DNA binding protein Nucleus transcription regulator 1.88 0.047 
P35914 HMGCL 3-hydroxymethyl-3-methylglutaryl-CoA lyase Cytoplasm enzyme 1.86 0.039 
P05109 S100A8 S100 calcium binding protein A8 Cytoplasm other 1.78 0.006 
P18031 PTPN1 protein tyrosine phosphatase. non-receptor type 1 Cytoplasm phosphatase 1.73 0.05 
P07305 H1F0 H1 histone family member 0 Nucleus other 1.58 0.016 
Q02543 RPL18A ribosomal protein L18a Cytoplasm other 1.58 0.016 
P06702 S100A9 S100 calcium binding protein A9 Cytoplasm other 1.58 0.039 
P62269 RPS18 ribosomal protein S18 Cytoplasm other 1.56 0.05 
O75533 SF3B1 splicing factor 3b subunit 1 Nucleus other 1.54 0.009 
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UniProt Symbol Entrez Gene Name Location Type(s) Fold Change P-Value 
Q8IXB1 DNAJC10 DnaJ heat shock protein family (Hsp40) member C10 Cytoplasm enzyme 1.50 0.013 
Q5JRX3 PITRM1 pitrilysin metallopeptidase 1 Cytoplasm peptidase 1.48 0.039 
P10515 DLAT dihydrolipoamide S-acetyltransferase Cytoplasm enzyme 1.46 0.013 
P14854 COX6B1 cytochrome c oxidase subunit 6B1 Cytoplasm enzyme 1.45 0.013 
Q9P2E9 RRBP1 ribosome binding protein 1 Cytoplasm other 1.43 0.009 
P62820 RAB1A RAB1A. member RAS oncogene family Cytoplasm enzyme 1.41 0.001 
P49748 ACADVL acyl-CoA dehydrogenase. very long chain Cytoplasm enzyme 1.41 0.034 
P48163 ME1 malic enzyme 1 Cytoplasm enzyme 1.40 0.007 
Q7Z7H5 TMED4 transmembrane p24 trafficking protein 4 Cytoplasm transporter 1.40 0.047 
P51148 RAB5C RAB5C. member RAS oncogene family Cytoplasm enzyme 1.38 0.019 
P23786 CPT2 carnitine palmitoyltransferase 2 Cytoplasm enzyme 1.34 0.003 
Q15067 ACOX1 acyl-CoA oxidase 1. palmitoyl Cytoplasm enzyme 1.33 0.013 
P54920 NAPA NSF attachment protein alpha Cytoplasm transporter 1.33 0.035 
P28066 PSMA5 proteasome subunit alpha 5 Cytoplasm peptidase 1.31 0.024 
P43490 NAMPT nicotinamide phosphoribosyltransferase Extracellular Space cytokine 1.29 0.003 
P13804 ETFA electron transfer flavoprotein alpha subunit Cytoplasm transporter 1.24 0.003 
P11387 TOP1 topoisomerase (DNA) I Nucleus enzyme 1.24 0.017 
P52272 HNRNPM heterogeneous nuclear ribonucleoprotein M Nucleus other 1.20 0.034 
P07602 PSAP prosaposin Extracellular Space other 1.13 0.006 
P25774 CTSS cathepsin S Cytoplasm peptidase 1.13 0.007 
P0DMV8 HSPA1A/HSPA1B heat shock protein family A (Hsp70) member 1A Cytoplasm enzyme 1.13 0.047 
P07910 HNRNPC heterogeneous nuclear ribonucleoprotein C (C1/C2) Nucleus other 1.12 0 
P99999 CYCS cytochrome c. somatic Cytoplasm transporter 1.11 0.024 
P27797 CALR calreticulin Cytoplasm transcription regulator 1.10 0.049 
Q99536 VAT1 vesicle amine transport 1 Plasma Membrane transporter 1.09 0.013 
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UniProt Symbol Entrez Gene Name Location Type(s) Fold Change P-Value 
Q68CZ2 TNS3 tensin 3 Plasma Membrane phosphatase 1.07 0.03 
Q9Y6N5 SQRDL sulfide quinone reductase-like (yeast) Cytoplasm enzyme 1.05 0.038 
P62937 PPIA peptidylprolyl isomerase A Cytoplasm enzyme 1.03 0.007 
P26641 EEF1G eukaryotic translation elongation factor 1 gamma Cytoplasm translation regulator 1.02 0.019 
P06576 ATP5B ATP synthase. H+ transporting. mitochondrial F1 
complex. beta polypeptide 
Cytoplasm transporter 1.01 0.005 
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Supplementary Table 7 
UniProt Symbol Entrez Gene Name Location Type(s) Fold Change P-Value 
P60709 ACTB actin. beta Cytoplasm other 0.99 0.039 
P06733 ENO1 enolase 1 Cytoplasm enzyme 0.99 0.032 
P49368 CCT3 chaperonin containing TCP1 subunit 3 Cytoplasm other 0.97 0.024 
Q9Y490 TLN1 talin 1 Plasma Membrane other 0.97 0.026 
P04075 ALDOA aldolase. fructose-bisphosphate A Cytoplasm enzyme 0.97 0.043 
P07437 TUBB tubulin beta class I Cytoplasm other 0.96 0.03 
P07355 ANXA2 annexin A2 Plasma Membrane other 0.94 0.033 
Q15365 PCBP1 poly(rC) binding protein 1 Nucleus translation regulator 0.94 0.046 
P40121 CAPG capping actin protein. gelsolin like Nucleus other 0.91 0.002 
Q06830 PRDX1 peroxiredoxin 1 Cytoplasm enzyme 0.91 0.034 
Q06323 PSME1 proteasome activator subunit 1 Cytoplasm other 0.90 0.013 
Q9BQE3 TUBA1C tubulin alpha 1c Cytoplasm other 0.90 0.003 
P18669 PGAM1 phosphoglycerate mutase 1 Cytoplasm phosphatase 0.88 0.043 
P07900 HSP90AA1 heat shock protein 90kDa alpha family class A member 1 Cytoplasm enzyme 0.88 0.027 
P27348 YWHAQ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein theta 
Cytoplasm other 0.86 0.003 
P52907 CAPZA1 capping actin protein of muscle Z-line alpha subunit 1 Cytoplasm other 0.86 0.013 
Q99798 ACO2 aconitase 2 Cytoplasm enzyme 0.85 0.016 
P18621 RPL17 ribosomal protein L17 Cytoplasm other 0.84 0.024 
P20702 ITGAX integrin subunit alpha X Plasma Membrane transmembrane receptor 0.83 0.015 
P09211 GSTP1 glutathione S-transferase pi 1 Cytoplasm enzyme 0.82 0.008 
P54136 RARS arginyl-tRNA synthetase Cytoplasm enzyme 0.82 0.016 
Q32P28 P3H1 prolyl 3-hydroxylase 1 Nucleus enzyme 0.81 0.047 
P68104 EEF1A1 eukaryotic translation elongation factor 1 alpha 1 Cytoplasm translation regulator 0.79 0.036 
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UniProt Symbol Entrez Gene Name Location Type(s) Fold Change P-Value 
Q92598 HSPH1 heat shock protein family H (Hsp110) member 1 Cytoplasm other 0.78 0.044 
O43312 MTSS1 metastasis suppressor 1 Cytoplasm other 0.77 0.047 
Q9UI12 ATP6V1H ATPase H+ transporting V1 subunit H Cytoplasm transporter 0.75 0.016 
Q16831 UPP1 uridine phosphorylase 1 Cytoplasm enzyme 0.73 0.05 
Q9UQ80 PA2G4 proliferation-associated 2G4 Nucleus transcription regulator 0.72 0.001 
P30153 PPP2R1A protein phosphatase 2 regulatory subunit A. alpha Cytoplasm phosphatase 0.71 0.033 
Q96KP4 CNDP2 CNDP dipeptidase 2 (metallopeptidase M20 family) Cytoplasm peptidase 0.71 0.014 
P63313 TMSB10/TMSB4X thymosin beta 10 Cytoplasm other 0.70 0.035 
P15311 EZR ezrin Plasma Membrane other 0.69 0.021 
O14579 COPE coatomer protein complex subunit epsilon Cytoplasm transporter 0.69 0.025 
Q15185 PTGES3 prostaglandin E synthase 3 Cytoplasm enzyme 0.65 0.023 
P40429 RPL13A ribosomal protein L13a Cytoplasm other 0.64 0.026 
P31146 CORO1A coronin 1A Cytoplasm other 0.64 0.007 
Q8NCW5 NAXE NAD(P)HX epimerase Extracellular Space enzyme 0.63 0.008 
Q15019 SEPT2 septin 2 Cytoplasm enzyme 0.63 0.039 
P30041 PRDX6 peroxiredoxin 6 Cytoplasm enzyme 0.62 0.034 
P49327 FASN fatty acid synthase Cytoplasm enzyme 0.60 0.009 
O60749 SNX2 sorting nexin 2 Cytoplasm transporter 0.54 0.012 
P12955 PEPD peptidase D Cytoplasm peptidase 0.54 0.033 
Q14318 FKBP8 FK506 binding protein 8 Cytoplasm other 0.50 0.047 
Q9GZY6 LAT2 linker for activation of T-cells family member 2 Plasma Membrane other 0.47 0.034 
P14174 MIF macrophage migration inhibitory factor (glycosylation-
inhibiting factor) 
Extracellular Space cytokine 0.45 0.023 
P17858 PFKL phosphofructokinase. liver type Cytoplasm kinase 0.34 0.02 
Q9UL25 RAB21 RAB21. member RAS oncogene family Cytoplasm enzyme 0.33 0.001 
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UniProt Symbol Entrez Gene Name Location Type(s) Fold Change P-Value 
Q14012 CAMK1 calcium/calmodulin dependent protein kinase I Cytoplasm kinase 0.33 0.002 
Q9HB71 CACYBP calcyclin binding protein Nucleus other 0.30 0.002 
Q06210 GFPT1 glutamine--fructose-6-phosphate transaminase 1 Cytoplasm enzyme 0.30 0.002 
P62899 RPL31 ribosomal protein L31 Cytoplasm other 0.30 0.002 
P13473 LAMP2 lysosomal associated membrane protein 2 Plasma Membrane enzyme 0.30 0.002 
Q14257 RCN2 reticulocalbin 2 Cytoplasm other 0.30 0.002 
O95352 ATG7 autophagy related 7 Cytoplasm enzyme 0.30 0.002 
P21291 CSRP1 cysteine and glycine rich protein 1 Nucleus other 0.27 0.001 
P16949 STMN1 stathmin 1 Cytoplasm other 0.23 0.001 
Q13177 PAK2 p21 protein (Cdc42/Rac)-activated kinase 2 Cytoplasm kinase 0.23 0.007 
P13798 APEH acylaminoacyl-peptide hydrolase Cytoplasm peptidase 0.23 0.014 
P98171 ARHGAP4 Rho GTPase activating protein 4 Cytoplasm other 0.20 0.001 
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ABSTRACT 
The role of resident microglial cells in the pathogenesis and progression of glial tumors 
is still obscure mainly due to a lack of specific markers. Recently P2RY12, a P2 purinergic 
receptor, was introduced as a specific marker for microglial cells under normal and 
pathologic conditions. Here we analyzed the expression of P2RY12 in astrocytomas of 
various malignancy grades in relation to markers for M1 and M2 macrophage activation 
profiles by using two web-based glioma datasets and confocal immunohistochemistry 
to 28 astrocytoma samples grades II-IV. In the gliomas, P2RY12 immunoreactivity delin-
eated CD68 negative cells with otherwise microglial features from CD68 positive tumor 
associated macrophages (TAMs). The presence of P2RY12 positive cells correlated posi-
tively with overall survival. P2RY12 mRNA levels and membrane-bound localization of 
P2RY12 were inversely correlated with increasing malignancy grade, and the expression 
site of P2RY12 shifted from cytoplasmic in low-grade gliomas, to nuclear in high-grade 
tumors. The cytoplasmic expression of P2RY12 was associated with the expression of 
M1 markers, characteristic of the pro-inflammatory macrophage response. In contrast, 
the nuclear localization of P2RY12 was predominant in the higher graded tumors and 
associated with the expression of the M2 marker CD163. 
We conclude that P2RY12 is a specific marker for resident microglia in glioma and its 
expression and localization correspond to tumor grade and predominant stage of 
M1/M2 immune response. 
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INTRODUCTION 
Microglial cells are brain-specific tissue resident macrophages that are directly derived 
from yolk-sac erythromyeloid precursor cells (EMP) during embryonic development (1). As 
major contributors to the immune status of the central nervous system (CNS) microglial 
cells scan the CNS for cellular debris by continuously protract and retract their cell process-
es (2). The microglial survey mediates the immune response, supports the homeostasis of 
the neurons and, in collaboration with astrocytes, maintains the integrity of the blood-brain 
barrier (BBB) (3-5). Microglial cells become activated by a large variety of pathogenic situa-
tions. Upon activation, the cells take on an amoeboid shape and initiate the paracrine re-
cruitment of blood-derived macrophages into the altered brain parenchyma, initiating an 
inflammatory response (6, 7). Microglia serves additional, only partly known, roles in repair 
processes following the acute stage of tissue damage (8, 9). Recent studies addressing the 
phenotypic adaptations of peripheral macrophages in cancer have shown that tumor asso-
ciated macrophages (TAMs), similar to the M1 and M2 activation states of macrophages, 
display particular marker profiles of pro- and anti-oncogenic action (10, 11). TAMs with 
anti-tumor action share characteristics with M1 macrophages; are capable of antigen 
presentation and paracrine signaling to promote inflammation, thereby hampering tumor 
growth and prolonging patient survival (12, 13). These cells are referred to as M1-like cells. 
In contrast, TAMs that promote tumor progression are associated with an immunosuppres-
sive response; contribute to tumor angiogenesis and proliferation, and are associated with 
poor clinical outcomes (14-16) and these cells are referred to as M2-like cells. In general, 
TAMs are more similar to M2 - than M1 macrophages (17).  
Recent reports have pointed to the heterogeneity of microglial cells (16). In glioblas-
toma, microglia displays a pro-oncogenic phenotype resembling that of M2-like macro-
phages, because the cells are in a microenvironment rich in glioma (stem) cell derived 
factors like TGF-β1, MCP-1, PGE-2, and soluble colony stimulating factors (18). There is 
data showing that resident microglia in glioblastomas plays a role in tumor progression 
and invasion by the release of cytokines and proteases (19-21). However, the mecha-
nism of microglial activation and the contribution of microglia to tumor progression are 
largely unknown. In order to obtain insight in the specific action of residential microglial 
cells in gliomas, proper discrimination of these cells from TAMs is necessary. So far, 
specific markers for residential microglial cells that delineate these cells from other 
recruited cells of monocyte lineage, are lacking. As a matter of fact, TAMs share many 
markers with microglial cells. The microglial marker Iba-1 is co-expressed with CD45 and 
is therefore, not discriminative between residential microglia and monocytic cells that 
migrated into the brain (22). In the brains of patients who suffered from Alzheimer 
disease (AD) the markers CD45 and Iba-1 were used in combination with P2RY12 to 
separate macrophages from microglia (22). Considering the growing interest in under-
standing the role of microglial cells in gliomas, specific markers for the identification of 
resident microglia in the context of primary brain tumors are urgently needed. 
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Recently, the Purinergic Receptor P2Y12 (P2RY12) was proposed as a specific marker 
for healthy rodent CNS microglial cells, discriminating these cells from other types of 
tissue resident macrophages or blood-derived monocytes (23). P2RY12 was claimed as a 
specific marker for microglial cells in human brains (24-26). P2RY12 belongs to the fami-
ly of P2 purinergic receptors, consisting of seven transmembrane G protein coupled 
receptors (GPCRs) that contribute to ATP-and ADP-mediated cell migration in vitro (27). 
P2RY12 is expressed in activated platelets and notoriously, in microglial cells (28). 
P2RY12 deficiency in P2RY12 knockdown mice significantly compromised microglial 
chemotaxis and extension of microglial foot processes in response to CNS injury (29, 
30). In this study, we scrutinized P2RY12 as a marker for microglial cells in glial tumors. 
We also investigated the relation between the expression of P2RY12 and that of pro- or 
anti-inflammatory markers; the expression sites in the microglial cells and the relation 
with tumor progression. 
MATERIAL AND METHODS 
Patient samples  
All patient samples were obtained from the Archives of the Department of Pathology, 
Erasmus Medical Center, Rotterdam, with approval of medical ethical committee of the 
Erasmus Medical Center. Twenty-eight glioma samples (11 astrocytomas WHO grade II 
(A II), 7 anaplastic astrocytomas (WHO grade III; AA) and 10 glioblastomas (GBMs) were 
collected and all diagnoses were confirmed by a certified pathologist (JMK). The mean 
ages ± standard deviations and the male/female ratio are summarized in (Table 1). Four 
autopsy brains of patients who did not have brain tumors were used as a control. Post-
mortem times of the control cases were 8 hours or less. 
 
Table 1. summary of the patients used for immunohistochemistry  
 Astrocytoma grade II  
(All) 
Anaplastic Astrocytoma 
(AA) 
Glioblastoma  
(GBM) 
Control 
(autopsy brains) 
Mean age ± st. dev. 42 ± 12.8 40 ± 12.8 45 ± 14.9 58 ± 13.3 
Male/Female 4/7 4/3 7/3 2/2 
Immunostaining 
Adjacent sections of 5µm thickness from Formalin Fixed Paraffin Embedded (FFPE) 
samples were used for immunohistochemical analysis. The sections were incubated 
with antibodies against P2RY12 (1:100; Sigma, Sweden); CD68 (1:800; Dako, Denmark) 
GFAP (1:200; Dako, Denmark); CD45 (1:100; Dako, Denmark) and CD163 (1:400; Abd 
Serotec, USA). The staining procedure and scanning of the stained sections were per-
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formed according to the protocol described previously (31). For double labeling, Alexa 
Fluor 488 and 555-conjugated secondary antibodies (1:200, Thermo Fisher Scientific, 
The Netherlands) were used for detection. For triple staining, Goat anti-Mouse F(ab)2 
fragment (Jackson ImmunoResearch, WestGrove, PA, USA) was used to block back-
ground epitopes and Alexa Fluor 647-conjugated secondary antibody (Thermo Fisher 
Scientific, The Netherlands) was used for detection. The fluorescent labeled samples 
were analyzed by using the confocal microscope LSM 700 (Zeiss, The Netherlands). 
Signal positive areas and staining intensity were quantified using the Image J program to 
five high power field (40x) areas of each immunostained slide. 
Public database 
The transcription level of P2RY12 was assessed in human gliomas of various WHO 
grades, using 2 different datasets derived from the public NCBI GEO database (GDS 
4467 Gene ID 64805 and GDS1816 Gene ID 64805). In addition, transcriptional data of 
P2ry12 in a murine glioma model were obtained from the GEO database (GSE 86573) 
(32). RNA-sequencing data of P2RY12 combined with clinical data were obtained from 
two TCGA glioblastoma databases (Provisional: 166 GBM patients (33). In addition, 
information on IDH1 mutation as well as MGMT methylation status were also obtained 
from the TCGA GBM database (Cell, 2013). The R program and CGDS-R package provid-
ed by the cBioPortal for cancer genomics from Memorial Sloan-Kettering Cancer Center 
was used to download and process data.  
To study the relation between P2RY12 mRNA expression levels and markers for mi-
croglia identification, a mutual exclusivity analysis was performed as described previ-
ously (34, 35). The GBM TCGA dataset (GBM, provisional) and a low-grade glioma TCGA 
dataset were selected for analysis using the cBioPortal websource (Supplementary Ta-
ble 1). High P2RY12 expression was defined by a Z score ≥ 2. Z score = (individual 
P2RY12 value – mean P2RY12 value) / std. dev. of the whole sample set. A log Odd Ratio 
(OR) >0 indicates a trend of co-occurrence in expression of P2RY12 with the listed genes 
and log (OR) <0 indicates a trend of mutual exclusivity in expression pattern.  
Statistics 
The results of immunostaining and the data from public database were analyzed by the 
Mann-Whitney U test (P<0.05 was considered significant). Survival analysis was per-
formed using the Log-rank test (P<0.05 was considered significant). All data and graphs 
were analyzed and made by using Graph pad Prism 5.0.  
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RESULTS 
Reduction of membrane P2RY12 signal correlates with glioma grade. 
The analysis of the public databases revealed that P2RY12 is mainly expressed in A II, 
while less in AA and GBM (Figure 1a). The results of immunostaining for P2RY12 are 
shown in Figure 1b. P2RY12 positive cells in autopsy brains and A II presented the typi-
cal ramified morphology with extended processes. In contrast, in AA a mixture of both 
ramified and amoeboid P2RY12 positive cells were noticed. In the GBMs the P2RY12 
staining was less on the cell membranes while the signal was mainly visible in the nuclei 
(P2RY12
nuclei+
). Quantitative analysis of the percentage of P2RY12 positive areas per 
image view revealed a significant smaller number of P2RY12 positive cells in the AA and 
GBM as compared to A II (Figure 1b, c). Double staining of P2RY12 with the pan- macro-
phage marker CD68 revealed a large population of CD68 negative, P2RY12 positive cells 
(CD68
- 
P2RY12
+
) distinct from TAMs (CD68
+
 P2RY12
-
) in all glioma samples (Figure 1e). 
The population of P2RY12
+
 cells did not overlap with the population of GFAP positive 
tumor cells or reactive astrocytes (Figure 1f). In autopsy brain, A II and AA, the CD68
+
 
TAMs generally had round cell bodies and were located around the blood vessels. In 
GBM, CD68
+
 TAMs were not only located around the blood vessels (Figure 1e, white 
arrows), but were spatially mixed with the P2RY12
nuclei+
 cells. 
 
Figure 1 Legends to Figure 1. Reduced P2RY12 expression and nucleus translocation in microglia/macrophages 
correlated with glioma progression. 
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a: Analysis of GEO databases reveals decrease of P2RY12 mRNA expression with progression of glioma. Results 
are shown in the median values of P2RY12 mRNA levels. ** P<0.01; ***P<0.005. A II: Astrocytoma WHO grade 
II, AA: Anaplastic Astrocytoma (WHO grade III), GBM: Glioblastoma. b: Immunohistochemical staining for 
P2RY12 in normal brain and different grades of glioma. Representative pictures were selected from each group. 
Cells with the P2RY12 signal localized mainly in the cytoplasm display the classic ramified microglial morphology 
in autopsy brain, A II and AA. Cells with nuclear location of P2RY12 are mainly observed in GBM samples (scale 
bar: 100 µm). c: Quantification of percentages of P2RY12 positive areas per image field in autopsy brain, A II and 
GBM. Mean values of each group are indicated. * P<0.05, ** P<0.01 ****P<0.001. d: Confocal images showing 
CD68 and P2RY12 staining in tissue samples of liver and kidney (scale bar: 50 µm).e: Confocal images showing 
the spatial relation between CD68 and P2RY12 positive cells in autopsy brain, A II, AA and GBM (scale bar: 50 
µm). f: Confocal images showing no overlap between GFAP and P2RY12 staining in astrocytoma grade II (scale 
bar: 20 µm). 
P2RY12nuclei+ cells are not of myeloid origin, but represent resident microglia. 
Higher numbers of CD45 positive cells were observed in AA and GBM than in A II. The 
CD45+ cells were mostly present around the blood vessels (Figure 2a, A II versus AA 
versus GBM). Double staining for CD45 and P2RY12 did not reveal double-stained cells, 
indicating that the P2RY12 positive cells are not derived from myeloid lineage (Figure 
2a). CD45 positive cells were observed in higher graded tumors, prominently around 
blood vessels (Figure 2a, A II versus AA versus GBM). To further evaluate the identity of 
CD68
+
P2RY12
nuclei+
 cells double immunostaining for CD45 and CD68 (Figure 2b and e) 
and triple immunostaining for CD68, CD45 and P2RY12 was carried out. Two large cell 
populations were observed, namely CD68
+
CD45
+
P2RY12
-
 and CD68
+
CD45
-
P2RY12
nuclei+
 
cells, the former to be interpreted as monocytes/macrophages, and the latter as the 
resident microglial population (Figure 2c, d, f, g). 
In the GEO dataset GSE 86573 generated from a murine glioma model the expres-
sion of P2ry12 by microglia (MG) was significantly higher than that by bone marrow- 
derived macrophages (BMDM) (Supplementary Figure 1). 
Cytoplasmic or nuclear distribution of P2RY12 in microglia relates to the 
functional marker profiles. 
The results of immunostaining for the M2 markers CD163, CD204 and P2RY12 showed 
that cytoplasmic P2RY12 expression did not overlap with CD163 and CD204 positivity 
(Figure 3a1-3, d1-3). In contrast, cells with nuclear located P2RY12 showed distinct 
overlap with CD163 and CD204 (Figure 3c1-3, f1-3). Confocal analysis revealed that cells 
with a low CD163 signal show ramified cell processes and higher P2RY12 signals. Cells 
with a high CD163 signal are either negative for P2RY12, or display nuclear localization 
of P2RY12 (Figure 4a and b, cyan and white arrows). Triple labeling for CD45, CD163 and 
P2RY12 differentiated between two cell populations: CD163
+ 
P2RY12
nuclei+
 cells devoid of 
CD45 signals and CD163
+
 CD45
+
 P2RY12
+
 cells (Figure 4c and d). 
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Figure 2.  
 
a: Cells in high grade glioma expressing P2RY12 in the nuclei are not recruited cells of myeloid origin, but resi-
dent microglia. b: Confocal images showing CD68 and CD45 signals in AA (scale bars: left image; 50 µm, right 
panel; 20 µm). c: Confocal images of triple staining for CD68, P2RY12 and CD45 in AA. Left image: Merged 
overview of triple staining (scale bar: 50 µm). Right image: Merged high magnification of a P2RY12 positive cell 
(scale bar: 10 µm). d: Panel of single channel images of a P2RY12 positive cell in AA (scale bar: 10 µm). e: Confo-
cal images showing CD68 and CD45 staining in GBM (scale bar: left image; 50 µm, right panel; 20 µm). f: Confo-
cal images showing triple staining for CD68, P2RY12 and CD45 in GBM. Left panel: Merged overview of triple 
staining (scale bar: 50 µm). Right panel: Merged higher magnification view of P2RY12 positive cells (scale bar: 
10 µm). g: Panel of high magnification single channel images of P2RY12 positive cells in GBM (scale bar: 10 µm). 
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Figure 3 Cytoplasmatic and nuclear distribution of P2RY12 in microglia is correlated with M2-like activation in 
high grade glioma. 
 
a1-a3: Co-expression of cytoplasmic P2RY12 with CD163 and CD204 in AA (scale bar: 200 µm). b1-b3: Over-
view of AA tissue samples (scale bar: 10mm). c1-c3: Co-expression of nuclear P2RY12 with CD163 and CD204 
in AA (scale bar: 200 µm). d1-d3: Co-expression of cytoplasmic P2RY12 with CD163 and CD204 in GBM (scale 
bar: 200 µm). e1-e3: Overview of GBM tissue samples (scale bar: 10mm). f1-f3: Co-expression of nuclear 
P2RY12 with CD163 and CD204 in GBM (scale bar: 200 µm). 
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Figure 4 Confocal analysis of co-localization of P2RY12, CD163 and CD45 in GBM. 
  
a: Upper row: overview of immunostaining for P2RY12 and CD163 in a representative GBM. White arrows 
indicate nuclear P2RY12 signal in cells with high CD163 signal; Cyan arrows indicate cytoplasmic P2RY12 signal 
in cells with low CD163 signal (scale bar:100 µm). Lower row: selected view of P2RY12 and CD163 staining in 
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glioblastoma. White arrows indicate cells with weak P2RY12 and high CD163 signal (scale bar: 50 µm). Inserts: 
details of cells with low CD163 and strong cytoplasmic P2RY12 signals, and cells with strong CD163 and weak 
P2RY12 signals. b: Overview with two inserts. Upper panel: area with cells with nuclear P2RY12 signal with 
strong CD163 expression (scale bar: 50 µm). Lower panel: area with cytoplasmic P2RY12 signals and weak 
CD163 expression (scale bar: 50 µm). White arrows: nuclear P2RY12 expression with strong CD163 signals. c: 
Overview: triple staining for CD163, P2RY12 and CD45 in GBM (scale bar: 50 µm). Inserts (scale bar: 20 µm): 
Cells with high CD163 and nuclear P2RY12 signals did not overlap with CD45. d: Confocal images showing 
triple staining for CD163, P2RY12 and CD45 in GBM (scale bar: 20 µm). Cells with high CD163 and nuclear 
P2RY12 signal did not overlap with CD45. 
High expression levels of P2RY12 are associated with favorable clinical 
outcomes. 
P2RY12 RNA expression data was obtained from two TCGA glioma databases. From the 
glioma database (33), 151 patients were collected for analysis (Table 2). Twenty-one 
tumors with at least 1-fold increase of P2RY12 expression were defined as the “P2RY12 
high” group, while the tumors expressing P2RY12 al lower levels than 1-fold increase 
were defined as the “P2RY12-low” group. Patients with tumors of the P2RY12-high 
group had longer overall survival times (P=0.03), but not a longer disease free survival 
than those in the P2RY12-low group (Figure 5a). In the glioma provisional database from 
TCGA the P2RY12-high group showed a trend of longer disease free survival (P=0.0608) 
as well as a significant increase in overall survival time (P=0.0446) (Supplementary Fig-
ure 1a and b, upper and lower graph). Univariate analysis by the Log-rank test revealed 
that patients in the P2RY12-high group have lower hazard ratios for disease recurrence 
(HR=0.445, P=0.0187) than patients in the P2RY12 low group. Similarly, the P2RY12-high 
group has a lower hazard ratio for overall survival versus the P2RY12-low group 
(HR=0.4598, P=0.04) (Supplementary Figure 1c). The data show that P2RY12 up-
regulation positively correlates with prognosis and overall survival of GBM patients. The 
expressional levels of P2RY12 are significantly higher in gliomas with the IDH1 (R132H) 
mutation as compared to the IDH wt gliomas (Supplementary Figure 3a). There is, how-
ever, no effect of P2RY12 expression on overall survival when the population was strati-
fied for IDH1 mutation status (Supplementary Figures 3b and c). There were no expres-
sional differences of P2RY12 between gliomas with or without MGMT promoter meth-
ylation (Supplementary Figure 4a). The expression of P2RY12 did not affect the overall 
survival of the patients when stratified for MGMT promoter methylation status (Sup-
plementary Figures 4b and c).   
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Table 2. Summary of patients’ information from TCGA GBM database   
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Figure 5 Analysis of TCGA datasets: High expression levels of P2RY12 in GBM patients predict a favorable 
outcome. 
 
a: Kaplan-Meier curves showing disease free survival and overall survival curves of patients with different 
P2RY12 expression levels. b: Overlap of the genes found in the two datasets that positively correlate with 
P2RY12 expression. c: Top 20 most significant biological processes resulting from functional annotation of the 
222 overlapping genes. The GO terms are shown on the y-axis. The numbers of input genes per GO term are 
indicated on the x-axis. d: Overlap of the genes found in the two datasets that negatively correlate with 
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P2RY12 expression. e: Top 20 most significant biological processes resulting from functional annotation of the 
58 overlapping genes. The GO terms are shown on the y-axis. The numbers of input genes per GO term are 
indicated on the x-axis. 
P2RY12 expression correlates with microglia/macrophage function. 
P2RY12 had a significant likelihood for co-occurrence with the microglia markers Iba-1 
and CX3CR1 in GBM, and CX3CR1, CD11b in low grade glioma. Likewise, IRF8, a tran-
scription factor for the function and development of microglia cells (36, 37) is expressed 
simultaneous with P2RY12 in both GBM and low grade gliomas. Due to the limited 
number of samples in the high P2RY12 expression group, the p-values of associations 
with log(OR) <-3 remain non-significant, despite a high probability and tendency for 
mutual exclusion.  
The associations between P2RY12 and other markers are listed in the Supplemen-
tary Table. Genes positively (Spearman r ≥0.5) or negatively (Spearman r≤-0.3) correlat-
ed with P2RY12 from the two TCGA GBM database were selected for pathway enrich-
ment analysis (Figure 5b, d). Pathway analysis from Gene Ontology based on 222 
P2RY12 positively correlating genes included the regulation of immune response includ-
ing defense response, leukocyte activation, T cell activation (Figure 5c). Pathway analy-
sis on 58 P2RY12 negatively correlating genes mainly included cell cycle regulation and 
cell proliferation (Figure 5e). The findings indicate that P2RY12 expression is positively 
correlated with markers commonly used for microglia in the CNS and positive immune 
response, but is inversely associated with markers for peripheral recruited macrophag-
es, M2-like microglia/macrophage activation and cell proliferation. 
DISCUSSION 
In the present study, we found that resident microglial cells in gliomas specifically ex-
press P2RY12 and that the expression distinguishes microglia from other monocytes and 
macrophages. This finding in human gliomas corroborates the data we generated from 
the murine gliomas represented in the GEO database. The analysis of the public glioma 
datasets and the multi-labeling experiments of the glioma biopsy specimens confirmed 
that P2RY12 mRNA and protein expression is confined to resident microglial cells. In 
addition, P2RY12 expression is associated with tumor grade: the expression is less in AA 
and GBM, as compared to A II. However, the expression of P2RY12 is not an independ-
ent prognosticator in gliomas; when strong prognostic factors as IDH mutational status 
or methylation status of MGMT are taken into consideration, no additional effects of 
the expression are found. The expression of P2RY12 appeared to be higher in the IDH 
mutated tumors, which is in line with the association of IDH mutation and better prog-
nosis on the one hand, and the pro-inflammatory status on the other. Remarkably, with 
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increasing malignancy grade there is a shift from cytoplasmic to nuclear expression, and 
in the high-grade tumors the nuclear expression of P2RY12 coincides with that of the 
M2 markers CD163 and CD204 (Figure 1a and c, Figure 4). We also observed that in the 
high-grade gliomas the P2RY12
 
positive microglial cells have taken an amoeboid pheno-
type (Figure 1b).  
Upon pathologic stimuli, resting microglia adopt a highly dynamic phenotype re-
ferred to as “ramified microglia”, with an extensive motile set of foot processes that 
continuously survey the local environment to recognize and eliminate pathogens (25). 
Loss of microglial expression of P2RY12 in knockout mice resulted in impaired polariza-
tion, migration and extension of microglial processes towards extracellular nucleotides 
released from damaged cells, indicating that P2RY12 is required to guide microglial 
chemotaxis (29). Further studies revealed that a raise of local extracellular ATP/ADP 
levels at the site of CNS injury activates Gi/o-coupled P2RY12, followed by PI3K and PLC 
signaling-mediated migration of microglial cells towards the chemotactic source (27). 
Exogenous stimuli like lipopolysaccharides (LPS) can cause a dramatic reduction of the 
P2RY12 expression in microglia cells in vitro accompanied by the retraction of microglial 
processes and metamorphosis into an amoeboid shape (29). These phenomena indicate 
a function of P2RY12 in the activation of immune regulation during inflammation.  
The environmental changes taking place under various pathological conditions cause 
ATP/ADP leaks that are noticed by the P2RY12 receptors of microglia and lead to chang-
es affecting the cell processes and motility of the cells (38). High concentrations of pu-
rinergic nucleotides and nucleosides such as adenosine and ATP were shown to work in 
synergy with LPS activation of microglial cells, promoting chemo repulsion away from 
the ATP source, a process that is associated with increased local adenosine A2A recep-
tor signaling (38, 39). The expression of the adenosine A2A receptor increases signifi-
cantly in response to LPS, while P2RY12 expression decreased by LPS, indicating that the 
shift from a ramified towards an amoeboid phenotype depends on the balance be-
tween P2RY12 and A2A receptor signaling, respectively (38). More studies are required 
to elucidate the exact regulatory mechanism of microglia immune-activation by these 
two significant signaling pathways. 
In this study we observed nuclear localization of P2RY12 in microglial cells in the 
high-grade tumors, while in the lower graded astrocytomas P2RY12 was expressed in 
the cytoplasm. G protein-coupled receptors (GPCRs), such as P2RY12 and its family 
members are considered as cell surface bound mediators of intracellular signaling. From 
in vitro and in vivo studies, it is known that some receptors have a nuclear localization. 
These receptors include the receptors for apelin, angiotensin II AT1, parathyroid hor-
mone, glutamate mGluR5, endothelin ETA and ETB, and the prostaglandins EP1, EP3, 
and EP4 (40). The mechanism and functional implications of nuclear translocation re-
mains obscure. It has been suggested that nuclear import is programmed by the DNA 
sequence of the receptors. Nuclear GPCRs complex proteins such as heterotrimeric G 
proteins, phospholipase A2, and phospholipase C seem to remain active in intracellular 
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signaling, similar to the activation of nuclear endothelin and prostaglandin receptors 
that were proven to increase nuclear Ca
2+
concentrations (40). However, the functional 
implications of nuclear localization of the P2RY12 receptor and its association with ad-
vanced tumor grade needs to be further unraveled. 
CONCLUSION 
The expression site of P2RY12 matches astrocytoma grade, and also reflects the activa-
tion status of microglia cells in the tumors. Because of its association with the stage of 
immune response, P2RY12 may become an interesting drug target for future immune-
modulation based therapy for the patients suffering from these tumors. 
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SUPPLEMENTARY DATA 
Supplementary Figure 2. High expression levels of P2RY12 in GBM patients predict a favorable outcome based 
on analysis of TCGA GBM database provisional  
 
a: Overview of P2RY12 expression level of 166 GBM patient samples in TCGA GBM provisional database. b: 
Kaplan-Meier graphs showing disease free survival and overall survival in patients with different P2RY12 
expression levels. c: Graphs showing hazard ratios (HR) with 95% confidential interval (CI) of disease free 
survival (left) and overall survival (right) in different groups of patients.  
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Supplementary Figure 3. High expression of P2RY12 did not predict overall survival in GBM patients either with 
IDH1 WT (Wild Type) or mutant statue 
 
a. Analysis of TCGA GBM database (Cell, 2013) reveals increased P2RY12 mRNA expression in patients with 
IDH1 mutation(R132H). Results are shown in the median values of P2RY12 mRNA levels. * P<0.05. WT: Wild 
type. b. Kaplan-Meier graph showing overall survival in IDH1 wild type patients with different P2RY12 expres-
sion levels c. Kaplan-Meier graph showing overall survival in IDH1 mutant (R132H) patients with different 
P2RY12 expression levels. 
 
Supplementary Figure 4. High expression of P2RY12 did not correlate with overall survival of GBM patients 
with either MGMT unmenthylation or MGMT methylation status 
 
a. Analysis of TCGA GBM database (Cell, 2013) reveals stable expression of P2RY12 mRNA in patients 
with/without MGMT methylation. Results are shown in the median values of P2RY12 mRNA levels. b. Kaplan-
Meier graph showing overall survival in MGMT-methylated patients with different P2RY12 expression levels c. 
Kaplan-Meier graph showing overall survival in MGMT unmethylated patients with different P2RY12 expres-
sion levels. 
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Supplementary Table 1. Summary of mutual exclusivity analysis from two TCGA glioma database 
 
TCGA GBM provisional database and low grade glioma database were analyzed from cBioPortal.  P2RY12 
upregulation was defined by Z score. Z score=(Individual P2RY12 value-mean value)/Standard deviation of 
whole sample set. Odd ratio(OR) represents the co-occurrence of P2RY12 with listed molecules in the sup-
plementary table. The significance was examed by fisher’s test.  Log(OR)>0, with P<0.05 indicates a trend of 
co-occurrence. Log(OR)<0 indicated the trend of mutual exclusivity.  
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CECR1 is a highly conserved protein that reportedly regulates embryo and larva devel-
opment in both vertebrates and invertebrate with adenosine deaminase activity [1-4]. 
Studies in both drosophila [5] and humans [6] point to a putative role of CECR1 in regu-
lating immune functions through mediating the proliferation of monocytes, lympho-
cytes and the differentiation of monocytes into macrophages. CECR1 loss of functions 
mutations in patients result in clinical manifestations related to hyper reactivity of the 
immune system [4, 7-9]. The candidate effector cell for CECR1 expression is the mono-
cyte/macrophage. So far, most studies on the functions of CECR1 have only associated 
CECR1 with inflammation in general, without further specification of the immune re-
sponse, especially in relation to cancer. The investigations reported in this thesis link 
CECR1 expression in glioma to tumor associated macrophages (TAMs). 
In Chapter 3 the expression of CECR1 by pro-M2 macrophages was demonstrated by 
using various immunohistochemical lineage markers and cytokines. In skin biopsies of 
patients with CECR1 mutations overproduction of TNF-α was found together with over-
expression of IL-1β and iNOS [9]. In adenoid cystic carcinoma of salivary glands the 
promotor of CECR1 appears to be hypo-methylated [10], indicative of over-transcription 
of CECR1 during carcinogenesis. Furthermore, high levels of CECR1 were detected in the 
serum of patients with breast cancer [11]. These findings are in line with the hypo-
methylated state of CECR1 and the over-expression of CECR1 in glioma and are illustra-
tive of the association between CECR1 and tumorigenesis. Starting from the idea that 
M2-like macrophages promote carcinogenesis, we showed that the expression of CECR1 
is increased in M2-like macrophages in glioblastoma. Furthermore, the contribution of 
CECR1 in M2-like polarization of CECR1 producing macrophages was confirmed by ei-
ther CECR1 depletion or CECR1 overexpression. We showed that CECR1 is a tumor-
promoting molecule that is mainly expressed and released by macrophages in glioma. 
The direct pro-tumoral effect of CECR1 is accompanied by M2 polarization of these 
cells. The paracrine effects of CECR1 include cell proliferation, migration and upregula-
tion of the intracellular MAPK pathway in glioma cells. The direct effector molecules 
regulated by CECR1 remain unknown so far. It is very likely that CECR1 mediated ex-
pression of cytokines in TAMs stimulate these intracellular signalling pathways in glioma 
cells (Chapter 3). For example: the immune modulating molecule IL-10 is not only in-
volved in mediating an immune suppressive microenvironment but also plays a role in 
enhancing the progression of cancer cells via STAT3 activation in cancer cells [12]. 
CCL18, which takes part in tumor progression including adherence to the extracellular 
matrix, migration, invasion and tumor angiogenesis, activates the intracellular PLCγ1, 
PKCζ, and Ca
2+
 pathways through interaction with its receptor PITPNM3 [13].  It may 
well activate focal adhesion kinase (FAK)-triggered clustering of integrin β1 [13]. 
CXCL12, a classic pro-tumoral molecule, that interacts with CXCR4 and regulates multi-
ple biological functions in cancer development including thee MAPK pathway [14]. 
In order to obtain a complete picture of the CECR1-mediatated response in macro-
phages, a proteome analysis-based analysis was applied (Chapter 6). Surprisingly, CECR1 
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expression appeared to be negatively related to proteins involved in the innate immune 
response including phagocytosis, phagosome maturation, antigen presentation and the 
type I interferon signalling pathway. Among these pathways, antigen presentation and 
processes related to phagocytosis, are tightly regulated by IFN-γ. Two studies from 
patients bearing CECR1 mutations reported an increased expression of IFN-γ induced 
genes in peripheral monocyte [15] and a neutrophil-derived gene signature [16]. In our 
dataset the up-regulation of several proteins in response to CECR1 silencing in macro-
phages downstream of IFN-γ were predicted by Ingenuity Pathway Analysis (Chapter 6). 
The suppression of CECR1 expression in macrophages significantly increases the expres-
sion of MHC-I molecules like HLA-A, B, C. Furthermore, several phagosome proteins 
such as TAPBP, TAP1, TAP2 are upregulated upon CECR1 depletion. Macrophages func-
tion as antigen presenting cells when stimulated by exogenous pathogens or endoge-
nous debris. The antigen peptides processed by phagocytosis are presented by either 
MHC II molecules to CD4
+ 
T cells or MHC I molecules to CD8
+
 T cells. Taken together, 
suppression of CECR1 enhances the phagocytosis ability and the IFN-γ mediated MHC I 
antigen presentation to CD8
+
 T cells [17]. These data are promising for the development 
of immune therapies for gliomas. Both in vitro studies focusing on deciphering the 
mechanisms and assessing the pre-clinical therapeutic effect are required to further 
develop these ideas. Unfortunately, the majority of secreted factors are missing from 
the proteome analysis because cell lysates were used. Analysis of the TCGA GBM data-
base revealed that, among other monocyte/macrophage markers, S100A9 and PLAU 
positively correlated with the expression of CECR1. S100A9 and PLAU have been found 
in myeloid cells, and S100A9 was shown to promote glioma growth and angiogenesis by 
interaction with its receptor RAGE on the surface of tumor cells [18]. S100A9 was prov-
en to trigger activation of MAPK and NF-κB pathways [19], promoting tumor growth and 
angiogenesis [20]. PLAU was one of the proangiogenic factors produced by tumor asso-
ciated macrophages [21]. PLAU aids in the invasion and metastasis of various tumor 
types via binding to PLAUR, activating downstream pathways like ERK1/2 [22], PI3K/Akt 
signaling transduction [23]. Another interesting finding following CECR1 knockdown was 
the identification of LAT2. This protein was upregulated in CECR1 knockdown macro-
phages co-cultured with U87, and down-regulated in pure U87 co-cultured macro-
phage. The function of LAT2 is to mediate the response of B cells and monocytes / mac-
rophages [24]. The expression of LAT2 appeared to be increased in matured macro-
phages, but decreased in monocyte [25].  The function of LAT2 includes mediation of 
the B cell response and affects monocytes /macrophages [24]. LAT2 knockout macro-
phages and dendritic cells lose the ability to produce pro-inflammatory cytokines like IL-
12, IFN-γ and IL-23 [25, 26]. In our own dataset, in macrophages under U87-coculture 
conditions, CECR1 knockdown not only increased the LAT2 expression, but also in-
creased the IL-12 transcriptional level, while decreasing the IL-10 level. The data in 
Chapter 3 on the cytokines profile under CECR1 depletion and CECR1 treatment shows a 
similar trend of cytokine expression. Taken together, the data indicates that CECR1 
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depletion may function through LAT2 regulating expression and secretion of pro-
inflammatory factors by macrophages, thereby promoting anti-tumoral immunity in 
glioma. 
 
Angiogenesis is a prominent feature of glioblastoma [27] and is regulated by tumor-
associated macrophages [28]. The matricellular protein periostin was shown to serve as 
a potent chemoattractant for TAMs [29]. In this thesis, we discovered that the source of 
periostin is not glioma initiating cells or glioma stem cells, but mainly pericytes. Only 
part of the PDGFB+ pericytes appeared also OLIG2+/SOX2+. We screened various pro-
angiogenic molecules such as VEGFA, Angiopoietin1, 2, IL-8, VWF as well as PDGFB in 
macrophages with CECR1 silencing and those cells being treated by CECR1 protein. Only 
PDGFB was significantly influenced by CECR1 in macrophages (Chapter 4). Pericytes 
exclusively express the PDGFB receptor, PDGFRB. CECR1 mutations cause vascular in-
stability [30], thus presenting a possible link between CECR1 and pericyte function. The 
findings prompted us to focus on the cross-talk between macrophage and pericytes, not 
endothelial cells. The PDGFB-PDGFRβ axis in pericytes takes part in various aspects of 
biological functions including cell proliferation, migration, secretion of cytokines and 
growth factors [31]. We confirmed that the pro-angiogenic action of periostin is under 
the control of macrophages through paracrine interactions involving PDGFB-PDGFRβ. 
Periostin appears to serve as a terminal effector molecule for the upstream CECR1 sig-
nal from macrophages. Periostin affects migration and the pro-angiogenesis action of 
the pericytes. The studies described in Chapter 4 reveal the positive feedback between 
tumor associated macrophage infiltration and pericyte functions in angiogenesis. Infil-
trated macrophages secreted higher levels of CECR1 in the tumor microenvironment, 
leading to more PDGFB secretion from macrophages via autocrine activation. This 
PDGFB trigger causes the secretion of periostin into extracellular matrix by pericytes. 
Periostin seems to have many more functions, since it enhances the mono-
cyte/macrophage infiltration, increases the production of VEGFA and other pro-
angiogenic molecules, and influences the migration by regulating focal adhesion mole-
cules. Consequently, the CECR1-PDGFB-PDGFRB-Periostin mediated cross talk between 
pericytes and macrophages accelerates the neo-vascularization and tumor associated 
macrophage infiltration in GBM. 
Microglia and macrophages coexist in the neuropil and perivascular areas of glioma 
[28]. Mature microglia and infiltrated macrophages share many cell markers [32]. How-
ever, these cell types do differ in their immune modulatory actions. In Chapter 3 we 
showed that CECR1 is expressed by microglia and / or macrophages and additional im-
munophenotypical characterization is necessary to distinguish between the two cell 
types. As shown by Butovsky et al, P2RY12 is uniquely expressed by microglia but not by 
peripheral macrophages [33] and we were able to also make a distinction between 
these cell types in the context of glioma by using anti-P2RY12 antibody. In Chapter 7 we 
noticed P2RY12 expression in glioma. Remarkably, in high-grade glioma (glioblastoma, 
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GBM) P2RY12 showed nuclear localization. In autopsy brains and in grade II astrocyto-
mas P2RY12 specifically stained microglia. Interestingly, in anaplastic astrocytoma 
P2RY12 was seen in the cytoplasm and the nuclei of the microglial cells. Cells with either 
P2RY12 cytoplasm and nuclear localization also expressed the pan-macrophage marker 
CD68. To confirm the origin of P2RY12 positive cells, CD45 was applied. CD45 positive 
cells were negative for P2RY12 suggestive of the non-myeloid origin of the cells. In the 
grade III astrocytomas and glioblastomas the cells with P2RY12 nuclear translocation 
were also immunopositive for the markers of M2 microglia/macrophages such as CD163 
and CD204. Therefore, downregulation and nuclear translocation of P2RY12 seems to 
be a feature of microglial cells with a M2 phenotype in high grade glioma. 
Previous studies have suggested that microglial cells, representing the initial respon-
sive innate immune cells, form the initial host immune response against the glial tumor 
cells. The immune-profile of microglia in low-grade glioma resembles that of the M1 
state, i.e., pro-inflammation and equipped for antigen presentation [34, 35]. Along with 
tumor progression peripheral monocytes are increasingly recruited to become glioma 
associated macrophages by the interference of various factors derived from the glioma 
cells and due to the hypoxic microenvironment. The shift in intracellular P2RY12 expres-
sion site during the progression from low- to high-grade glioma may be related to the 
distribution of microglia and macrophages in the tumors. Based on the TCGA GBM and 
low-grade glioma database, particular sets of genes correlate with P2RY12 expression 
and reflect an immune and pro-inflammatory response. In parallel, other sets of genes 
that negatively correlate with P2RY12 expression are related to the cell cycle and path-
ways operating during cell proliferation, corroborating data in the literature on 
P2RY12[36]. P2RY12 expression status is associated with tumor grade and also with 
immune status of the tumor, and with overall survival time. The development of strate-
gies to manipulate the P2RY12 positive cells may become important to future therapeu-
tic strategies for glioma. 
PERSPECTIVES:  
Better understanding the biology of CECR1 in glioma associated 
microglia/macrophage benefits future clinical care 
Only recently the adenosine deaminase activity of CECR1 was recognized [11, 37-41], 
and the expression and function of CECR1 in monocyte/macrophages and its immune 
modulatory roles in various inflammatory diseases from both human and porcine were 
reported [4, 6-9, 30, 42-44].  In auto-immune diseases, the loss of function mutation of 
CECR1 leads to a hyper-reactive immune response characterized by augmented TNF-α 
and IL-β levels [30], upregulated neutrophil gene signatures [16] and upregulation of 
interferon stimulating genes [15]. Due to the over-reactivated systemic inflammation, 
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patients with CECR1 mutations may present with immune cell infiltrations and instable 
vascular architecture [30]. Elevated CECR1 levels are found in breast cancers [11] and 
also in glial tumors as described in this thesis. CECR1 overexpression leads to immune 
suppression and a tumor promoting profile of macrophages. Overexpressed or down-
regulated CECR1 influences vascular formation by mediating the migration and pro-
angiogenic properties of pericytes that contribute to the integrity of endothelial cells 
and vessel maturations. The proteomic data suggests that CECR1 silenced macrophages 
activate CD8+ T cells by stimulation of the antigen presenting pathways. It would be 
interesting if this in sillico prediction could be validated in vivo and eventually translated 
into clinical practice. The inhibition of CECR1 expression in macrophages seems to be 
promising for the development of new therapies like immunotherapy or anti-vascular 
therapy by targeting CECR1 in glioma associated macrophages.  
The siRNA mediated CECR1 knockdown could not be maintained for long. However, 
the effects of siRNA in gene silencing were confirmed at both transcriptional and pro-
tein level, and the high rate of off-target effects of siRNA could be ignored. The effects 
of CECR1 depletion in macrophages could be enhanced if CECR1 could be totally re-
moved from the genome by either Cre-Loxp or CRISPR-Cas9 system. Previous work 
pointed out that CECR1 is a vital mediator in maintaining survival of monocyte and mac-
rophages and M2 macrophages in particular. It would be interesting to design inducible 
CECR1 knockout monocyte cell lines (THP-1, U937) or monocyte-specific inducible 
CECR1 knockout zebrafish, to study the effects of elimination of CECR1 in a longer time 
frame.  
A glioma Patient-derived Tumor Xenograft (PTX) model could be applied to conduct 
in vivo investigation of the contribution of CECR1 in the gliomagenesis. It would enable 
the exploration of the contribution of CECR1 in the various steps associated with glioma 
associated macrophages (GAMs) including ontogeny, macrophage differentiation and 
the preclinical value of CECR1 depletion in vitro, ex-vivo and in vivo. Moreover, further 
experiments could also be carried out to study the restored anti-tumor innate immune 
response by total depletion of CECR1 in glioma associated macrophages in vivo. 
A limitation of the proteomics measurements of the macrophage lysates is the fact 
that the majority of secreted factors which may exist in the supernatant of culture me-
dium are missed. It would be interesting to harvest proteins in the culture medium 
followed by mass spectrometry for identifying the secreted cytokines under CECR1 
regulation. Another drawback of the current studies is that we were unable to explore 
the effects of CECR1 at the transcriptional level. We only rendered data of the down-
stream effects  of CECR1 at the proteomic level. The data was quite limited due to the 
insufficient harvested protein samples. A whole transcriptome RNA-sequencing ap-
proach would be beneficial to future studies on the functions of CECR1.  
Exploring the mechanisms by which CECR1 mediates macrophages and related in-
flammatory responses to promote tumor progression as well as angiogenesis in more 
detail is necessary. There are 3 aspects of the downstream targets of CECR1 in macro-
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phages:  a) Increasing the IFN-γ induced antigen presentation followed by CD8+T cells 
activation, b) Suppressing the expression of S100A9 and PLAU attenuating the various 
intracellular signalling pathways including the MAPK pathway in both glioma and vascu-
lar cells, c) Upregulating of LAT2 expression in macrophage enhancing the pro-
inflammatory factors secretion. We hypothesize that CECR1 regulates the expression of 
LAT2 that subsequently triggers pro-inflammatory cytokines secretion. Among these 
cytokines, IFN-γ may be candidate activator on MHC I antigen presentation process in 
macrophage and on CD8+ T cells. 
LAT2, as a lipid raft adaptor protein, was proved to interact with GRB2, activating 
downstream PI3K [45]. Phosphorylation of PI3K transduces the signal to AKT followed by 
mediating nuclear localization of NF-κB[46] as well as NF-ATc[47] which aid the tran-
scription of pro-inflammatory factors. Intracellular β-catenin would be phosphorylated 
as well, but labeled β-catenin would be further degraded rather than entering into nu-
cleus recruiting TCF4 [48].  Therefore, validating the CECR1-LAT2 axis may provide a 
better explanation of how CECR1 depletion mediates the immune function of macro-
phages. Whether the LAT2 signaling pathway is also related to the expression of S100A9 
as well as PLAU needs further investigation. 
As a growth factor like molecule, CECR1 was shown to anchor on the surface of im-
mune cells including monocytes, macrophages and T cells. In recent studies on CECR1 a 
diagram of CECR1 mediated immune regulation was made [49]. CECR1 interacts with 
several molecules of different types of immune cells like CD16+ non-classical mono-
cytes, neutrophils, regulatory T cells, and B cells that do not express CD26, a nature 
receptor of ADA1. The focus is on CECR1 function in tumor-associated macrophages 
and the proteins putatively recognizing and interacting with CECR1in macrophages and 
tumor associated macrophages. How do they contribute to mediate CECR1 functions? Is 
there any link to the established downstream molecule like LAT2 expression? Are there 
other binding proteins and related mechanisms active in the CECR1 mediating immune 
modulation and survival of other immune cells besides CD39 on the surface of T regula-
tory cells? Are there adenosine receptors on macrophages and T lymphocytes, and are 
there other binding proteins and related mechanisms on CECR1 mediating immune 
modulation and survival of other immune cells? These questions can be answered by 
analysing whole tissue lysates and subsequent protein pull down. Such proteomic anal-
ysis will give indications on potential partner molecules of CECR1 which subsequently 
should be validated by IHC or IF. Thus, applying immunoprecipitation combining with 
mass spectrometry would be the next step to get in depth ideas about potential partner 
proteins of CECR1 in tumor associated macrophages and in other types of immune cells. 
Deciphering the details on the CECR1-mediated macrophage response and the contri-
bution of CECR1 in tumor immune microenvironment is most challenging. It should be 
kept in mind that microglia and monocyte-derived macrophages stem from two differ-
ent precursor cells[28]. Because of the different lineages the effects of CECR1 expres-
sion may be different. Isolating microglia as well as tumor associated macrophages from 
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the same glioma patient followed by CECR1 knockdown and full transcriptome RNA-
sequencing may be an appropriate approach to capture possible differences.  
 
In conclusion, the studies carried out in this thesis are pioneers to scientific work fo-
cusing on CECR1 in tumor associated macrophage especially in glioblastoma. There are 
still many unclear aspects waiting for further in depth and dedicated investigation. From 
the studies it may be concluded that CECR1 as a promising therapeutic target for cancer 
immunotherapy.  
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Summary 
Summary 
The complex tumor microenvironment of glioma, constituting various cell population, 
supports the progression, resistance and recurrence of tumors. Among these types of 
cells, resident microglia and macrophages contribute almost 30-50% of tumor tissues 
depending on individuals. Latest studies defined these cells as glioma supporting cells 
by supporting growth of glioma cells and developing GBM angiogenesis. Thus, exploring 
novel molecular targets and their functions in glioma microglia/macrophage would 
definitely be urgent and useful in benefiting future clinical practice 
In this thesis, the ontogeny of macrophage and its contribution on glial tumor de-
velopment and angiogenesis was systematically reviewed to get an overall picture of 
the importance of macrophage in malignant cancers (Chapter 1，2).  As a novel discov-
ered molecule, CECR1 was first of our knowledge reported in microglia/macrophage in 
glioma. CECR1 was displayed as a M2-like macrophage-specific oncogenic protein af-
fecting MAPK pathway in glioma cells (Chapter 3).    
 Abundant angiogenesis is highly characteristic for gliomas. CECR1 not only mediates 
the biological behavior of glial tumor cells, it also enhanced the angiogenesis process 
under the influence of GBM cells. The proangiogenic property was tightly linked to M2-
like phenotype. PDGF-B, as a M2-macrophage expressing molecule, was a promising 
downstream target of CECR1. It serves as a “bridge” integrating the functions of macro-
phage with pericyte. Moreover, it transduced the signal from CECR1 to pericyte activat-
ing periostin expression through PDGFB-PDGFRB axis (Chapter 4). As a predefined pro-
angiogenic extracellular matrix component, periostin, was further proved to be ex-
pressed by pericyte and reactive astrocytes, other than glioma initiating cells, resulting a 
regulatory role in angiogenesis (Chapter 5).In order to validate and expand the 
knowledge on CECR1 mediated response in macrophage, proteomic analysis was ap-
plied. CECR1 in macrophage negatively regulated innate immune response. However, as 
glioma cells applied to culture system, CECR1 mainly regulated survival and proliferation 
of macrophage, other than regulating immune response (Chapter 6).  Microglia belongs 
to monocyte/phagocytosis system. It shares most of macrophage markers, which makes 
it difficult to distinguish from myeloid originated macrophage in GBM. P2RY12, as a 
microglia specific receptor, was surprisingly found translocated to nucleus in M2-like 
microglia cells with a dramatic expression level. By utilizing TCGA database, P2RY12 is 
related to activated immune response and pro-inflammatory signalling, while it reverse-
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ly correlated to cell proliferation and cell cycle transition (Chapter 7). Thus, P2RY12 
potentially serves as a microglia-specific tumor suppressor molecule.       
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Samenvatting 
Macrofagen en microglia maken tot 50% van de celpopulatie van gliomen uit, en zijn 
betrokken bij de tumor progressie, therapie resistentie en tumor recidieven na thera-
pie. Recente studies beschrijven niet alleen betrokkenheid van deze cellen bij tumor-
groei, maar ook specifiek bij tumor angiogenese. De functies van deze cellen, en de 
daaraan ten grondslag liggende moleculaire paden, zijn derhalve belangrijk voor nieuwe 
inzichten in de tumor genese en het ontwikkelen van nieuwe therapieën (Hoofdstukken 
1 en 2).     
In dit proefschrift worden de macrofagen die in gliomen voorkomen onder de loep 
genomen en hun belang voor de tumor biologie in kaart gebracht (Hoofdstukken 1 en 
2). Het CECR1 molecuul werd recentelijk met angiogenese in verband gebracht en in dit 
proefschrift wordt CECR1 expressie door macrofagen en microgliale cellen in gliomen 
verder uitgewerkt. Het blijkt dat CECR1 tot expressie komt in de context van het M2-
macrofagen profiel en dat CECR1 invloed heeft op de MAPK pathway (Hoofdstuk 3). 
Tevens blijkt dat CECR1 onder invloed van de gliale tumorcellen, angiogenese in glio-
men bevordert (Hoofdstuk 4). CECR1 afkomstig uit de M2-macrofagen medieert de 
productie van periostine door pericyten via paracrine effecten van PDGFB-PDGFRβ 
signaling, waardoor tumor angiogenesis wordt gestimuleerd (Hoofdstuk 5). Door middel 
van proteoom studies werd het negatieve effect van de expressie van CECR1 op de 
immuunrespons aangetoond (Hoofdstuk 6). Om microgliale cellen te onderscheiden van 
andere macrofagen (die bijvoorbeeld CECR1 tot expressie kunnen brengen) werd in 
Hoofdstuk 7 de waarde van de microglia-specifieke receptor P2RY12 aangetoond. 
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